Transdermal delivery of large agents
Microneedling combined with emulsion compositions addresses the challenge of transdermal delivery for large drugs by enhancing skin penetration and stability, providing a more effective and safer administration method.
Patent Information
- Application Number
- JP2024150911
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-11-21
- Filing Date
- 2024-09-02
- Publication Date
- 2024-12-03
AI Technical Summary
Existing transdermal delivery technologies face challenges in effectively administering large drugs, such as botulinum toxin and antibodies, due to decreased percutaneous penetration and susceptibility to degradation, especially when molecular size increases.
Combining microneedling technology with emulsion compositions, specifically macroemulsion or nanoemulsion, to facilitate transdermal delivery of large drugs without the need for additional skin-disrupting penetration enhancers.
Enhances the transdermal delivery of large drugs by improving skin penetration and maintaining drug stability, reducing the risk of degradation and skin irritation.
Smart Images

Figure 2024167362000007 
Figure 2024167362000008 
Figure 2024167362000001
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 424,937, filed November 21, 2016, which is incorporated by reference in its entirety. [Background technology]
[0002] A great deal of money has been invested in the development of effective transdermal delivery technology. Those skilled in the art are well aware of the challenges associated with achieving effective transdermal delivery, especially for large drugs. As molecular size increases, transdermal penetration decreases to the extent that it becomes insignificant or even nonexistent. Even in those cases where there is some penetration, large drugs tend to degrade and become biologically inactive. There remains a need for new and effective technologies for the effective transdermal administration of such drugs, particularly botulinum toxin and antibody drugs, which are large drugs and are also susceptible to degradation. Summary of the Invention [Means for solving the problem]
[0003] Transdermal administration has generally been the subject of research in an attempt to provide an alternative route of administration of drugs that does not involve the undesirable consequences associated with injections and oral delivery.For example, needles often cause local pain, bleeding and bruising, potentially exposing the patient to infectious diseases; oral administration can suffer from poor bioavailability of drugs due to the highly acidic environment of the patient's stomach.In some embodiments, transdermal delivery has a more uniform, regular, and / or consistent pharmacokinetic profile compared to other routes of administration.
[0004] While transdermal drug delivery has many advantages, it also poses numerous logistical problems. Only a limited number of drugs have been shown to be administrable by this route. It continues to be difficult to deliver active agents transdermally, including but not limited to hydrophilic molecules, large molecular structures (e.g., greater than several hundred daltons), gene therapy, vaccines, etc. Prausnitz, MR & Langer, R. “Transdermal drug delivery,” Nat Biotechnol. 26(11):1261-1268 (2008).
[0005] The present disclosure provides an improved technique for transdermal delivery of a target agent. In particular, the present disclosure provides insight that certain advantages can be achieved when microneedle processing technology is combined with emulsion technology for transdermal delivery of a target agent. Alternatively or additionally, in some embodiments, the present disclosure demonstrates that surprising enhancements for transdermal delivery of large molecular structures can be achieved when microneedle processing technology is utilized.
[0006] A variety of microneedle processing techniques have been developed that may be useful for the administration of a given agent of interest. Microneedle processing can avoid certain drawbacks (e.g., pain and / or amount of bleeding) often associated with the use of larger needles (e.g., with standard injection techniques). Microneedle processing techniques may utilize one or more hollow or solid microneedles (e.g., arrays thereof). The agent of interest may be disposed in (e.g., when the microneedle is hollow and / or when the agent is incorporated into the microneedle material) or on (i.e., on the surface of the microneedle(s)) the microneedle(s) and / or applied to the site of skin before, during, or after microneedling the site. The agent in or on the microneedle may be released, for example, by diffusion or release from the microneedle, or by breakage and / or fragmentation of the microneedle material after application to the site.
[0007] In some embodiments, the present disclosure provides a strategy for using microneedle processing to "condition" the skin to which a transdermal product has been, is being, or will be applied (and specifically, to precondition the skin prior to administration of a large drug). A study analyzing the transdermal delivery of small molecules (specifically, short hydrophilic peptides with molecular weights in the range of 400-1000 Da) found that "skin penetration of peptides depends on their molecular weight and decreases as molecular weight increases" (Zhang, S., et al., "Enhanced delivery of Thus, despite previous reports that such an approach was likely only useful for low molecular weight drugs, the present disclosure provides an insight that such microneedle preparation can surprisingly provide significant benefits in facilitating transdermal delivery of large drugs (e.g., having a molecular weight of about 100 kDa or more), as we have found that the transdermal delivery of large drugs can be effectively promoted by microneedle pretreatment of hydrophilic peptides in vitro by transdermal microneedle pretreatment. Acta Pharmaceutica Sinica B. 4(1):100-104 (2014)).
[0008] Therefore, prior to this disclosure, those skilled in the art would have understood from the literature that microneedle preparation of the skin would not be expected to promote transdermal delivery of large drugs.This disclosure surprisingly demonstrates that microneedle preparation of the skin can significantly promote the transdermal delivery of drugs such as botulinum toxin, which has a molecular weight of about 150,000 KDa.Standard antibodies also have a similar molecular weight.
[0009] The present disclosure specifically demonstrates that microneedle processing techniques (e.g., microneedle conditioning of the skin) can significantly enhance the transdermal delivery of large agents in emulsion compositions (e.g., macroemulsion compositions and / or nanoemulsion compositions). As illustrated, preconditioning of the skin, for example by applying microneedles prior to any administration of the relevant large agent (botulinum toxin), surprisingly enhanced the delivery of the large agent through the skin. Specific examples included herein document such enhanced delivery under various conditions and / or circumstances (e.g., different skin sites, number of applications, etc.). Those skilled in the art will recognize other typologies (e.g., for site of application, number of doses, etc.) that fall within the scope of the present disclosure.
[0010] Particular nanoemulsion compositions of interest include water-in-oil and oil-in-water nanoemulsions characterized by droplet sizes ranging from about 10 nm to about 300 nm in diameter, ratios of aqueous dispersion medium to oil ranging from about 0.01:1 to about 20:1; oil-to-surfactant ratios ranging from about 0.1 to about 40, and / or zeta potentials ranging from about -80 mV to about +80 mV (see, e.g., the descriptions of nanoemulsion compositions in one or more of PCT / US2006 / 26918; PCT US06 / 46236; PCT / US2012 / 22276; and PCT / US2012 / 22279, the disclosures of each of which are incorporated herein by reference in their entireties).
[0011] The findings presented herein are particularly surprising in light of reports that transdermal delivery of solid nanoparticles of sizes comparable to those of the droplets in the nanoemulsion compositions utilized herein (e.g., 105±2.92 nm) does not effectively deliver (or facilitate delivery of) even small molecule drugs transdermally through the skin. For example, Gomaa et al. described a study in which a solution of rhodamine dye (molecular weight 479 Da) encapsulated in PLGA nanoparticles was applied to skin preconditioned by microneedle treatment and skin penetration was evaluated. Gomaa, Y., et al., “Effect of microneedle treatment See, “J Pharm Pharmacol. 2012 November;64(11):1592-1602.” The data showed that very small amounts of dye began to penetrate the skin after 6 hours of continuous application; no significant increase in penetration was observed until the skin had been treated continuously for 24 hours. The researchers explained that “there is an emerging consensus that NPs [nanoparticles] are not normally able to penetrate the stratum corneum, but can deposit well within hair follicles.” Thus, one of skill in the art would expect that prior to the present disclosure, the use of microneedling techniques with nano-sized vehicles would have been considered unable to effectively deliver even small molecule drugs (e.g., rhodamine dyes) transdermally; delivery of larger drugs certainly would not be possible. However, the present disclosure demonstrates that microneedling can significantly enhance the transdermal delivery of larger drugs, especially when utilized in conjunction with nanoemulsion systems.
[0012] In particular, the present disclosure demonstrates that microneedling techniques can facilitate transdermal delivery (e.g., of large agents, especially from macroemulsion or nanoemulsion compositions) when no other disintegrating agents are utilized (i.e., no chemical penetration enhancers are utilized, and no other techniques that disrupt or puncture the skin structure are utilized). Previous studies of transdermal delivery of agents as large as botulinum toxin (i.e., approximately 150 kDa) using microneedles have reported that delivery is not successful unless additional treatments are applied to disrupt the skin. For example, U.S. Patent Publication No. 2010 / 0196445 reports that botulinum toxin is not effectively delivered from pre-coated microneedles unless skin digestive enzymes are also applied to disrupt the skin structure at the site of microneedling.
[0013] In some embodiments, the present disclosure provides techniques to achieve enhanced transdermal delivery of large agents (e.g., botulinum toxin, antibodies, etc.) by utilizing microneedle processing techniques without the additional use of penetration enhancers. Alternatively or additionally, in some embodiments, the present disclosure provides techniques to achieve enhanced transdermal delivery of large agents (e.g., botulinum toxin, antibodies, etc.) by utilizing microneedle processing techniques without any other disrupting measures. As such, the provided techniques may achieve effective delivery without the inflammation, irritation, and / or allergic reactions that often accompany the use of skin disrupting agents.
[0014] Alternatively or additionally, the present disclosure identifies the source of problems with certain conventional approaches to associating large agents, particularly large protein agents (e.g., botulinum toxin, antibodies, etc.), in or on microneedle structures. Typically, such conventional approaches utilize a solution of the agent that is applied to the microneedle and allowed to air dry. Such an approach was utilized in the above-mentioned U.S. Patent Publication No. 2010 / 0228225 to coat microneedles with botulinum toxin. U.S. Patent Publication No. 2017 / 0209553 describes a microneedle array in which botulinum is loaded into the needles. The present disclosure understands that the botulinum coating or loading material produced thereby is not stable and therefore not commercially viable when used to manufacture products. Indeed, even if such liquids are prepared from powder materials, the present disclosure understands that for many large agents (e.g., botulinum toxin), powders and other solid materials not formed by the freeze-drying process can be very unstable. For example, according to Johnson, E., et al., "Botulinum toxin is highly susceptible to denaturation due to surface denaturation, heat, and alkaline conditions. Lyophilization or freeze-drying of botulinum toxin is the most economically rational and practical method of distributing the product in a form that is stable and easily used by clinicians." U.S. Patent No. 5,512,547. Similarly, such an approach would not work for the administration of therapeutic antibodies, which have their own stability and storage challenges. The present disclosure provides insight that the use of the emulsion compositions described herein (e.g., in some embodiments, nanoemulsion compositions, and / or in some embodiments, macroemulsion compositions) can protect or otherwise improve the stability of large agents, particularly large protein agents (including specifically botulinum toxin and / or antibody agents), in the context of microneedles.
[0015] The present disclosure provides a surprisingly effective technique for transdermal delivery of large drugs. In particular, the present disclosure teaches that transdermal delivery of such drugs can be significantly enhanced through the use of certain microneedle processing techniques. In some embodiments, the present disclosure teaches that particularly advantageous results are achieved when microneedle processing techniques are combined with emulsion compositions (e.g., in some embodiments, nanoemulsion compositions, and / or in some embodiments, macroemulsion compositions). In some embodiments, the microneedle processing techniques are combined with lotions, creams, or liquid compositions that may subsequently become or include emulsion compositions (e.g., in some embodiments, nanoemulsion embodiments, and / or in some embodiments, macroemulsion compositions). In some embodiments, the techniques provided do not utilize skin disruption techniques such as chemical penetration enhancers. [Brief description of the drawings]
[0016] [Figure 1] 1 illustrates the results of digit abduction scoring from a rat study of the effect of MSCs ("microneedle skin conditioning") on the bioavailability of a botulinum nanoemulsion formulation. [Diagram 2] 1 illustrates the viability of a rat study of the effect of MSCs on the bioavailability of a botulinum nanoemulsion formulation. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0017] definition In this application, unless otherwise clear from the context, (i) the term "a" may be understood to mean "at least one"; (ii) the term "or" may be understood to mean "and / or"; (iii) the terms "comprising" and "including" may be understood to include the listed components or steps, whether listed by themselves or with one or more additional components or steps; (iv) the terms "about" and "approximately" may be understood to allow for standard deviation, as would be understood by one of ordinary skill in the art; and (v) when ranges are provided, the endpoints are included.
[0018] Abrasion: The term "abrasion" as used herein refers to any means that alters, disrupts, removes, or destroys the top layer of the skin. In some embodiments, abrasion refers to mechanical means that alters, disrupts, removes, or destroys the top layer of the skin. In some embodiments, abrasion refers to chemical means that alters, disrupts, removes, or destroys the top layer of the skin. Agents such as scrubbing agents, microparticles (e.g., magnesium or aluminum particles), acids (e.g., alpha-hydroxy acids or beta-hydroxy acids), alcohols, to name a few, may cause abrasion. In general, penetration enhancers such as those described by Donovan (e.g., U.S. Publications 2004 / 009180 and 2005 / 175636, and PCT Publication WO04 / 06954), and Graham (e.g., U.S. Patent 6,939,852 and U.S. Publication 2006 / 093624) are expected to cause abrasion. Of course, those skilled in the art will understand that a particular agent may cause abrasion when present at one concentration or with one or more other agents, but may not cause abrasion under different circumstances. Therefore, whether a particular material is an "abrasive" depends on the circumstances. Abrasion can be easily evaluated by those skilled in the art, for example, by observing redness or irritation of the skin and / or observing histological examination of the skin, which shows changes, breakdown, removal, or sores of the stratum corneum.
[0019] Administration: As used herein, the term "administration" typically refers to the administration of a composition to a subject or system. Those skilled in the art will recognize various routes that may be utilized for administration to a subject, e.g., a human, in appropriate circumstances. For example, in some embodiments, administration may be intraocular, oral, parenteral, topical, etc. In some embodiments, administration may be intrabronchial (e.g., by intrabronchial instillation), buccal, transdermal (e.g., may be or may include one or more of topical to the dermis, intradermal, interdermal, transdermal, etc.), intestinal, intraarterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, intraspecific organ (e.g., intrahepatic), mucosal, intranasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), intravaginal, vitreous, etc. In some embodiments, administration can include dosing that is intermittent (e.g., multiple doses separated in time) and / or periodic (e.g., individual doses separated by a common period of time) dosing. In some embodiments, administration can include continuous dosing (e.g., perfusion) over at least a selected period of time.
[0020] Agent: In general, the term "agent", as used herein, may be used to refer to any chemical class of compound or entity, including, for example, polypeptides, nucleic acids, saccharides, lipids, small molecules, metals, or combinations or complexes thereof. In appropriate circumstances, as will be clear from the context to one of skill in the art, the term may be utilized to refer to an entity that is or includes a cell or organism, or a fraction, extract, or component thereof. Alternatively or additionally, as will be clear from the context, the term may be utilized to refer to a natural product, in that it is found in nature and / or is obtained from nature. In some cases, as will also be clear from the context, the term may be utilized to refer to one or more entities that are man-made, in that they are designed, conceived, and / or produced by the action of the human hand, and / or are not found in nature. In some embodiments, the agent may be utilized in an isolated or pure form; in some embodiments, the agent may be utilized in a crude form. In some embodiments, the potential agent may be provided as a collection or collection that may be screened, for example, to identify or characterize active agents therein. In some cases, the term "agent" may refer to a compound or entity that is or comprises a polymer; in some cases, the term may refer to a compound or entity that comprises one or more polymeric moieties. In some embodiments, the term "agent" may refer to a compound or entity that is not a polymer and / or is substantially free of any polymer and / or one or more specific polymeric moieties. In some embodiments, the term may refer to a compound or entity that is devoid of or substantially free of any polymeric moieties. In some embodiments, the term may refer to a molecular complex.
[0021] Antibody: As used herein, the term "antibody" refers to a polypeptide that contains sufficient standard immunoglobulin sequence elements to confer specific binding to a particular target antigen. As is known in the art, an intact antibody, as produced in nature, is a tetrameric agent of approximately 150 kDa, comprising two identical heavy chain polypeptides (about 50 kDa each) and two identical light chain polypeptides (about 25 kDa each) that associate with each other into what is commonly referred to as a "Y-shaped" structure. Each heavy chain comprises at least four domains (each about 110 amino acids long) - an amino-terminal variable (VH) domain (located at the tip of the Y structure), followed by three constant domains: CH1, CH2, and a carboxy-terminal CH3 (located at the base of the stem of the Y'). A short region known as the "switch" connects the heavy chain variable and constant regions. A "hinge" connects the CH2 and CH3 domains to the rest of the antibody. Two disulfide bonds in this hinge region bind the two heavy chain polypeptides to each other in an intact antibody. Each light chain comprises two domains, an amino-terminal variable (VL) domain followed by a carboxy-terminal constant (CL) domain, which are separated from each other by another "switch". An intact antibody tetramer comprises two heavy-light chain dimers in which the heavy and light chains are linked together by a single disulfide bond; two other disulfide bonds connect the heavy chain hinge regions together, which connect the dimers together to form a tetramer. Naturally produced antibodies are also typically glycosylated on the CH2 domain. Each domain in a natural antibody has a structure characterized by an "immunoglobulin fold" formed from two beta sheets (e.g., 3-, 4-, or 5-stranded sheets) packed against each other in a compressed antiparallel beta barrel. Each variable domain contains three hypervariable loops known as "complementarity determining regions" (CDR1, CDR2, and CDR3), and four somewhat invariant "framework" regions (FR1, FR2, FR3, and FR4).When a natural antibody folds, the FR regions form beta sheets that provide the structural framework of the domain, and the CDR loop regions from both the heavy and light chains come together in three-dimensional space, so that they create a single hypervariable antigen-binding site located at the tip of a Y-structure. The Fc region of a naturally occurring antibody binds to elements of the complementation system and also to receptors on effector cells, including, for example, effector cells that mediate cytotoxicity. As is known in the art, the affinity and / or other binding properties of the Fc region for the Fc receptor can be modulated by glycosylation or other modifications. In some embodiments, the antibodies produced and / or utilized according to the present invention comprise a glycosylated Fc domain, including an Fc domain with such glycosylation that has been modified or altered. For purposes of the present invention, in some embodiments, any polypeptide or complex of polypeptides that includes sufficient immunoglobulin domain sequences as found in a naturally occurring antibody may be referred to and / or used as an "antibody," regardless of whether such polypeptide is naturally generated (e.g., generated by an organism reacting to an antigen) or generated by recombinant technology, chemical synthesis, or other artificial systems or methodologies. In some embodiments, an antibody is polyclonal; in some embodiments, an antibody is monoclonal. In some embodiments, an antibody has constant region sequences characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, antibody sequence elements are humanized, primatized, chimerized, etc., as known in the art. Moreover, the term "antibody" as used herein may, in appropriate embodiments (unless otherwise stated or clear from the context), refer to any of the constructs or formats known or developed in the art for utilizing the structural and functional characteristics of antibodies in alternative presentations.For example, in embodiments, antibodies utilized in accordance with the present invention may include intact IgG, IgE and IgM, bi- or multispecific antibodies (such as, for example, Zybodies®), single chain Fvs, polypeptide-Fc fusions, Fab, camelid antibodies, masked antibodies (such as, for example, Probody®), small modular immunopharmaceuticals (SMPs), and the like. ImmunoPharmaceuticals ("SMIP™")), single chain or tandem diabodies (TandAbs®), VHHs, Anticalins®, Nanobodies®, minibodies, BiTEs®, ankyrin repeat proteins or DARPINs®, Avimers®, DARTs, TCR-like antibodies, Adnectins®, Affilins®, Trans-bodies®, Affibodies®, TrimerX®, MicroProteins, Fynomers®, Centyrin®, and KALBITOR®. In some embodiments, the antibody may lack covalent modifications (e.g., glycan attachment) that it would have if it were naturally produced. In some embodiments, the antibodies may contain covalent modifications (e.g., attachment of a glycan, a payload (e.g., a detectable moiety, a therapeutic moiety, a catalytic moiety, etc.), or other pendant groups (e.g., polyethylene glycol, etc.).
[0022] Antibody drug: As used herein, the term "antibody drug" refers to an agent that specifically binds to a particular antigen. In some embodiments, the term encompasses any polypeptide or polypeptide complex that contains sufficient immunoglobulin structural elements to confer specific binding. Exemplary antibody drugs include, but are not limited to, human antibodies, primatized antibodies, chimeric antibodies, bispecific antibodies, humanized antibodies, conjugated antibodies (i.e., antibodies conjugated or fused to other proteins, radiolabels, cytotoxins), small modular immunopharmaceuticals ("SMIPs™"), single chain antibodies, camelid antibodies, and antibody fragments. As used herein, the term "antibody drug" also includes intact monoclonal antibodies, polyclonal antibodies, single domain antibodies (e.g., shark single domain antibodies (e.g., IgNAR or fragments thereof)), multispecific antibodies (e.g., bispecific antibodies) formed from at least two intact antibodies, and antibody fragments (so long as they exhibit the desired biological activity). In some embodiments, the term encompasses stapled peptides. In some embodiments, the term encompasses one or more antibody-like binding peptidomimetics. In some embodiments, the term encompasses one or more antibody-like binding scaffold proteins. In some embodiments, the term encompasses monobodies or adnectins. In many embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes one or more structural elements recognized by those of skill in the art as complementarity determining regions (CDRs); in some embodiments, an antibody agent is or comprises a polypeptide whose amino acid sequence includes at least one CDR (e.g., at least one heavy chain CDR and / or at least one light chain CDR) that is substantially identical to that found in a reference antibody. In some embodiments, the included CDR is substantially identical to the reference CDR in that it is identical in sequence compared to the reference CDR or contains 1-5 amino acid substitutions.In some embodiments, the included CDRs are substantially identical to the reference CDRs in that they exhibit at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDRs. In some embodiments, the included CDRs are substantially identical to the reference CDRs in that they exhibit at least 96%, 96%, 97%, 98%, 99%, or 100% sequence identity with the reference CDRs. In some embodiments, the included CDRs are substantially identical to the reference CDRs in that at least one amino acid in the included CDR is deleted, added, or substituted compared to the reference CDR, but otherwise the included CDR has the same amino acid sequence as that of the reference CDR. In some embodiments, the included CDRs are substantially identical to the reference CDRs in that 1-5 amino acids within the included CDRs have been deleted, added, or substituted relative to the reference CDR, but otherwise the included CDRs have the same amino acid sequence as the reference CDR. In some embodiments, the included CDRs are substantially identical to the reference CDRs in that at least one amino acid within the included CDRs has been substituted relative to the reference CDR, but otherwise the included CDRs have the same amino acid sequence as that of the reference CDR. In some embodiments, the included CDRs are substantially identical to the reference CDRs in that 1-5 amino acids within the included CDRs have been deleted, added, or substituted relative to the reference CDR, but otherwise the included CDRs have the same amino acid sequence as the reference CDR. In some embodiments, the antibody drug is or comprises a polypeptide whose amino acid sequence comprises structural elements recognized by those skilled in the art as immunoglobulin variable domains. In some embodiments, the antibody drug is a polypeptide protein having a binding domain that is homologous or largely homologous to an immunoglobulin binding domain. In some embodiments, the antibody drug is or comprises an antibody-drug conjugate.
[0023] Antibody component: as used herein, refers to a polypeptide element (which may be a complete polypeptide or a portion of a larger polypeptide, such as, for example, a fusion polypeptide as described herein) that specifically binds to an epitope or antigen and contains one or more immunoglobulin structural features. In general, an antibody component is any polypeptide whose amino acid sequence contains elements characteristic of an antibody binding region (e.g., an antibody light chain or variable region or one or more complementarity determining regions ("CDRs") thereof, or an antibody heavy chain or variable region or one or more CDRs thereof, optionally in the presence of one or more framework regions). In some embodiments, the antibody component is or includes a full-length antibody. In some embodiments, the antibody component is less than full-length but includes at least one binding site (including at least one, and preferably at least two sequences with the structure of a "variable region" of a known antibody). In some embodiments, the term "antibody component" encompasses any protein having a binding domain that is homologous or largely homologous to an immunoglobulin binding domain. In certain embodiments, the "antibody component" encompassed encompasses a polypeptide having a binding domain that exhibits at least 99% identity to an immunoglobulin binding domain. In some embodiments, the "antibody component" included is any polypeptide having an immunoglobulin binding domain, e.g., a binding domain that exhibits at least 70%, 75%, 80%, 85%, 90%, 95% or 98% identity to a reference immunoglobulin binding domain. The "antibody component" included may have an amino acid sequence identical to that of an antibody (or a portion thereof, e.g., an antigen-binding portion thereof) found in a natural source. The antibody component may be monospecific, bispecific, or multispecific. The antibody component may include structural elements characteristic of any immunoglobulin class, including any of the human classes: IgG, IgM, IgA, IgD, and IgE. It has been shown that the antigen-binding function of an antibody may be performed by fragments of a full-length antibody. Such antibody embodiments may also be bispecific, dual specific, or in a multispecific format that specifically binds to two or more different antigens.Examples of binding fragments encompassed by the term "antigen-binding portion" of an antibody include: (i) V. H , V L , C H 1 and C L (ii) a F(ab')2 fragment, which is a bivalent fragment containing two Fab fragments linked by a disulfide bridge at the hinge region; (iii) a V H and C H (iv) a single-arm V of an antibody; H and V L (v) a dAb fragment comprising a single variable domain (Ward et al., (1989) Nature 341:544-546); and (vi) an isolated complementarity determining region (CDR). In addition, two domains of the Fv fragment, the V H and V L Although the V and VL are encoded by separate genes, they can be synthesized using recombinant methods to produce a single protein chain (V H and V L The domains may be linked by synthetic linkers that allow them to be paired to form monovalent molecules (known as single chain Fvs (scFVs); see, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883). In some embodiments, the "antibody component" as described herein is or comprises such a single chain antibody. In some embodiments, the "antibody component" is or comprises a diabody. Diabodies are V H and V LBivalent, bispecific antibodies in which the domains are expressed on a single polypeptide chain but use a linker that is too short to allow pairing between the two domains on the same chain, thereby allowing them to pair with complementary domains on another chain and create two antigen-binding sites (see, e.g., Holliger, P., et al., (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, RJ, (1994) Structure 2(12):1121-1123). Such antibody binding moieties are known in the art (Kontermann and Dubel eds., Antibody Engineering (2001) Springer-Verlag. New York. 790 pp. (ISBN 3-540-41354-5). In some embodiments, the antibody component comprises a pair of tandem Fv segments (V H -C H 1-V H -C H 1) (Zapata et al., (1995) Protein Eng. 8(10):1057-1062; and U.S. Pat. No. 5,641,870). In some embodiments, the antibody component may possess structural elements characteristic of chimeric or humanized antibodies. In general, humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementarity determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity, and capacity. In some embodiments, the antibody component may possess structural elements characteristic of human antibodies.
[0024] Antibody fragment: As used herein, "antibody fragment" includes a portion of an intact antibody, such as, for example, the antigen-binding or variable region of the antibody. Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; triabodies; tetrabodies; linear antibodies; single-chain antibody molecules; and multispecific antibodies formed from antibody fragments. For example, antibody fragments include isolated fragments, "Fv" fragments consisting of the variable regions of the heavy and light chains, recombinant single-chain polypeptide molecules in which the light and heavy chain variable regions are joined by a peptide linker ("ScFv protein"), and minimal recognition units consisting of amino acid residues that mimic the hypervariable region. In many embodiments, an antibody fragment contains sufficient sequence of the parent antibody such that it binds to the same antigen as the parent antibody; in some embodiments, the fragment binds to the antigen with an affinity comparable to that of the parent antibody and / or competes with the parent antibody for binding to the antigen. Examples of antigen-binding fragments of antibodies include, but are not limited to, Fab fragments, Fab' fragments, F(ab')2 fragments, scFv fragments, Fv fragments, dsFv diabodies, dAb fragments, Fd' fragments, Fd fragments, and isolated complementarity determining region (CDR) regions. Antigen-binding fragments of antibodies can be produced by any means. For example, antigen-binding fragments of antibodies can be produced enzymatically or chemically by fragmentation of an intact antibody and / or they can be produced recombinantly from a gene encoding a partial antibody sequence. Alternatively or additionally, antigen-binding fragments of antibodies can be wholly or partially synthetically produced. Antigen-binding fragments of antibodies can optionally include single chain antibody fragments. Alternatively or additionally, antigen-binding fragments of antibodies can include multiple chains linked primarily by disulfide bonds, for example. Antigen-binding fragments of antibodies can optionally include multimolecular complexes. Functional antibody fragments typically include at least about 50 amino acids, more typically include at least about 200 amino acids.
[0025] Approximately: As used herein, the term "approximately" or "about" refers to a value similar to the stated reference value when applied to one or more values of interest. In some embodiments, the term "approximately" or "about" refers to a range of values that falls within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less of the stated reference value in either direction (greater or smaller), unless otherwise stated or otherwise clear from the context (e.g., if one or more values of interest define a sufficiently narrow range, the application of such percentage discrepancies will remove the stated range).
[0026] Associated with: As the term is used herein, two events or entities are "associated" with each other if the presence, level and / or form of one correlates with that of the other. For example, if the presence, level and / or form of a particular entity (e.g., a polypeptide, gene signature, metabolite, microorganism, etc.) correlates (e.g., across a relevant population) with the incidence and / or susceptibility of a particular disease, disorder, or condition, then that entity is considered to be associated with that disease, disorder, or condition. In some embodiments, two or more entities are physically "associated" with each other if they interact directly or indirectly such that they are in and / or remain in close physical proximity to each other. In some embodiments, two or more entities that are physically associated with each other are covalently bound to each other; in some embodiments, two or more entities that are physically associated with each other are not covalently bound to each other, but are non-covalently associated by, for example, hydrogen bonds, van der Waals interactions, hydrophobic interactions, magnetism, and combinations thereof.
[0027] Biocompatible: The term "biocompatible," as used herein, refers to materials that do not cause significant harm to living tissues, for example, when placed in contact with such tissues in vivo. In some embodiments, materials are "biocompatible" if they are not toxic to cells. In some embodiments, materials are "biocompatible" if their addition to cells in vitro results in 20% or less cell death and / or if their administration in vivo does not induce significant inflammation or other such adverse effects.
[0028] Biodegradable: As used herein, the term "biodegradable" refers to a material that, when introduced into a cell, is broken down (e.g., by cellular mechanisms such as enzymatic degradation, hydrolysis, and / or a combination thereof) into components that the cell can reuse or discard without significant toxic effects to the cell. In some embodiments, the components produced by the degradation of the biodegradable material are biocompatible and therefore do not induce significant inflammation and / or other adverse effects in vivo. In some embodiments, biodegradable polymeric materials break down into their constituent monomers. In some embodiments, the degradation of biodegradable materials (e.g., including biodegradable polymeric materials) includes hydrolysis of ester bonds. Alternatively or additionally, in some embodiments, the degradation of biodegradable materials (e.g., including biodegradable polymeric materials) includes cleavage of urethane bonds. Exemplary biodegradable polymers include, for example, polymers of hydroxy acids such as lactic acid and glycolic acid, including, but not limited to, poly(hydroxyl acids), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), and copolymers with PEG, polyanhydrides, poly(ortho)esters, polyesters, polyurethanes, poly(butyric acid), poly(valeric acid), poly(caprolactone), poly(hydroxyalkanoates, poly(lactide-co-caprolactone), blends and copolymers thereof. For example, proteins, e.g., a Many naturally occurring polymers are also biodegradable, including albumin, collagen, gelatin, and prolamines, such as zein, and polysaccharides, such as alginates, cellulose derivatives, and polyhydroxyalkanoates, such as polyhydroxybutyrate blends and copolymers thereof. One of skill in the art will understand or be able to determine when such a polymer is a biocompatible and / or biodegradable derivative thereof (e.g., related to the parent polymer by substantially the same structure differing only in the substitution or addition of certain chemical groups, as known in the art).
[0029] Biologically active agent: As used herein, the term "biologically active agent" refers to an agent that exerts a particular biological effect when administered to a subject, e.g., a human. In some embodiments, the biologically active agent may be a therapeutically active agent, a cosmetically active agent, and / or a diagnostically active agent. In some embodiments, the biologically active agent may be or include an entity or moiety that would be classified as an "active pharmaceutical ingredient" by the U.S. Food and Drug Administration. In some embodiments, the biologically active agent is a large drug. In some embodiments, the biologically active agent may be or include an agent whose presence correlates with a desired pharmacological and / or therapeutic, cosmetic and / or diagnostic effect. In some embodiments, the biologically active agent is characterized in that its biological effect is dose-dependent (e.g., increases linearly with increasing dose, optionally over at least a first concentration range). In some embodiments, an agent is not considered to be a "biologically active agent" if it merely facilitates the delivery of a different agent that actually achieves the desired effect.
[0030] Botulinum macroemulsion composition: The term "botulinum macroemulsion composition" as used herein refers to any macroemulsion composition in which at least one macroemulsion contains a botulinum toxin. The botulinum toxin may be present within the macroemulsion, on the surface of the macroemulsion, and / or within the micellar membrane that defines the macroemulsion.
[0031] Botulinum nanoemulsion composition: The term "botulinum nanoemulsion composition," as used herein, refers to any nanoemulsion composition in which at least one nanoemulsion contains a botulinum toxin. The botulinum toxin may be present within the nanoemulsion, on the surface of the nanoemulsion, and / or within the micellar membrane that defines the nanoemulsion.
[0032] Botulinum toxin The term "botulinum toxin" as used herein refers to any neurotoxin produced by Clostridium botulinum. Unless otherwise indicated, the term includes fragments or portions (e.g., light and / or heavy chains) of such neurotoxins that retain the appropriate activity (e.g., muscle relaxant activity). The phrase "botulinum toxin" as used herein includes botulinum toxin serotypes A, B, C, D, E, F, and G. Botulinum toxin as used herein also includes both botulinum toxin complexes (i.e., e.g., 300, 600, and 900 kDa complexes) and purified (i.e., e.g., isolated) botulinum toxins (i.e., e.g., about 150 kDa). A "purified botulinum toxin" is defined as a botulinum toxin that has been isolated or substantially isolated from other proteins, including proteins for the botulinum toxin complex. The purified toxin may be greater than 95% pure, and preferably greater than 99% pure. Those skilled in the art will appreciate that the present invention is not limited to any particular source of botulinum toxin. For example, botulinum toxins for use according to the present invention may be isolated from Clostridium botulinum, chemically synthesized, recombinantly produced (i.e., in a host cell or organism other than Clostridium botulinum), and the like. Botulinum may be genetically engineered or chemically modified to act for a longer or shorter duration than botulinum toxin serotype A.
[0033] Carrier: as used herein, refers to a diluent, adjuvant, excipient, or vehicle with which the composition is administered. In some exemplary embodiments, the carrier may include sterile liquids, such as water and oils, including those of petroleum, animal, vegetable, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like. In some embodiments, the carrier is or includes one or more solid ingredients.
[0034] Combination therapy: As used herein, the term "combination therapy" refers to those situations in which a subject is exposed to two or more therapeutic regimens (e.g., two or more therapeutic agents, therapeutic agents and therapeutic modalities, etc.) simultaneously. In some embodiments, the two or more regimens may be administered simultaneously; in some embodiments, such regimens may be administered sequentially (e.g., all "doses" of a first regimen are administered prior to administration of any dose of a second regimen); in some embodiments, such agents are administered in overlapping dosing regimens. In some embodiments, "administration" of a combination therapy may include administration of one or more agents and / or modalities to a subject receiving the other agent or modality in combination. For clarity, combination therapy does not require that the individual agents be administered together in a single composition (or even necessarily administered simultaneously), although in some embodiments, two or more agents, or active portions thereof, may be administered together in a combination composition or even in a combination compound (e.g., as part of a single chemical complex or covalent entity).
[0035] Equivalent: As used herein, the term "equivalent" refers to two or more agents, entities, situations, sets of conditions, etc. that may not be identical to each other, but are sufficiently similar to allow comparison between them, so that a person skilled in the art would understand that conclusions can be reasonably drawn based on observed differences or similarities. In some embodiments, an equivalent set of states, circumstances, individuals, or populations is characterized by multiple substantially identical characteristics and one or a few different characteristics. A person skilled in the art will understand, in context, what degree of identity is required in any given situation for two or more such agents, entities, situations, sets of conditions, etc. to be considered equivalent. For example, a person skilled in the art will understand that a set of circumstances, individuals, or populations is comparable to each other when it is characterized by a sufficient number and substantially identical types of characteristics to justify a reasonable conclusion that the differences in the results obtained or phenomena observed under or with the different sets of circumstances, individuals, or populations are caused by or indicate variations in those characteristics that vary.
[0036] Composition: Those skilled in the art will understand that the term "composition", as used herein, may be used to refer to a separate physical entity that includes one or more specific components. In general, unless otherwise specified, a composition may be in any form, such as a gas, gel, liquid, solid, etc.
[0037] Comprising: A composition or method described herein as "comprising" one or more named elements or steps is open-ended, meaning that the named elements or steps are essential, but that other elements or steps may be added within the scope of the composition or method. To avoid redundancy, it is understood that any composition or method described as "comprising" (or "which comprises") one or more named elements or steps also describes a corresponding more limited composition or method that "consisting essentially of" (or "which consists essentially of") the same named elements or steps, meaning that the composition or method includes the essential named elements or steps, and may also include additional elements or steps that do not materially affect the basic novel characteristic(s) of the composition or method. Any composition or method described herein as "comprising" or "consisting essentially of" one or more named elements or steps is also understood to describe a corresponding more limited closed-ended composition or method that "consisting of" (or "consists of") the named elements or steps, to the exclusion of any other unnamed elements or steps. In any composition or method disclosed herein, known or disclosed equivalents of any named essential element or step may be substituted for that element or step.
[0038] Dosage form or unit dosage form: Those skilled in the art will appreciate that the term "dosage form" can be used to refer to a physically discrete unit of active agent (e.g., therapeutic or diagnostic agent) for administration to a subject. Typically, each such unit contains a predetermined amount of active agent. In some embodiments, such amount is a unit dosage (or a whole fraction thereof) appropriate for administration according to a dosing regimen determined to correlate with a desired or beneficial outcome (i.e., a therapeutic dosing regimen) when administered to a relevant population. Those skilled in the art will appreciate that the total amount of a therapeutic composition or agent to be administered to a particular subject is determined by one or more attending physicians and may include administration of multiple dosage forms.
[0039] Dosing regimen: Those skilled in the art will appreciate that the term "dosing regimen" may be used to refer to a set of unit doses (typically multiple) administered individually to a subject, typically separated by a period of time. In some embodiments, a given therapeutic agent has a recommended dosing regimen, which may include one or more doses. In some embodiments, a dosing regimen includes multiple doses, each separated in time from the other doses. In some embodiments, the individual doses are separated from each other by the same length of time period; in some embodiments, a dosing regimen includes multiple doses and at least two different periods separating the individual doses. In some embodiments, all doses within a dosing regimen are of the same unit dose amount. In some embodiments, different doses within a dosing regimen are of different amounts. In some embodiments, a dosing regimen includes a first dose in a first dose amount, followed by one or more additional doses in a second dose amount that is different from the amount of the first dose. In some embodiments, the dosing regimen includes a first dose in a first dose amount, followed by one or more additional doses in a second dose amount that is the same as the amount of the first dose. In some embodiments, the dosing regimen correlates with a desired or beneficial outcome when administered across a relevant population (i.e., is a therapeutic dosing regimen).
[0040] Emulsion: The term "emulsion" is used herein in accordance with its understanding in the art as "a system consisting of a liquid dispersed, with or without an emulsifying agent, in an immiscible liquid, usually in droplets larger than colloidal size." See, e.g., the definition in the Medline Plus Online Medical Dictionary, Merriam Webster (2005).
[0041] Excipient: as used herein refers to a non-therapeutic agent that may be included in a pharmaceutical composition, for example, to provide or contribute to a desired consistency or stabilizing effect. Suitable pharmaceutical excipients include, for example, starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol, etc.
[0042] Human: In some embodiments, the human is an embryo, fetus, infant, child, teenager, adult, or elderly.
[0043] Hydrophilic: As used herein, the terms "hydrophilic" and / or "polar" refer to the tendency to mix with or dissolve readily in water.
[0044] Hydrophobic: As used herein, the terms "hydrophobic" and / or "non-polar" refer to a tendency to not mix or combine with water, or the inability to readily dissolve in water.
[0045] Improve, increase or decrease: As used herein or its grammatical equivalents, the terms "improve," "increase," or "decrease" refer to a value relative to a baseline measurement, such as a measurement in the same individual prior to the initiation of a treatment described herein, or a measurement in a control individual (or control individuals) in the absence of a treatment described herein. In some embodiments, a "control individual" is an individual suffering from the same form of disease or injury as the individual being treated.
[0046] Large molecule: The term "large molecule" is generally used herein to describe a molecule that is greater than about 100 kilodaltons (KDa) in size. In some embodiments, a large molecule is greater than about 110 KDa, 120 KDa, 130 KDa, 140 KDa, 150 KDa, 160 KDa, 170 KDa, 180 KDa, 190 KDa, 200 KDa, 250 KDa, 300 KDa, 400 KDa, or 500 KDa. In some embodiments, a large molecule is a polymer or comprises a polymeric moiety or entity. In some embodiments, a large molecule is or comprises a polypeptide. In some embodiments, a large molecule is or comprises a nucleic acid.
[0047] Large Agents: As used herein, the term "large agent" generally refers to an agent having a molecular weight greater than about 100 kilodaltons (KDa) in size. In some embodiments, the large molecule is greater than about 110 KDa, 120 KDa, 130 KDa, 140 KDa, 150 KDa, 160 KDa, 170 KDa, 180 KDa, 190 KDa, 200 KDa, 250 KDa, 300 KDa, 400 KDa, or 500 KDa. In some embodiments, the large agent is a biologically active agent. In some embodiments, the large agent is or includes one or more large molecules. In some embodiments, the large agent is or includes one or more molecular complexes. In some embodiments, the large agent is or includes a polypeptide. In some embodiments, the large agent is or includes a complex of polypeptides. In some embodiments, the large agent is or includes a bacterial toxin (e.g., botulinum toxin). In some embodiments, the large drug is or comprises an antibody drug.
[0048] Macroemulsion: The term "macroemulsion," as used herein, refers to an emulsion in which at least some of the droplets have diameters in the size range of hundreds of nanometers to micrometers. As will be appreciated by those of skill in the art, macroemulsions are characterized by droplets that are greater than 300 nm in diameter. In some embodiments, the macroemulsion compositions utilized in accordance with the present disclosure include one or more large agents or one or more biologically active agents. In some embodiments, the large agents included in the macroemulsion composition can be biologically active agents. It will be appreciated by those of skill in the art that the macroemulsion compositions for use in accordance with the present disclosure can be prepared according to any available means, including, for example, chemical or mechanical means. In some embodiments, the droplets in the macroemulsion have a size in the range of about 301 nm to about 1000 μm. In some embodiments, the macroemulsion has a droplet size distribution of about 301 nm to about 1000 μm. In some embodiments, the droplets in the macroemulsion have a size in the range of about 500 nm to about 5000 μm. In some embodiments, macroemulsions have a droplet size distribution of about 500 nm to about 5000 μm.
[0049] Microneedle: As used herein, the term "microneedle" generally refers to an elongated structure of length, diameter, and shape suitable for penetrating the skin. In some embodiments, the microneedle is prepared and configured (by itself or in a device) to minimize contact with nerves when inserted into the skin while still creating an efficient pathway for drug delivery. In some embodiments, the microneedle has a constant diameter along the length of the microneedle. In some embodiments, the microneedle has a diameter that varies along the length of the microneedle. In some embodiments, the microneedle has a diameter that tapers along the length of the microneedle. In some embodiments, the diameter of the microneedle is narrowest at the tip that penetrates the skin. In some embodiments, the microneedle may be solid. In some embodiments, the microneedle may be hollow. In some embodiments, the microneedle may be tubular. In some embodiments, the microneedle may be sealed at one end. In some embodiments, multiple microneedles are utilized. In some embodiments, multiple microneedles are utilized in an array format. In some embodiments, the microneedle may have a length in the range of about 1 μm to about 4,000 μm. In some embodiments, the microneedles may have a length of about 1 μm to about 2,000 μm. In some embodiments, the microneedles may have a length of about 50 μm to about 400 μm. In some embodiments, the microneedles may have a length of about 800 μm to about 1500 μm.
[0050] Nanoemulsion: The term "nanoemulsion," as used herein, refers to an emulsion in which at least some of the droplets have diameters in the nanometer size range. As will be appreciated by those of skill in the art, nanoemulsions are characterized by droplets with diameters of 300 nm or less. In some embodiments, the nanoemulsion compositions utilized in accordance with the present disclosure include one or more large agents or one or more biologically active agents. In some embodiments, the large agents included in the nanoemulsion composition can be biologically active agents. It will be appreciated by those of skill in the art that nanoemulsion compositions for use in accordance with the present disclosure can be prepared according to any available means, including, for example, chemical or mechanical means. In some embodiments, the droplets in the nanoemulsion have a size in the range of about 1 nm to about 300 nm. In some embodiments, the nanoemulsion has droplets with a size distribution of about 1 nm to about 300 nm.
[0051] Nanoparticles: As used herein, the term "nanoparticles" refers to solid particles having a diameter of less than 300 nm as defined by the National Science Foundation. In some embodiments, nanoparticles have a diameter of less than 100 nm as defined by the National Institutes of Health.
[0052] Patient: As used herein, the term "patient" refers to any organism to which a provided composition is or can be administered, for example, for experimental, diagnostic, prophylactic, cosmetic, and / or therapeutic purposes. Exemplary patients include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and / or humans). In some embodiments, the patient is human. In some embodiments, the patient is suffering from or susceptible to one or more disorders or conditions. In some embodiments, the patient exhibits one or more symptoms of a disorder or condition. In some embodiments, the patient has been diagnosed with one or more disorders or conditions. In some embodiments, the disorder or condition is or includes cancer, or the presence of one or more tumors. In some embodiments, the patient is undergoing or continuing to undergo a prescribed therapy to diagnose and / or treat the disease, disorder, or condition.
[0053] Penetration enhancer: As used herein, the term "penetration enhancer" refers to an agent whose presence or level correlates with increased penetration of a subject agent through the skin compared to that observed in its absence. In some embodiments, a penetration enhancer is characterized in that it degrades and / or disrupts skin structure. In some embodiments, the penetration enhancer is or includes a chemical agent (e.g., a chemical or enzyme, etc.). For example, chemical agents that may damage, disrupt, and / or decompose one or more keratinous components include, for example, alcohols, such as short-chain alcohols, long-chain alcohols, or polyalcohols; amines and amides, such as urea, amino acids or their esters, amides, AZONE®, derivatives of AZONE®, pyrrolidones, or derivatives of pyrrolidones; terpenes and derivatives of terpenes; fatty acids and their esters; macrocyclic compounds; surfactants; or sulfoxides (e.g., dimethyl sulfoxide (DMSO)), decyl methyl sulfoxide, etc.); surfactants, such as anionic, cationic, and nonionic surfactants; polyols; essential oils; and / or hyaluronidase. In some embodiments, the penetration enhancer may be an irritant in that an inflammatory and / or allergic reaction occurs when the agent is applied to the skin. In some embodiments, the penetration enhancer is not an irritant. In some embodiments, the penetration enhancer may be or may include a chemical agent that does not damage, disrupt, or degrade skin structures, but whose presence or level nonetheless correlates with increased penetration of the agent of interest through the skin compared to that observed in its absence. In some embodiments, the copeptides, carrier molecules, and carrier peptides may be penetration enhancers that do not damage, disrupt, and / or degrade skin structure(s). In some embodiments, the copeptides, carrier molecules, and carrier peptides may be penetration enhancers that do not irritate the skin. The term "penetration enhancer" does not encompass mechanical devices (e.g., needles, scalpels, etc.) or equivalents thereof (e.g., other wound treatments).Additionally, those skilled in the art will understand that structures such as nanoparticles or emulsions are not chemical agents and therefore are not chemical penetration enhancers, even if their presence correlates with enhanced skin penetration of an agent of interest that may be associated with the structure.
[0054] Pharmaceutical composition: As used herein, the term "pharmaceutical composition" refers to a composition in which an active agent is formulated with one or more pharma- ceutical acceptable carriers. In some embodiments, the active agent is present in an amount of a unit dose suitable for administration in a treatment regimen that exhibits a statistically significant likelihood of achieving a predefined therapeutic effect when administered to a relevant population. In some embodiments, the pharmaceutical composition may be specially formulated for administration in solid or liquid form, including those adapted for local administration, e.g., sterile solutions or suspensions, or sustained release formulations as gels, creams, ointments, or controlled release patches or sprays applied to the skin, lungs, or oral cavity; vaginally or rectally, e.g., as pessaries, creams, or foams; sublingually; intraocularly; transdermally; or to nasal, pulmonary, and other mucosal surfaces.
[0055] Pharmaceutically acceptable: As used herein, the term "pharmaceutical acceptable" applied to a carrier, diluent, or excipient used to formulate a composition disclosed herein means that the carrier, diluent, or excipient must be compatible with the other ingredients of the composition and not deleterious to the recipient thereof.
[0056] Pharmaceutically acceptable carrier: As used herein, the term "pharmaceutical acceptable carrier" refers to a pharma-ceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, involved in carrying or transporting a compound of interest from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the subject or patient. Some examples of materials which may function as pharma- ceutically acceptable carriers include sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, medium chain triglycerides, and soybean oil; glycols such as propylene glycol; polyols such as glycerin, sorbitol, mannitol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffer solutions; polyesters, polycarbonates and / or polyanhydrides; and other non-toxic compatible substances used in pharmaceutical formulations.
[0057] Premix: As used herein, the term "premix" refers to any combination of ingredients that are subsequently used to generate a nanoemulsion composition according to the present invention. For example, a premix is any collection of ingredients that, when subjected to high shear forces, generates a nanoemulsion composition according to the present invention. In some embodiments, a premix is a collection of ingredients that, when subjected to high shear forces, generates a nanoemulsion composition, such as a homogenous nanoemulsion composition. A premix often contains a liquid dispersion medium and sufficient other ingredients to generate a nanoemulsion within the dispersion medium. According to some embodiments of the present disclosure, one or more large agents may be included in the premix. According to some embodiments of the present disclosure, one or more biological agents may be included in the premix. According to the present invention, a botulinum toxin may be included in the premix. According to the present invention, one or more antibodies may be included in the premix. In some embodiments, a premix may contain one or more surfactants, penetration enhancers, and / or other agents. In some embodiments, a premix comprises a solution. In some embodiments in which the premix comprises a botulinum toxin, an antibody, another biologically active agent, and / or a penetration enhancer, the botulinum toxin, the antibody, another biologically active agent, and / or the penetration enhancer are in solution before high shear forces are applied to the premix.
[0058] Prevent or prophylaxis: As used herein, when used in relation to the occurrence of a disease, disorder, and / or condition, refers to reducing the risk of developing the disease, disorder, and / or condition and / or delaying the onset of one or more characteristics or symptoms of the disease, disorder, or condition. Prevention may be considered complete when the onset of the disease, disorder, or condition has been delayed for a predefined period of time.
[0059] Protein: As used herein, the term "protein" refers to a polypeptide (i.e., a chain of at least two amino acids linked together by peptide bonds). A protein may contain moieties other than amino acids (e.g., may be a glycoprotein, proteoglycan, etc.) and / or may be otherwise processed or modified. Those skilled in the art will understand that a "protein" may be an entire polypeptide chain (with or without a signal sequence) as produced by a cell, or may be a characteristic portion thereof. Those skilled in the art will understand that a protein may sometimes include multiple polypeptide chains, for example, linked by one or more disulfide bonds or associated by other means. Polypeptides may contain L-amino acids, D-amino acids, or both, and may contain any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, for example, terminal acetylation, amidation, methylation, etc. In some embodiments, a protein may include natural amino acids, unnatural amino acids, synthetic amino acids, and combinations thereof. The term "peptide" is generally used to refer to a polypeptide having a length of less than about 100 amino acids, less than about 50 amino acids, less than 20 amino acids, or less than 10 amino acids. In some embodiments, the protein is an antibody, an antibody fragment, a biologically active portion thereof, and / or a characteristic portion thereof.
[0060] Polypeptide: The term "polypeptide" as used herein generally has its art-recognized meaning of a polymer of at least three amino acids. Those skilled in the art will appreciate that the term "polypeptide" is intended to be general enough to encompass not only polypeptides having the complete sequences listed herein, but also polypeptides that represent functional fragments of such complete polypeptides (i.e., fragments that retain at least one activity). Moreover, those skilled in the art will appreciate that protein sequences generally tolerate some substitutions without destroying activity. Thus, any polypeptide that retains activity and shares at least about 30-40% overall sequence identity, often greater than about 50%, 60%, 70%, or 80%, and more usually includes at least one region of much higher identity (often greater than 90% or even 95%, 96%, 97%, 98%, or 99%) in one or more highly conserved regions that usually encompass at least 3-4 and often up to 20 or more amino acids, with another polypeptide of the same class is encompassed within the related term "polypeptide" as used herein. Polypeptides may contain L-amino acids, D-amino acids, or both, and may contain any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, for example, terminal acetylation, amidation, methylation, and the like. In some embodiments, proteins may contain natural amino acids, unnatural amino acids, synthetic amino acids, and combinations thereof. The term "peptide" is generally used to refer to a polypeptide having a length of less than about 100 amino acids, less than about 50 amino acids, less than 20 amino acids, or less than 10 amino acids. In some embodiments, the protein is an antibody, an antibody fragment, a biologically active portion thereof, and / or a characteristic portion thereof.
[0061] Reference: as used herein refers to a standard or control against which a comparison is made. For example, in some embodiments, an agent, animal, individual, population, sample, regimen, sequence, or value of interest is compared to a reference or control agent, animal, individual, population, sample, regimen, sequence, or value. In some embodiments, the reference or control is tested and / or determined substantially simultaneously with the test or determination of interest. In some embodiments, the reference or control is a historical reference or control, optionally embodied in a tangible medium of expression. Typically, as will be understood by those of skill in the art, the reference or control is determined or characterized under conditions or circumstances equivalent to those under evaluation. Those of skill in the art will understand when there is sufficient similarity to justify reliance on and / or comparison to a particular possible reference or control.
[0062] Self-administration: The term "self-administration" as used herein refers to a situation in which a subject has the ability to administer a composition to himself without the need for medical supervision.In some embodiments of the present invention, self-administration can be carried out outside of a clinical environment.As one example, in some embodiments of the present invention, a facial beauty cream can be administered by a subject in his own home.
[0063] Small molecule: Generally, a "small molecule" is understood in the art to be an organic molecule less than about 5 kilodaltons (Kd) in size. In some embodiments, a small molecule is less than about 3 Kd, 2 Kd, or 1 Kd. In some embodiments, a small molecule is less than about 800 Daltons (D), 600 D, 500 D, 400 D, 300 D, 200 D, or 100 D. In some embodiments, a small molecule is non-polymeric. In some embodiments, a small molecule is not a protein, peptide, or amino acid. In some embodiments, a small molecule is not a nucleic acid or nucleotide. In some embodiments, a small molecule is not a saccharide or polysaccharide.
[0064] Subject: As used herein, "subject" refers to an organism, typically a mammal (e.g., a human, including in some embodiments prenatal human forms). In some embodiments, the subject is afflicted with a relevant disease, disorder, or condition. In some embodiments, the subject is susceptible to a disease, disorder, or condition. In some embodiments, the subject exhibits one or more symptoms or characteristics of a disease, disorder, or condition. In some embodiments, the subject does not exhibit any symptoms or characteristics of a disease, disorder, or condition. In some embodiments, the subject is one who possesses one or more characteristics characteristic of susceptibility or risk of a disease, disorder, or condition. In some embodiments, the subject is a patient. In some embodiments, the subject is an individual for whom diagnosis and / or therapy is and / or has been performed.
[0065] Substantially: As used herein, the term "substantially" refers to a qualitative state exhibiting a total or near total extent or degree of a feature or characteristic of interest. Those skilled in the art of biology will understand that biological and chemical phenomena rarely, if ever, progress to completion and / or do not progress to perfection or achieve or avoid absolute results. As such, the term "substantially" is used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
[0066] Therapeutic Agent: As used herein, the phrase "therapeutic agent" generally refers to any agent that elicits a desired pharmacological effect when administered to an organism. In some embodiments, an agent is considered to be a therapeutic agent if it demonstrates a statistically significant effect across an appropriate population. In some embodiments, the appropriate population may be a population of model organisms. In some embodiments, the appropriate population may be defined by various criteria, such as a given age range, sex, genetic background, pre-existing clinical pathology, etc. In some embodiments, a therapeutic agent is a substance that may be used to alleviate, ameliorate, mitigate, inhibit, prevent, delay the onset, reduce the severity, and / or reduce the incidence of one or more symptoms or characteristics of a disease, disorder, and / or condition. In some embodiments, a "therapeutic agent" is an agent that has been approved or is required to be approved by a government agency before it may be commercially available for administration to humans. In some embodiments, a "therapeutic agent" is an agent that requires a medical prescription for administration to humans. In some embodiments, an agent is not considered to be a "therapeutic agent" if it merely facilitates the delivery of a different agent that actually achieves the desired effect.
[0067] Therapeutically effective amount: as used herein, refers to an amount that produces a desired effect when administered. In some embodiments, the term refers to an amount sufficient to treat a disease, disorder, and / or condition when administered to a population suffering from or susceptible to the disease, disorder, and / or condition according to a therapeutic dosing regimen. In some embodiments, a therapeutically effective amount is one that reduces the incidence and / or severity and / or delays the onset of one or more symptoms of the disease, disorder, and / or condition. Those skilled in the art will appreciate that the term "therapeutically effective amount" does not actually require that successful treatment is achieved in a particular individual. Rather, a therapeutically effective amount may be an amount that provides a particular desired pharmacological response in a significant number of subjects when administered to a patient in need of such treatment. In some embodiments, reference to a therapeutically effective amount may be a reference to an amount measured in one or more specific tissues (e.g., tissues affected by a disease, disorder, or condition) or bodily fluids (e.g., blood, saliva, serum, sweat, tears, urine, etc.). One of skill in the art will appreciate that in some embodiments, a therapeutically effective amount of a particular agent or therapy may be formulated and / or administered in a single dose, while in some embodiments, a therapeutically effective agent may be formulated and / or administered in multiple doses, e.g., as part of a dosing regimen.
[0068] Therapeutic regimen: "Therapeutic regimen," as that term is used herein, refers to a dosing regimen whose administration across a relevant population can be correlated with a desired or beneficial therapeutic outcome.
[0069] Treatment: As used herein, the term "treatment" (also "treat" or "treating") refers to any administration of therapy that partially or completely relieves, ameliorates, alleviates, inhibits, delays the onset, reduces the severity, and / or reduces the incidence of one or more symptoms, characteristics, and / or causes of a particular disease, disorder, and / or condition. In some embodiments, such treatment may be of a subject who does not exhibit symptoms of the relevant disease, disorder, and / or condition, and / or of a subject who exhibits only early signs of the disease, disorder, and / or condition. Alternatively or additionally, such treatment may be of a subject who exhibits one or more established signs of the relevant disease, disorder, and / or condition. In some embodiments, treatment may be of a subject who has been diagnosed as suffering from the relevant disease, disorder, and / or condition. In some embodiments, treatment may be of a subject who is known to have one or more susceptibility factors that are statistically correlated with an increased risk of developing the relevant disease, disorder, and / or condition.
[0070] Uniform: The term "uniform," as used herein with respect to nanoemulsion compositions, refers to a nanoemulsion composition in which the individual droplets have a particular range of droplet diameter sizes. For example, in some embodiments, a uniform nanoemulsion composition is one in which the difference between the smallest diameter and the largest diameter is no more than about 300 nm, 250 nm, 200 nm, 150 nm, 100 nm, 90 nm, 80 nm, 70 nm, 60 nm, 50 nm, or less. In some embodiments, the droplets (e.g., large drug-containing droplets) within a uniform large drug nanoemulsion composition of the invention have a diameter less than about 300 nm, 250 nm, 200 nm, 150 nm, 130 nm, 120 nm, 115 nm, 110 nm, 100 nm, 90 nm, 80 nm, or less. In some embodiments, the droplets (e.g., large drug-containing droplets) within a uniform large drug nanoemulsion composition of the invention have a diameter within the range of about 10 to about 300 nanometers. In some embodiments, the droplets within the large uniform drug nanoemulsion compositions of the invention have diameters within the range of about 10-300, 10-200, 10-150, 10-130, 10-120, 10-115, 10-110, 10-100, or 10-90 nm. In some embodiments, the droplets (e.g., large drug-containing droplets) within the large drug nanoemulsion compositions of the invention have an average droplet size that is less than about 300, 250, 200, 150, 130, 120, or 115, 110, 100, or 90 nm. In some embodiments, the average droplet size is within the range of about 10-300, 50-250, 60-200, 65-150, 70-130 nm. In some embodiments, the average droplet size is about 80-110 nm. In some embodiments, the average droplet size is about 90-100 nm. In some embodiments, a majority of droplets (e.g., large drug-containing droplets) within a homogenous nanoemulsion composition of the invention have diameters less than a particular size or within a particular range, in some embodiments, the majority is greater than 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.6%, 99.7%, 99.8%, 99.9% or more of the droplets in the composition.In some embodiments of the invention, a homogenous nanoemulsion composition is achieved by microfluidization of the sample.
[0071] DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS Transdermal Drug Delivery In some embodiments, the present invention provides techniques for transdermal administration of large agents (e.g., botulinum toxin, antibodies). In some embodiments, the present disclosure teaches that particularly advantageous results are achieved when microneedle processing techniques are combined with emulsion compositions. In some embodiments, microneedle processing techniques are combined with lotions, creams, or liquid compositions that may subsequently become or include emulsion compositions (e.g., macroemulsion and / or nanoemulsion compositions). In some embodiments, the provided techniques do not utilize penetration enhancers. In some embodiments, the provided techniques do not utilize chemical penetration enhancers that damage, disrupt, and / or break down the skin. In some embodiments, the provided techniques do not utilize chemical penetration enhancers.
[0072] Human skin comprises the dermis and the epidermis. The epidermis has several tissue layers, namely the stratum corneum, the stratum lucidum, the stratum granulosum, the stratum spinosum, and the stratum basale (identified in order from the outer surface of the skin inwards).
[0073] The stratum corneum presents the most significant obstacle in general, and perhaps in particular, in the transdermal delivery of large drugs. The stratum corneum is typically about 10-15 μm thick, and it consists of flattened keratised cells (keratinocytes) arranged in several layers. The intercellular spaces between the keratinocytes are filled with lipid structures, which may play an important role in the penetration of substances through the skin (Bauerova et al., 2001, European Journal of Drug Metabolism and Pharmacokinetics, 26:85).
[0074] The remainder of the epidermis below the stratum corneum is approximately 150 μm thick. The dermis is approximately 1-2 mm thick and lies below the epidermis. The dermis is innervated by various capillaries and nerve processes.
[0075] Transdermal administration continues to be the subject of research in an attempt to provide alternative routes of administration that do not have the undesirable consequences associated with injections and oral delivery in general. For example, needles often cause localized pain and potentially expose the patient receiving the injection to blood-borne diseases. Oral administration often suffers from poor bioavailability of the drug due to the extremely acidic environment of the patient's stomach.
[0076] In an attempt to overcome these shortcomings by providing non-invasive administration, efforts have been made to develop transdermal administration techniques for certain pharmaceuticals. In transdermal administration, it is generally desirable to minimize damage to the patient's skin. Therefore, transdermal administration can reduce or eliminate the pain associated with injections, reduce the possibility of blood contamination, and improve the bioavailability of drugs when they are incorporated systemically.
[0077] Traditionally, attempts at transdermal administration have focused on disrupting and / or disintegrating the stratum corneum. Some attempts have included the use of chemical penetration enhancers. Penetration enhancers may function to disrupt and / or disintegrate skin structures. In some embodiments, the penetration enhancer is or includes a chemical agent (e.g., a chemical or enzyme that can disrupt and / or degrade one or more stratum corneum components). In some embodiments, the penetration enhancer may be an irritant in that an inflammatory and / or allergic reaction occurs when the agent is applied to the skin.
[0078] "However, the main limitation of penetration enhancers is that their efficacy is often closely associated with the occurrence of skin irritation." Alkilani, AZ, et al., "Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum." Pharmaceutics. 7:438-470 (2015). Penetration enhancers tend to have poor efficacy and safety profiles. "They do not achieve the desired skin breakdown and their ability to increase transport through the skin is low and variable." Ibid.
[0079] Some attempts have included using mechanical devices to bypass or remove parts of the stratum corneum. Attempts have also included using ultrasound or iontophoresis to facilitate the infiltration of pharmaceuticals through the skin. In most cases, the goal remains to make pharmaceuticals, typically small molecules, available so that they can pass through the capillary bed in the dermis, where they can be systemically incorporated into the subject to achieve a therapeutic effect. These methods are limited by the amount of energy that can be applied to the skin without causing discomfort and / or skin damage.
[0080] Transdermal Delivery of Large Molecules Microneedle processing technology has been shown to facilitate transdermal delivery of a variety of small drugs, such as calcein (about 623 Da), desmopressin (about 1070 Da), diclofenac (about 270 Da), methyl nicotinate (about 40 Da), bischloroethylnitrosourea (about 214 Da), insulin (about 5.8 KDa), bovine serum albumin (about 66.5 KDa) and ovalbumin (about 45 KDa), however, until the present disclosure, delivery of larger drugs, especially those above 100 KDa, remained problematic.
[0081] It is recognized that transdermal delivery of large molecules poses significant challenges. Until the present disclosure, microneedle treatment, and in particular microneedle skin preconditioning, was not thought to affect or result in transdermal administration of large drugs. For example, a study of the use of solid microneedles for the delivery of four hydrophilic peptides of low molecular weight, tetrapeptide-3 (456.6 Da); hexapeptide (498.6 Da); acetyl hexapeptide-3 (889 Da); and oxytocin (1007.2 Da), as well as L-carnitine (161.2 Da), showed that while microneedle pretreatment significantly enhanced the penetration of each of these peptides, the skin penetration of the peptides was dependent on their molecular weight, decreasing as the molecular weight increased. Zhang, S., et al., “Enhanced delivery of hydrophilic peptides in vitro by transdermal microneedle pretreatment.” Acta Pharmaceutica Sinica B.4(1):100-104(2014).
[0082] When sandpaper abrasion, tape stripping, and single puncture hypodermic needle models of MSCs were compared in a study of the effect of molecular size of larger FITC (fluorescein isothiocyanate)-conjugated molecules on transdermal delivery, it was found that all methods, as tested on untreated skin, again showed a decrease in transdermal drug delivery with increasing size of the tested molecule (4.3, 9.6, and 42.0 KDa FITC conjugates). Tape stripping was the most effective technique, while sandpaper abrasion was found to be the most damaging to the skin. Wu, X., et al., “Effects of pretreatment of needle puncture and sandpaper abrasion on the in vitro skin permeation of fluorescein isothiocyanate (FITC)-dextran.” International Journal of Pharmaceutics. 316:102-108 (2006).
[0083] Other studies have attempted to deliver even larger molecules: Cascade Blue (CB, Mw 538), Dextran-Cascade Blue (DCB, Mw 10 kDa), and FITC-conjugated dextran (FITC-Dex, Mw 72 kDa). In those studies, microneedles of various lengths (300, 550, 700 or 900 μm) were used to pierce dermatomed human skin and evaluate the diffusion of each of the aforementioned compounds. Transport of each of the compounds was seen in all but the 300 μm microneedle array, although degradation of DCB and FITC-Dex was observed.
[0084] As the prior art demonstrates, as molecular size increases, transdermal penetration using MSCs ("microneedle skin preparation") decreases to the extent that it becomes insignificant or even non-existent. Even in those cases where some insignificant penetration was observed, the larger molecules were observed to degrade and become biologically inactive. Thus, until the present invention, one skilled in the art would have predicted that even with the use of mechanical or chemical penetration enhancers, a large agent such as botulinum, approximately 150 KDa and more than twice the size of FITC-Dex, would have no penetration at all, let alone bioavailability of the intact active agent. Botulinum is a complex protein that requires three regions or functional parts to be intact for the protein to be biologically active. Therefore, damage to any one of the three regions of the protein renders the protein biologically inactive. According to Johnson, E. et al., "Botulinum toxin is highly susceptible to denaturation due to surface denaturation, heat, and alkaline conditions." U.S. Patent Publication No. 5,512,547. Therefore, under the microneedle processing conditions described by Wu, a significant level of degradation and inactivation of botulinum would be expected.
[0085] In particular, the present disclosure demonstrates that microneedle processing techniques can enhance transdermal delivery (e.g., of large drugs, particularly from macroemulsion or nanoemulsion compositions) when other penetration enhancers, particularly disintegrants, are not utilized (i.e., chemical penetration enhancers are not utilized and other techniques that disrupt or puncture skin structures are not utilized).
[0086] Microneedle treatment The present disclosure provides the surprising finding that MSCs can surprisingly improve the transdermal delivery of large drugs. In some embodiments, the large drugs can be formulated as creams and / or lotions. In some embodiments, the large drugs can be combined with one or more biologically active agents. In some embodiments, the large drugs can be formulated as or in emulsion (e.g., as macroemulsions or as nanoemulsions) compositions. In some embodiments, emulsions containing one or more large drugs can be formulated as creams and / or lotions.
[0087] In some embodiments, microneedle (MN) arrays for use according to the present disclosure are, or share characteristics with, minimally invasive systems developed to overcome some of the drawbacks commonly associated with the use of hypodermic and subcutaneous needles and to improve patient comfort and compliance. Such drawbacks include, for example, the potential for misplacement of the needle tip with hypodermic needles due to the medical professional's inability to visualize where exactly the needle will go; such needle misplacement can cause adverse reactions such as droopy eyelids ("ptosis") when botulinum is injected inaccurately into the face. MNs would be less prone to such problems. Other advantages of MNs are that they do not cause bleeding, may minimize the introduction of pathogens through the holes created by MNs, and may eliminate transdermal dosing variability. Other advantages are the possibility of self-administration, reduced risk of accidental needlestick injury, reduced risk of transmission of infectious diseases, and ease of disposal. In some embodiments, the MNs are a plurality of microprojections assembled on one side of a support, such as a patch or a device (eg, a stamp, roller, array, applicator, pen).
[0088] In some embodiments, MNs for use according to the present disclosure may be designed and / or configured in an array to improve skin contact and facilitate penetration into the skin. In some embodiments, the MNs utilized are of suitable length, width and shape to minimize contact with nerves when inserted into the skin while still creating an efficient pathway for drug delivery. Alkilani, AZ, et al., "Transdermal drug delivery: Innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum." Pharmaceutics. 7: 438-470 (2015).
[0089] In some embodiments, suitable MNs can be solid, coated, porous, dissolvable, hollow, or hydrogel MNs. Solid MNs create micropores in the skin, thereby increasing the transport of drug formulations (e.g., the "poke and stick" method). Coated MNs allow for rapid dissolution of the coated drug into the skin (e.g., the "coat and poke" method). Dissolvable MNs allow for rapid and / or controlled release of drugs incorporated within the microneedles. Hollow MNs can be used to puncture the skin and allow release of the composition after active injection or diffusion of the formulation through the microneedle holes (e.g., the "poke and flush" method). In the case of dissolvable MNs, the MNs can act as drug depots and hold the drug composition until released by dissolution in the case of dissolvable MNs or swelling in the case of hydrogel MNs (e.g., the "poke and release" method). However, as previously described herein, in many embodiments, large drugs are not delivered by injection through one or more microneedles. That is, in many embodiments, any microneedles utilized in accordance with such embodiments are not coated, loaded, or configured with a large agent in any manner that would achieve delivery of the large agent. Alternatively, in some embodiments, as described herein, MNs (whether MSCs or not) utilized in accordance with the present disclosure may contain and / or deliver a large agent when the large agent is formulated in a macro- or nanoemulsion composition as described herein. Thus, as would be understood by one of skill in the art reading the specification contained herein, treatment of the skin with a microneedle(s) that delivers a large agent (e.g., by injection through the microneedle, by release of a microneedle coating, or by release from a dissolving microneedle) is not a microneedle skin preparation.
[0090] In some embodiments, the microneedle has a constant diameter throughout the length of the microneedle. In some embodiments, the diameter of the microneedle is greatest at the proximal end of the microneedle. In some embodiments, the microneedle tapers to a point at the end distal to the base of the microneedle. In some embodiments, the microneedle may be solid. In some embodiments, the microneedle may be hollow. In some embodiments, the microneedle may be tubular. In some embodiments, the microneedle may be sealed at one end. In some embodiments, the microneedle is part of an array of microneedles. In some embodiments, the microneedle may have a length of about 1 μm to about 4,000 μm. In some embodiments, the microneedle may have a length of about 1 μm to about 2,000 μm. In some embodiments, the microneedle may have a length of about 50 μm to about 400 μm. In some embodiments, the microneedle may have a length of about 800 μm to about 1500 μm.
[0091] In some embodiments, MNs for use according to the present disclosure may be constructed from a variety of materials using techniques including, but not limited to, micromolding processes or lasers. In some embodiments, MNs may be manufactured using a variety of types of biocompatible materials including polymers, metals, ceramics, semiconductors, organics, composites, or silicon. Unless they are designed to detach and dissolve in the skin, in some embodiments, the microneedles have the mechanical strength to remain intact while being inserted into the skin and / or removed from the skin after insertion to deliver drugs or collect biological fluids. In some embodiments, the MNs can remain in place for up to many days before removal intact. In some embodiments, the microneedles may be sterilizable using standard techniques. In some embodiments, the MNs are biodegradable. In some embodiments, the MNs comprise polymeric materials. In some embodiments, the polymeric material comprises poly-L-lactic acid, polyglycolic acid, polycarbonate, polylactic-co-glycolic acid (PLGA), polydimethylsiloxane, polyvinylpyrrolidone (PVP), copolymers of methyl vinyl ether and maleic anhydride, sodium hyaluronate, carboxymethylcellulose, maltose, dextrin, galactose, starch, gelatin, or combinations thereof.
[0092] MN arrays and MSC devices suitable for use in combination with compositions containing large drugs for transdermal delivery of large drugs include devices such as those described in U.S. Pat. Nos. 6,334,856; 6,503,231; 6,908,453; 8,257,324; and 9,144,671.
[0093] Blockbuster drugs In some embodiments, the compositions provided and / or utilized as described herein include one or more large agents. In some embodiments, the large agent utilized is a biologically active agent (e.g., a therapeutically active agent). In particular, the present disclosure provides strategies for locally administering compositions including large agents in combination with MSCs.
[0094] 1. Protein preparations Any of a variety of protein agents may be incorporated into the provided compositions and administered in combination with MSCs. In some embodiments, the protein agent may be a peptide agent. In some embodiments, the peptide has a molecular weight of more than 100 KDa. In some embodiments, the peptide agent has a molecular weight of at least 150 KDa. In some embodiments, the peptide agent is composed only of naturally occurring amino acids. In some embodiments, the peptide agent includes one or more non-naturally occurring amino acids.
[0095] (i) Botulinum toxin In some embodiments, the macro agent can be a botulinum toxin. Botulinum toxin (BTX) BTX is naturally produced by the anaerobic gram-positive bacillus Clostridium botulinum and is a potent polypeptide neurotoxin. Most notably, BTX causes a neuroparalytic illness in humans and animals called botulism. BTX can apparently cross the lining of the digestive tract and attack peripheral motor neurons. Symptoms of botulinum toxin poisoning can progress from difficulty walking, swallowing, and speaking to paralysis of the respiratory muscles and death.
[0096] The molecular weight of the botulinum toxin protein molecule for all seven known botulinum toxin serotypes is approximately 150 kDa. Botulinum toxins are released by Clostridium bacteria as complexes containing the 150 kDa botulinum toxin protein molecule along with associated non-toxin proteins. Thus, the BTX-A complex can be produced by Clostridium bacteria as 900 kDa, 500 kDa and 360 kDa forms. Botulinum toxin types B and C1 are apparently produced only as the 500 kDa complex. Botulinum toxin type D is produced as both a 300 kDa and a 500 kDa complex. Finally, botulinum toxin types E and F are produced only as approximately the 300 kDa complex.
[0097] BTX complexes (i.e., those compositions having a molecular weight greater than about 150 kDa) are believed to contain a non-toxin hemagglutinin protein and a non-toxin, non-toxic non-hemagglutinin protein. These two non-toxin proteins (which together comprise the botulinum toxin molecule and the associated neurotoxin complex) may act to provide stability to the botulinum toxin molecule against denaturation and protection against digestive acids when the toxin is ingested.
[0098] Either the BTX protein or the BTX complex may be utilized as a known therapeutic agent and / or an independently active biologically active agent in accordance with the present invention. Indeed, it will be understood by those of skill in the art that any portion or fragment of the BTX protein or complex that retains the appropriate activity may be utilized as described herein.
[0099] In some embodiments, the botulinum toxin may be selected from the group consisting of types A, Ab, Af, B, Bf, C1, C2, D, E, F, and G; mutants thereof; variants thereof; fragments thereof; characteristic portions thereof; and / or fusions thereof. In some embodiments, the botulinum toxin is present as any of the subtypes described in Sakaguchi, 1982, Pharmacol. Ther., 19:165; and / or Smith et al., 2005, Infect. Immun., 73:5450, both of which are incorporated herein by reference.
[0100] In some embodiments, the present invention provides a botulinum toxin composition. In some embodiments, the present invention provides a nanoemulsion botulinum toxin composition. Commercially available sources of botulinum toxin that may be utilized in accordance with the present invention include, but are not limited to, BOTOX®, DYSPORT® (Clostridium botulinum type A toxin hemagglutinin complex with human serum albumin and lactose; Ispen Limited, Berkshire UK), Xeomin®, PurTox®, Medy-Tox, NT-201 (Merz Pharmaceuticals), and / or MYOBLOC® (injectable solution of botulinum toxin type B, human serum albumin, sodium succinate, and sodium chloride, pH 5.6, Elan Pharmaceuticals, Dublin, Ireland), NEURONOX (Medytox), HENGLI (Lanzhou Institute), and the like. Those skilled in the art will be aware of the standard and / or approved administration regimens for such commercially available botulinum toxin compositions, and will understand that any such relevant compositions and / or regimens may be utilized in conjunction with microneedle processing technology (e.g., particularly MSCs) as described herein.
[0101] In some embodiments, provided compositions comprising botulinum toxin compositions and formulated as creams and / or lotions contain from about 1 to about 50,000 units of botulinum toxin per mL. In some embodiments, provided compositions comprising botulinum toxin compositions and formulated as creams and / or lotions contain from about 500 to about 20,000 units of botulinum toxin per mL. In some embodiments, provided compositions comprising botulinum toxin compositions and formulated as creams and / or lotions contain from about 100 to about 2,000 units of botulinum toxin per mL. In some embodiments, provided compositions comprising botulinum toxin compositions and formulated as creams and / or lotions contain from about 50 to about 500 units of botulinum toxin per mL. In some embodiments, provided compositions comprising botulinum toxin compositions and formulated as creams and / or lotions contain from about 25 to about 400 units of botulinum toxin per mL.
[0102] In some embodiments, the botulinum toxin composition comprises about 2 to about 40,000 units of botulinum toxin per mL. In some embodiments, the botulinum toxin composition comprises about 2 to about 12,000 units of botulinum toxin per mL. In some embodiments, the botulinum toxin composition comprises about 100 to about 2,000 units of botulinum toxin per mL. In some embodiments, the botulinum toxin composition comprises about 50 to about 1,000 units of botulinum toxin per mL.
[0103] In some embodiments, the botulinum toxin composition includes at least one biologically active agent other than a botulinum toxin. Alternatively or additionally, in some embodiments, the botulinum composition is administered in combination with at least one other composition that includes such a biologically active agent. In some embodiments, the botulinum composition is administered in combination with a penetration enhancer. In some embodiments, the botulinum composition is administered in combination with another biologically active agent. In some embodiments, the botulinum composition is administered in combination with another biologically active agent and a penetration enhancer.
[0104] In some embodiments, biologically active agents utilized in combination with the botulinum toxins described herein can be agents that act on or in the skin and / or impart a therapeutic and / or cosmetic effect. For example, in some embodiments, such biologically active agents can be selected from therapeutic agents such as anesthetics (e.g., lidocaine), steroids (e.g., hydrocortisone), and / or retinoids (e.g., Retin A), cosmetic agents such as dermal fillers, collagen, and / or silicones. In some embodiments, the botulinum compositions are administered in combination with a delivery modifier, such as a penetration enhancer (which in some embodiments is not an irritant and / or does not degrade, disrupt, and / or damage the skin structure(s) and / or skin).
[0105] In some embodiments, the non-irritating penetration enhancer may be selected from, for example, a copeptide, a carrier molecule, and a carrier peptide. In some embodiments, the carrier molecule is positively charged. In some embodiments, the carrier molecule may be a copeptide. In some embodiments, the carrier molecule may be a long chain positively charged polypeptide or a positively charged non-peptidyl polymer, such as a polyalkyleneimine. In some embodiments, the carrier peptide may be a cationic peptide. In some embodiments, the carrier peptide may be a peptide having the sequence RKKRRQRRRG-(K) 15-GRKKRRQRRR is a positively charged carrier. In some embodiments, the carrier molecule can be one disclosed in U.S. Patent Publication No. 2010 / 0168023 or U.S. Patent Publication No. 2009 / 0247464, the contents of which are incorporated herein by reference in their entireties.
[0106] In some embodiments, provided compositions, including both a botulinum toxin nanoemulsion composition and a cream and / or lotion formulation, contain from about 1 to about 50,000 units of botulinum toxin per mL. In some embodiments, provided compositions, including both a nanoemulsion composition and a cream and / or lotion formulation, contain from about 500 to about 20,000 units of botulinum toxin per mL. In some embodiments, provided compositions, including both a nanoemulsion composition and a cream and / or lotion formulation, contain from about 100 to about 2,000 units of botulinum toxin per mL. In some embodiments, provided compositions, including both a botulinum toxin nanoemulsion composition and a cream and / or lotion formulation, contain from about 50 to about 500 units of botulinum toxin per mL. In some embodiments, provided compositions, including both a botulinum toxin nanoemulsion composition and a cream and / or lotion formulation, contain from about 25 to about 400 units of botulinum toxin per mL.
[0107] In some embodiments, the botulinum toxin nanoemulsion composition comprises from about 2 to about 40,000 units of botulinum toxin per mL. In some embodiments, the botulinum toxin nanoemulsion composition comprises from about 2 to about 12,000 units of botulinum toxin per mL. In some embodiments, the botulinum toxin nanoemulsion composition comprises from about 100 to about 2,000 units of botulinum toxin per mL. In some embodiments, the botulinum toxin nanoemulsion composition comprises from about 50 to about 1,000 units of botulinum toxin per mL.
[0108] (ii) antibody drug In some embodiments, the present disclosure relates to the delivery of antibody drugs. In some embodiments, the large drug may be an antibody or a fragment or derivative thereof. In particular, the present disclosure provides certain compositions comprising antibody drugs, and also provides techniques for the administration of compositions comprising antibody drugs, such administration being combined with MSCs.
[0109] In some embodiments, the antibody drug may be suitable for treating a skin condition. In some embodiments, the antibody drug may be a fusion protein. In some embodiments, the antibody drug may be conjugated to another moiety. In some embodiments, the antibody drug may be conjugated to polyethylene glycol.
[0110] In some embodiments, the antibody drug targets TNFα (e.g., comprises an epitope binding element found in anti-TNFα antibodies such as infliximab, adalimumab, golimumab, etanercept, etanercept-szzs, and / or certolizumab pegol). In some embodiments, the antibody drug targets CD2 (e.g., comprises an epitope binding element found in anti-CD2 antibodies such as siplizumab). In some embodiments, the antibody drug targets CD4 (e.g., comprises an epitope binding element found in anti-CD4 antibodies such as zanolimumab).
[0111] In some embodiments, the antibody agent targets IL-12 (e.g., comprises an epitope binding element found in an anti-IL-12 antibody, such as briakinumab). In some embodiments, the antibody agent targets IL-17 (e.g., comprises an epitope binding element found in an anti-IL-17 antibody, such as secukinumab and / or brodalumab). In some embodiments, the antibody agent targets IL-22 (e.g., comprises an epitope binding element found in an anti-IL-22 antibody, such as fezakinumab). In some embodiments, the antibody agent targets IL-23 (e.g., comprises an epitope binding element found in ustekinumab and / or guselkumab, etc.).
[0112] In some embodiments, the antibody drug composition includes at least one biologically active agent other than the antibody drug. Alternatively or additionally, in some embodiments, the antibody drug composition is administered in combination with at least one other composition including such a biologically active agent. In some embodiments, the antibody drug composition is administered in combination with a penetration enhancer. In some embodiments, the antibody drug composition is administered in combination with another biologically active agent. In some embodiments, the antibody drug composition is administered in combination with another biologically active agent and a penetration enhancer. In some embodiments, the antibody drug composition is a nanoemulsion. In some embodiments, the antibody drug composition is a cream and / or lotion formulation.
[0113] In some embodiments, biologically active agents utilized in combination with the antibody drugs described herein can be agents that act on or in the skin and / or impart a therapeutic and / or cosmetic effect. For example, in some embodiments, such biologically active agents can be selected from therapeutic agents such as anesthetics (e.g., lidocaine), steroids (e.g., hydrocortisone), and / or retinoids (e.g., Retin A), cosmetic agents such as dermal fillers, collagen, and / or silicones. In some embodiments, the antibody drug composition is administered in combination with a delivery modifier such as a penetration enhancer (which in some embodiments is not an irritant and / or does not degrade, disrupt and / or damage the skin structure(s) and / or skin).
[0114] In some embodiments, the non-irritating penetration enhancer may be selected from, for example, a copeptide, a carrier molecule, and a carrier peptide. In some embodiments, the carrier molecule is positively charged. In some embodiments, the carrier molecule may be a copeptide. In some embodiments, the carrier molecule may be a long chain positively charged polypeptide or a positively charged non-peptidyl polymer, such as a polyalkyleneimine. In some embodiments, the carrier peptide may be a cationic peptide. In some embodiments, the carrier peptide may be a peptide having the sequence RKKRRQRRRG-(K) 15-GRKKRRQRRR is a positively charged carrier. In some embodiments, the carrier molecule can be one disclosed in U.S. Patent Publication No. 2010 / 0168023 or U.S. Patent Publication No. 2009 / 0247464, the contents of which are incorporated herein by reference in their entireties.
[0115] 2. Preventive drugs Any of a variety of prophylactic agents may be incorporated into the compositions provided and administered in combination with the MSCs of the present invention. In some embodiments, prophylactic agents include, but are not limited to, vaccines. In some embodiments, vaccines may include isolated proteins or peptides, inactivated organisms and viruses, killed organisms and viruses, genetically modified organisms or viruses, and cell extracts. In some embodiments, prophylactic agents may be combined with interleukins, interferons, cytokines, and adjuvants, such as cholera toxin, alum, Freund's adjuvant, and the like. In some embodiments, the prophylactic agent includes Streptococcus pnuemoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyrogenes, Corynebacterium diphtheriae, Listeria monocytogenes, Bacillus anthracis, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Neisseria meningitidis, Neisseria gonorrhoeae, Streptococcus mutans, Pseudomonas aeruginosa, Salmonella typhi, Haemophilus parainfluenzae, Bordetella pertussis, Francisella tularensis, Yersinia pestis, Vibrio cholerae, Legionella pneumophila, Mycobacterium tuberculosis, Mycobacterium leprae, Treponema pallidum, Leptospirosis antigens from bacterial organisms such as B. interrogans, Borrelia burgdorferi, and Camphylobacter jejuni;Antigens of viruses such as smallpox, influenza A and B, respiratory syncytial virus, parainfluenza, measles, HIV, varicella zoster, herpes simplex types 1 and 2, cytomegalovirus, Epstein-Barr virus, rotavirus, rhinovirus, adenovirus, papillomavirus, poliovirus, mumps, rabies, rubella, coxsackievirus, equine encephalitis, Japanese encephalitis, yellow fever, Rift Valley fever, hepatitis A, B, C, D, and E viruses; Cryptococcus neoformans, Histoplasma capsulatum, Candida albicans, Candida tropicalis, Nocardia asteroides, Rickettsia ricketsii, Rickettsia typhi, Mycoplasma pneumoniae, Chlamydial psittaci, Chlamydial trachomatis, Plasmodium falciparum, Trypanosoma Antigens may include fungal, protozoan, and parasitic antigens such as B. brucei, Entamoeba histolytica, Toxoplasma gondii, Trichomonas vaginalis, Schistosoma mansoni, etc. In some embodiments, these antigens may be in the form of whole killed organisms, peptides, proteins, glycoproteins, carbohydrates, or combinations thereof;
[0116] Those skilled in the art will recognize that the preceding paragraphs provide an exemplary, but not exhaustive, list of agents that may be delivered using the techniques according to the present invention. Any agent may be associated with the compositions provided in accordance with the present invention.
[0117] Topical preparations The compositions described herein are particularly useful in that they can be used to deliver large drugs to a subject in need thereof via topical and / or transdermal (e.g., by lotion, cream, powder, ointment, liniment, gel, drops, etc.) administration. In some embodiments, the provided cream and / or lotion formulations containing large drugs are administered to a subject in need thereof via topical and / or transdermal (e.g., by lotion, cream, powder, ointment, liniment, gel, drops, etc.) administration.
[0118] In some embodiments, the cream and / or lotion formulation comprises purified water, methylparaben, mineral oil, isopropyl myristate, white petrolatum, emulsifying wax, and propylparaben.In some embodiments, the cream and / or lotion formulation comprises purified water, mineral oil, isopropyl myristate, white petrolatum, and emulsifying wax.
[0119] In some embodiments, the present invention provides certain cream and / or lotion formulations described herein. In some embodiments, the provided cream and / or lotion formulations include water. In some embodiments, the provided cream and / or lotion formulations include methylparaben. In some embodiments, the provided cream and / or lotion formulations include mineral oil. In some embodiments, the provided cream and / or lotion formulations include isopropyl myristate. In some embodiments, the provided cream and / or lotion formulations include white petrolatum. In some embodiments, the provided cream and / or lotion formulations include emulsifying wax. In some embodiments, the provided cream and / or lotion formulations include propylparaben. In some embodiments, the provided cream and / or lotion formulations do not include any parabens. In some embodiments, the provided cream and / or lotion formulations do not include methylparaben. In some embodiments, the provided cream and / or lotion formulations do not include propylparaben. Exemplary lotion formulations are provided in Table 1. [Table 1]
[0120] In some embodiments, the cream and / or lotion formulations may be useful for topical and / or transdermal administration. The present invention encompasses the recognition that the cream and / or lotion formulations provided may be particularly useful for delivery of agents to the dermal layer of the skin. In some embodiments, the cream and / or lotion formulations provided are formulated for topical and / or transdermal delivery to a subject in need thereof. In some embodiments, the cream and / or lotion formulations provided are administered to a subject in need thereof via topical and / or transdermal delivery.
[0121] In some embodiments, the provided compositions are formulated with cosmetically acceptable ingredients. For example, in some embodiments, the provided compositions are formulated with water and any cosmetically acceptable solvents, in particular monoalcohols, such as alkanols having 1-8 carbon atoms (such as ethanol, isopropanol, benzyl alcohol and phenylethyl alcohol), polyalcohols, such as alkylene glycols (such as glycerin, ethylene glycol and propylene glycol), and glycol ethers, such as mono-, di-, and tri-ethylene glycol monoalkyl ethers, such as ethylene glycol monomethyl ether and diethylene glycol monomethyl ether, used alone or in mixtures. Such ingredients may be present, for example, in a proportion of up to 60%, 70%, 80%, or even 90% by weight based on the weight of the total composition.
[0122] In some embodiments, provided compositions for topical administration include one or more cosmetically acceptable ingredients that impart desirable or suitable appearance characteristics to the subject to which the composition is to be applied (e.g., a matte appearance that may be particularly desirable or suitable for administration to subjects with oily skin).
[0123] In some embodiments, provided compositions are formulated with at least one cosmetically acceptable filler material to obtain a matte product, which may be particularly desirable, for example, for individuals with oily skin.
[0124] In some embodiments, the large drug is formulated into a composition suitable for local administration. Exemplary large drugs include those described herein. In some embodiments, the provided compositions may be formulated and delivered in combination with MSCs to achieve systemic delivery; in some embodiments, the provided compositions may be formulated and / or delivered to achieve local, but not systemic, delivery.
[0125] In some embodiments, a composition suitable for topical formulation comprises a penetration enhancer. In some embodiments, the penetration enhancer degrades, disrupts and / or damages the skin structure(s) and / or skin. In some embodiments, the penetration enhancer does not degrade, disrupt and / or damage the skin structure(s) and / or skin. In some embodiments, the penetration enhancer is an irritant. In some embodiments, the penetration enhancer is not an irritant.
[0126] The present disclosure specifically demonstrates the effective and efficient delivery of therapeutic agents (and in particular large biological agents such as botulinum toxin and / or antibody agents) to the dermis using the compositions provided in combination with MSCs. For example, in some embodiments, the present invention provides methods that include administration of the compositions described herein without clinically significant side effects. By way of example only, when local delivery is contemplated, clinically significant side effects include, but are not limited to, undesirable systemic side effects, damage to nerve tissue underlying the dermis (e.g., nerve paralysis), undesirable effects on muscles (e.g., muscle paralysis), and / or undesirable blood levels of the therapeutic agent.
[0127] Those skilled in the art will understand that the provided compositions can be incorporated into devices such as, for example, patches. A variety of transdermal patch structures are known in the art; those skilled in the art will understand that the provided compositions can be easily incorporated into any of a variety of such structures. In some embodiments, the transdermal patch can include multiple needles extending from one side of the patch that is applied to the skin, and the needles extend from the patch and protrude through the stratum corneum of the skin. In some embodiments, the needles do not rupture blood vessels. In some embodiments, the needles do not penetrate deep enough to reach nerves in the dermis of the skin.
[0128] In some embodiments, the transdermal patch comprises an adhesive. Some examples of adhesive patches are well known (see, for example, U.S. Design Patent No. 296,006; and U.S. Patent Nos. 6,010,715; 5,591,767; 5,008,110; 5,683,712; 5,948,433; and 5,965,154; all of which are incorporated herein by reference). Adhesive patches are generally characterized as having an adhesive layer that is applied to the skin of a patient, a depot or carrier for holding the composition provided, and an outer surface that prevents the composition provided from leaking out of the depot. The outer surface of the patch can be non-adhesive.
[0129] According to the present invention, the provided composition is incorporated into the patch so that it is stable over time. For example, in some embodiments, the provided composition can be incorporated into a polymer matrix that stabilizes large drugs and allows the drug to diffuse out of the matrix and the patch. The provided composition can also be incorporated into the adhesive layer of the patch so that when the patch is applied to the skin, the provided composition can diffuse through the skin. In some embodiments, the adhesive layer can be heat activated where a temperature of about 37° C. gradually liquefies the adhesive so that the drug diffuses through the skin. The adhesive can remain tacky when stored below 37° C., and when applied to the skin, the adhesive loses its tackiness as it liquefies.
[0130] In some embodiments, the provided composition can be provided in a depot in the patch, so that pressure applied to the patch directs the provided composition through the microneedle and through the stratum corneum to the outside of the patch.Exemplary embodiments of microneedles are described above.Devices suitable for use in intradermal administration of the provided composition include those described in U.S. Patent Nos. 4,886,499; 5,190,521; 5,328,483; 5,527,288; 4,270,537; 5,015,235; 5,141,496; and 5,417,662.Intradermal compositions can be administered by devices that limit the effective penetration length of the needle into the skin, such as those described in PCT Publication WO99 / 34850 and its functional equivalents.
[0131] In some embodiments, it may be desirable to slow down the absorption of the provided composition into the skin, for example to prolong the effect of the provided composition.In some embodiments, this can be achieved by using a liquid suspension of crystalline or amorphous material with poor water solubility.The absorption rate of the provided composition then depends on its dissolution rate, which may also depend on crystal size and crystalline morphology.In some embodiments, depending on the ratio of the provided composition to the polymer and the nature of the specific polymer used, the release rate of the provided composition can be controlled.Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides).
[0132] Emulsions The present disclosure encompasses the recognition that emulsion technology can provide stabilization benefits to agents of interest, including large agents described herein, including, inter alia, botulinum toxins and / or antibody agents.
[0133] Moreover, the present disclosure recognizes that certain liquid nanoemulsion technologies have been demonstrated to provide significant transdermal delivery properties even for very large molecules such as botulinum and / or antibody drugs. See, for example, U.S. Patent Publication Nos. 2012 / 0328701, 2012 / 0328702, 8,318,181, and 8,658,391, the disclosures of which are incorporated herein by reference in their entirety. These liquid nanoemulsions are far superior to solid nanoparticle drug delivery, particularly transdermal drug delivery, where solid nanoparticles are unable to penetrate the skin and merely accumulate in hair follicles, as described by Gomaa. These liquid nanoemulsions are also stable for at least 34 months, making them commercially viable in this respect as well.
[0134] 1. Macroemulsion In some embodiments, the present disclosure provides a strategy for using microneedle processing to "condition" the skin to which a transdermal product has been, is being, or will be applied. A study analyzing the transdermal delivery of small molecules (specifically, short hydrophilic peptides with molecular weights in the range of 400-1000 Da) found that "skin penetration of peptides depends on their molecular weight and decreases as the molecular weight increases" (Zhang, S., et al., "Enhanced delivery of hydrophilic peptides in Thus, despite previous reports that such strategies were likely to be useful only for low molecular weight drugs, the present disclosure provides insight that such microneedle preparations can surprisingly provide significant benefits in facilitating transdermal delivery of large drugs (e.g., having a molecular weight of about 100 kDa or greater), as we have found that microneedle preparations can effectively enhance the transdermal delivery of large drugs (e.g., having a molecular weight of about 100 kDa or greater) despite previous reports that such strategies were likely to be useful only for low molecular weight drugs.
[0135] The present disclosure provides the insight that effective and rapid (i.e., administration over minutes) transdermal delivery of large molecules by such liquid macroemulsion compositions can surprisingly be improved by combining macroemulsion administration with microneedle skin preparation (MSC). The present disclosure specifically demonstrates that microneedle processing techniques (e.g., microneedle preparation of the skin) can significantly enhance the transdermal delivery of large agents (e.g., botulinum and / or antibody agents), especially when utilized in conjunction with macroemulsion technology. Particular macroemulsion compositions of interest include water-in-oil and oil-in-water macroemulsions characterized by droplet sizes ranging from greater than about 300 nm to about 5,000 μm in diameter, ratios of aqueous dispersion medium to oil ranging from about 0.01:1 to about 20:1; oil-to-surfactant ratios ranging from about 0.1 to about 40, and / or zeta potentials ranging from about -80 mV to about +80 mV. The surfactant portion of the composition may contain one or more surfactants. Macroemulsion formulation [Table 6] *Those of skill in the art, having regard to this specification, may make reasonable adjustments to this and other ingredients depending on the volume, weight, and / or dose of the large drug being utilized.
[0136] Macroemulsion formulations may act to stabilize large agents, such as botulinum and / or antibody agents. Although macroemulsion formulations by themselves would not necessarily be expected to achieve transdermal delivery of large agents, the present disclosure nevertheless embraces the insight that improved stabilization that may be provided by incorporation into a macroemulsion composition may achieve synergistic enhancement of transdermal delivery when combined with the microneedle processing techniques described herein.
[0137] The present disclosure teaches that, despite the expectation that MSCs are only useful in facilitating the transdermal delivery of small compounds, the transdermal delivery of large drugs by macroemulsion compositions can be made possible by combining with microneedle technology.And, the present disclosure is particularly surprising considering that, as described by Gomaa, microneedle preparation combined with the encapsulation of small molecule drugs in solid nanoparticles provides a small amount of penetration only after 6 hours of administration, and no penetration of the material is observed until 24 hours after administration.
[0138] In some embodiments, the macroemulsion formulation comprising a large drug is administered in conjunction with microneedle preparation using a solid microneedle. In some embodiments, MSC of the site is performed prior to application of the macroemulsion formulation comprising a large drug to the site (e.g., prior to certain applications and / or prior to each application). In some embodiments, MSC of the site is performed after application of the macroemulsion formulation comprising a large drug to the site. In some embodiments, application of the MSC of the site and the macroemulsion formulation comprising a large drug to the site is performed substantially simultaneously. In some embodiments, the macroemulsion formulation comprising a large drug is not injected through one or more microneedles. In some embodiments, the microneedle is part of an array of microneedles. In some embodiments, the microneedle may have a length of about 1 μm to about 4,000 μm. In some embodiments, the microneedle may have a length of about 1 μm to about 2,000 μm. In some embodiments, the microneedle may have a length of about 50 μm to about 400 μm. In some embodiments, the microneedles may have a length of about 800 μm to about 1500 μm.
[0139] The findings presented herein are particularly surprising in light of reports that transdermal delivery of solid nanoparticles, which are much smaller in size (e.g., 105±2.92 nm) than the droplets in the macroemulsion compositions utilized herein, do not effectively deliver (or facilitate delivery of) even small molecule drugs transdermally through the skin. See, e.g., Gomaa et al. al described a study in which a solution of rhodamine dye (molecular weight 479 Da) encapsulated in PLGA nanoparticles was applied to preconditioned skin by microneedle treatment and skin penetration was evaluated. See Gomaa, Y., et al, “Effect of microneedle treatment on the skin permeation of a nanoencapsulated dye.” J Pharm Pharmacol. 2012 November; 64(11): 1592-1602. The data showed that very small amounts of dye began to penetrate the skin after 6 hours of continuous application; no significant increase in penetration was observed until the skin had been treated continuously for 24 hours. The researchers explained that “there is an emerging consensus that NPs [nanoparticles] are not normally able to penetrate the stratum corneum, but can be well deposited within hair follicles.” Thus, prior to the present disclosure, one skilled in the art would expect that the use of microneedle processing techniques with vehicles significantly larger than 105 nm would have been thought to be unable to effectively deliver even small molecule drugs (e.g., rhodamine dyes) transdermally; certainly not capable of delivering larger drugs. However, the present disclosure demonstrates that microneedle processing, especially when utilized in conjunction with macroemulsion technology, can significantly facilitate the transdermal delivery of larger drugs.
[0140] In particular, the present disclosure demonstrates that microneedling techniques can facilitate transdermal delivery (e.g., of large agents, especially from macroemulsion compositions) when no other disintegrants are utilized (i.e., no chemical penetration enhancers are utilized, and no other techniques that disrupt or puncture the skin structure are utilized). Previous studies of transdermal delivery of agents as large as botulinum toxin (i.e., approximately 150 kDa) using microneedles have reported that delivery is not successful unless additional treatments are applied to disrupt the skin. For example, U.S. Patent Publication No. 2010 / 0196445 reports that botulinum toxin is not effectively delivered from pre-coated microneedles unless skin digestive enzymes are also applied to disrupt the skin structure at the site of microneedling.
[0141] The present disclosure demonstrates, inter alia, that microneedle processing techniques can achieve transdermal delivery (e.g., of larger agents, particularly from microemulsion and nanoemulsion compositions) when coating or loading of the microneedles is not utilized and / or the microneedles are not designed to remain within the skin. In particular, as previously noted, the present disclosure recognizes that coating or loading of such microneedles may not be commercially viable, at least due to the instability of the botulinum coating or loading material. See, e.g., Johnson, E., et al. According to al., "Botulinum toxin is highly susceptible to denaturation due to surface denaturation, heat, and alkaline conditions. Lyophilization, or freeze-drying, of botulinum toxin is the most economically rational and practical method of distributing the product in a form that is stable and easily used by clinicians." U.S. Pat. No. 5,512,547. Also, as will be appreciated by those of skill in the art upon reading this specification, the techniques described herein have certain advantages, including the absence of the need to leave microneedles in or with tissue. For example, those of skill in the art will appreciate that leaving microneedles in the skin may risk skin irritation, inflammation, allergic reactions, and / or cosmetically undesirable scarring. In contrast to the present invention, techniques such as those described in U.S. Patent Publication No. 2017 / 0209553 utilize microneedle arrays designed such that botulinum is loaded into the needles and the microneedles are released into the skin (per U.S. Patent Nos. 2017 / 0209553 and 2016 / 0263362).
[0142] The present disclosure provides a surprisingly effective technique for transdermal delivery of large agents (e.g., botulinum toxin, antibodies, etc.). In particular, the present disclosure teaches that transdermal delivery of such agents can be significantly facilitated through the use of microneedle processing techniques without any other disruption measures. As such, the provided techniques can achieve effective delivery without the inflammation, irritation, and / or allergic reactions that often accompany the use of skin-disintegrating agents. As will be appreciated by those of skill in the art upon reading this specification, the present disclosure teaches that transdermal delivery of such large agents can be significantly facilitated through the use of microneedle processing techniques even when the large agents are not loaded into, coated on, and / or configured as part of the microneedles. Similarly, as will be appreciated by those of skill in the art upon reading this specification, the present disclosure teaches that delivery of the large agents described herein can be significantly facilitated through the use of microneedle processing techniques (particularly through the use of MSCs) without leaving the microneedles in the skin (e.g., by detaching them and / or otherwise being retained and / or degraded in place). For example, one skilled in the art will appreciate that the provided technology can avoid issues related to long-term stability of large drugs necessary for commercially viable products, and can achieve effective delivery without inflammation, irritation, and / or allergic reactions that may result from skin disruptors and / or microneedles remaining in the skin. Indeed, in the examples and elsewhere, the present disclosure expressly teaches that MSCs performed with microneedles that do not contain botulinum toxin facilitate transdermal delivery of botulinum toxin from topical (e.g., creams, ointments) compositions, particularly those that include macro- or nanoemulsions.
[0143] In some embodiments, the present disclosure teaches that particularly advantageous results are achieved when microneedle processing technology is combined with a macroemulsion composition. In some embodiments, the microneedle processing technology is combined with a lotion, cream, or liquid composition that may subsequently become or contain a macroemulsion composition. In some embodiments, the provided technology does not utilize skin disruption technology such as chemical penetration enhancers.
[0144] In some embodiments, the present invention utilizes macroemulsion compositions that include large drugs that are particularly effective and / or useful in medical settings, for example, for therapeutic purposes. In some embodiments, certain macroemulsion compositions are particularly effective and / or useful for topical administration of drugs to subjects in need thereof. In some embodiments, the macroemulsion compositions may include one or more large drugs.
[0145] In some embodiments, the macroemulsions may be formulated into compositions suitable for topical administration on the skin, hi some embodiments, compositions suitable for topical administration may be lotions, creams, powders, ointments, liniments, gels, or drops.
[0146] In some embodiments, the macroemulsion formulation comprises water, medium chain triglycerides, Span 65, polysorbate 80, methylparaben, and propylparaben. In some embodiments, the macroemulsion formulation comprises water, medium chain triglycerides, Span 65, and polysorbate 80.
[0147] In some embodiments, provided compositions comprise a mixture of a provided macroemulsion composition and one or more pharma- ceutically acceptable excipients, hi some embodiments, cream and / or lotion formulations comprise a mixture of a provided macroemulsion composition and / or saline.
[0148] In some embodiments, the compositions provided comprise a macroemulsion composition comprising one or more macrophages. In some embodiments, the compositions provided are cream and / or lotion formulations. In some embodiments, the cream and / or lotion formulations provided comprise a macroemulsion composition. In some embodiments, the compositions comprise a macroemulsion composition provided but are not cream and / or lotion formulations. In some embodiments, suitable compositions are formulated into creams and / or lotions but do not comprise a macroemulsion composition.
[0149] In some embodiments, provided compositions comprise a mixture of a provided macroemulsion composition and one or more pharma- ceutically acceptable excipients, e.g., for topical and / or transdermal administration (e.g., via lotions, creams, powders, ointments, liniments, gels, drops, etc.).
[0150] 2. Nanoemulsion In some embodiments, the present disclosure provides a strategy for using microneedle processing to "condition" the skin to which a transdermal product has been, is being, or will be applied. A study analyzing the transdermal delivery of small molecules (specifically, short hydrophilic peptides with molecular weights in the range of 400-1000 Da) found that "skin penetration of peptides depends on their molecular weight and decreases as the molecular weight increases" (Zhang, S., et al., "Enhanced delivery of hydrophilic peptides in Thus, despite previous reports that such strategies were likely to be useful only for low molecular weight drugs, the present disclosure provides insight that such microneedle preparations can surprisingly provide significant benefits in facilitating transdermal delivery of large drugs (e.g., having a molecular weight of about 100 kDa or greater), as we have found that microneedle preparations can effectively enhance the transdermal delivery of large drugs (e.g., having a molecular weight of about 100 kDa or greater) despite previous reports that such strategies were likely to be useful only for low molecular weight drugs.
[0151] The present disclosure provides the insight that effective and rapid (i.e., administration over minutes) transdermal delivery of large molecules by such liquid nanoemulsion compositions can surprisingly be improved by combining nanoemulsion administration with microneedle skin preparation (MSC).
[0152] The present disclosure specifically demonstrates that microneedle processing techniques (e.g., microneedle preparation of the skin) can significantly enhance the transdermal delivery of large agents (e.g., botulinum and / or antibody agents), especially when utilized in conjunction with nanoemulsion technology. Particular nanoemulsion compositions of interest include water-in-oil and oil-in-water nanoemulsions characterized by droplet sizes ranging from about 1 nm to about 300 nm in diameter, ratios of aqueous dispersion medium to oil ranging from about 0.01:1 to about 20:1; oil-to-surfactant ratios ranging from about 0.1 to about 40, and / or zeta potentials ranging from about -80 mV to about +80 mV.
[0153] In some embodiments, provided nanoemulsion compositions include an oil and a surfactant in a ratio ranging from about 0.1:1 to about 2:1. In some embodiments, provided nanoemulsion compositions include an oil and a surfactant in a ratio of about 0.1:1 to about 1:1. In some embodiments, provided nanoemulsion compositions include an oil and a surfactant in a ratio of about 0.5:1 to about 1:1. In some embodiments, provided nanoemulsion compositions include an oil and a surfactant in a ratio of about 0.5:1 to about 1:1.5. In some embodiments, provided nanoemulsion compositions comprise an oil and surfactant in a ratio of about 0.1:1, about 0.15:1, about 0.2:1, about 0.25:1, about 0.3:1, about 0.35:1, about 0.4:1, about 0.45:1, about 0.5:1, about 0.5:1, about 0.55:1, about 0.6:1, about 0.65:1, about 0.7:1, about 0.75:1, about 0.8:1, about 0.85:1, about 0.9:1, about 0.95:1, or about 1:1. In some embodiments, provided nanoemulsion compositions comprise an oil and surfactant in a ratio of about 0.67:1.
[0154] In some embodiments, the aqueous dispersion medium (e.g., water, buffer, salt solution, etc.) and the surfactant are utilized in a ratio ranging from 0.01 to 20. In some embodiments, the aqueous dispersion medium (e.g., water, buffer, salt solution, etc.) and the surfactant are utilized in a ratio ranging from 0.1 to 20. In some embodiments, the aqueous dispersion medium (e.g., water, buffer, salt solution, etc.) and the surfactant are utilized in a ratio ranging from 0.5 to 10. In some embodiments, the aqueous dispersion medium (e.g., water, buffer, salt solution, etc.) and the surfactant are utilized in a ratio ranging from 0.5 to 1. In some embodiments, the ratio of aqueous dispersion medium (e.g., water, buffer, salt solution, etc.) to surfactant is about 0.01:1, about 0.02:1, about 0.03:1, about 0.04:1, about 0.05:1, about 0.06:1, about 0.07:1, about 0.08:1, about 0.0:1, about 0.1:1, about 0.2:1, about 0.3:1, about 0.4:1, about 0.5:1, about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, or 10:1. In some embodiments, the ratio of surfactant to water is about 0.5:1, about 1:1, about 2:1, about 3:1, about 4:1, about 5:1, about 6:1, about 7:1, about 8:1, about 9:1, about 10:1, about 11:1, about 12:1, about 13:1, about 14:1, about 15:1, about 16:1, about 17:1, about 18:1, about 19:1, or about 20:1. In some embodiments, the aqueous dispersion medium (e.g., water, buffer, salt solution, etc.) and surfactant are utilized in a ratio ranging from 0.5 to 2. In some embodiments, the ratio of aqueous dispersion medium (e.g., water, buffer, salt solution, etc.) to surfactant is about 0.5:1, about 1:1, or about 2:1. In some embodiments, the ratio of surfactant to aqueous dispersion medium (e.g., water, buffer, salt solution, etc.) is about 0.5:1, about 1:1, or about 2:1. In some embodiments, the ratio of aqueous dispersion medium (eg, water, buffer, salt solution, etc.) to surfactant is approximately 1:1.In some embodiments, compositions utilizing such ratios of aqueous dispersion medium (eg, water, buffer, salt solution, etc.) to surfactant include water-in-oil emulsions.
[0155] In some embodiments, the droplets in the nanoemulsion composition have a diameter (e.g., average and / or median diameter) within the range of about 10 nm to about 300 nm, about 10 nm to about 200 nm, about 10 nm to about 150 nm, about 10 nm to about 130 nm, about 10 nm to about 120 nm, about 10 nm to about 115 nm, about 10 nm to about 110 nm, about 10 nm to about 100 nm, or about 10 nm to about 90 nm. In some embodiments, the droplets in the nanoemulsion composition have a diameter (e.g., average and / or median diameter) within the range of 1 nm to 300 nm, 1 nm to 200 nm, 1 nm to 150 nm, 1 nm to 120 nm, 1 nm to 100 nm, 1 nm to 75 nm, 1 nm to 50 nm, or 1 nm to 25 nm. In some embodiments, the droplets within a nanoemulsion composition have a diameter (e.g., average and / or median size) between 1 nm and 15 nm, between 15 nm and 200 nm, between 25 nm and 200 nm, between 50 nm and 200 nm, or between 75 nm and 200 nm.
[0156] In some embodiments, the total droplet distribution falls within a particular range of droplet diameter sizes. In some embodiments, less than 50%, 25%, 10%, 5%, or 1% of the total droplet distribution is outside of a particular range of droplet diameter sizes. In some embodiments, less than 1% of the total droplet distribution is outside of a particular range of droplet diameter sizes. In some embodiments, the nanoemulsion composition is substantially free of droplets having a diameter greater than 300 nm, 250 nm, 200 nm, 150 nm, 120 nm, 100 nm, 75 nm, 50 nm, or 25 nm. In some embodiments, less than 50%, 25%, 10%, 5%, or 1% of the total droplet distribution has a diameter greater than 300 nm, 250 nm, 200 nm, 150 nm, 120 nm, 100 nm, 75 nm, 50 nm, or 25 nm.
[0157] In some embodiments, the droplets in the nanoemulsion composition have an average droplet size of about 300 nm, about 250 nm, about 200 nm, about 150 nm, about 130 nm, about 120 nm, about 115 nm, about 110 nm, about 100 nm, about 90 nm, or less than about 50 nm. In some embodiments, the average droplet size is within the range of about 10 nm to about 300 nm, about 50 nm to about 250, about 60 nm to about 200 nm, about 65 nm to about 150 nm, or about 70 nm to about 130 nm. In some embodiments, the average droplet size is about 80 nm to about 110 nm. In some embodiments, the average droplet size is about 90 nm to about 100 nm.
[0158] In some embodiments, the nanoemulsion droplets have a zeta potential ranging from -80 mV to +80 mV. In some embodiments, the nanoemulsion droplets have a zeta potential ranging from -50 mV to +50 mV. In some embodiments, the nanoemulsion droplets have a zeta potential ranging from -25 mV to +25 mV. In some embodiments, the nanoemulsion droplets have a zeta potential ranging from -10 mV to +10 mV. In some embodiments, the nanoemulsion droplets have a zeta potential of about -80 mV, about -70 mV, about -60 mV, about 50 mV, about -40 mV, about -30 mV, about -25 mV, about -20 mV, about -15 mV, about -10 mV, or about -5 mV. In some embodiments, the nanoemulsion droplets have a zeta potential of about +50 mV, about +40 mV, about +30 mV, about +25 mV, about +20 mV, about +15 mV, about +10 mV, or about +5 mV. In some embodiments, the nanoemulsion droplets have a zeta potential that is about 0 mV.
[0159] The present disclosure provides a surprisingly effective technique for transdermal delivery of large agents (e.g., botulinum toxin, antibodies, etc.). In particular, the present disclosure teaches that transdermal delivery of such agents can be significantly facilitated through the use of microneedle processing techniques without any other disrupting measures. As such, the provided techniques can achieve effective delivery without the inflammation, irritation, and / or allergic reactions that often accompany the use of skin-disrupting agents. As will be appreciated by those of skill in the art upon reading this specification, the present disclosure teaches that transdermal delivery of such large agents can be significantly facilitated through the use of microneedle processing techniques even when the large agents are not loaded into, coated on, and / or configured as part of the microneedles. Similarly, as will be appreciated by those of skill in the art upon reading this specification, the present disclosure teaches that delivery of the large agents described herein can be significantly facilitated through the use of microneedle processing techniques (and in particular through the use of MSCs) without leaving the microneedles in the skin (e.g., by detaching them and / or otherwise being retained and / or degraded in place). For example, one skilled in the art will appreciate that the provided technology can avoid issues related to long-term stability of large drugs necessary for commercially viable products, and can achieve effective delivery without inflammation, irritation, and / or allergic reactions that may result from skin disruptors and / or microneedles remaining in the skin. Indeed, in the examples and elsewhere, the present disclosure expressly teaches that MSCs performed with microneedles that do not contain botulinum toxin facilitate transdermal delivery of botulinum toxin from topical (e.g., creams, ointments) compositions, particularly those that include macro- or nanoemulsions.
[0160] In some embodiments, the present disclosure teaches that particularly advantageous results are achieved when microneedle processing technology is combined with a nanoemulsion composition. In some embodiments, the microneedle processing technology is combined with a lotion, cream, or liquid composition that may subsequently become or contain a nanoemulsion composition. In some embodiments, the provided technology does not utilize skin disruption technology such as chemical penetration enhancers.
[0161] The findings presented herein are particularly surprising in light of reports that transdermal delivery of solid nanoparticles of sizes comparable to those of the droplets in the nanoemulsion compositions utilized herein (e.g., 105±2.92 nm) does not effectively deliver (or facilitate delivery of) even small molecule drugs transdermally through the skin. For example, Gomaa et al. described a study in which a solution of rhodamine dye (molecular weight 479 Da) encapsulated in PLGA nanoparticles was applied to preconditioned skin by microneedle treatment and skin permeation was evaluated. See Gomaa, Y., et al., “Effect of microneedle treatment on the skin permeation of a nanoencapsulated dye.” J Pharm Pharmacol. 2012 November; 64(11): 1592-1602. The data showed that very small amounts of dye began to permeate the skin after 6 hours of continuous application; no significant increase in permeation was observed until the skin had been treated continuously for 24 hours. The researchers explained that "there is an emerging consensus that NPs [nanoparticles] are generally unable to penetrate the stratum corneum, but can be well deposited within hair follicles." Thus, one skilled in the art would expect that prior to this disclosure, the use of microneedle processing techniques with nano-sized vehicles would have been thought to be unable to effectively deliver even small molecule drugs (e.g., rhodamine dyes) transdermally; certainly not for larger drugs. However, this disclosure demonstrates that microneedle processing can significantly facilitate the transdermal delivery of larger drugs, especially when utilized in conjunction with nanoemulsion systems.
[0162] In particular, the present disclosure demonstrates that microneedle processing techniques can facilitate transdermal delivery (e.g., of large agents, especially from nanoemulsion compositions) when no other disintegration agents are utilized (i.e., no chemical penetration enhancers are utilized, and no other techniques that disrupt or puncture the skin structure are utilized). Previous studies of transdermal delivery of agents as large as botulinum toxin (i.e., approximately 150 kDa) using microneedles have reported that delivery is not successful unless additional treatments are applied to disrupt the skin. For example, U.S. Patent Publication No. 2010 / 0196445 reports that botulinum toxin is not effectively delivered from pre-coated microneedles unless skin digestive enzymes are also applied to disrupt the skin structure at the site of microneedle processing.
[0163] The present disclosure demonstrates, inter alia, that microneedle processing techniques can achieve transdermal delivery (e.g., of larger agents, particularly from microemulsion and nanoemulsion compositions) when coating or loading of the microneedles is not utilized and / or the microneedles are not designed to remain within the skin. In particular, as previously noted, the present disclosure recognizes that coating or loading of such microneedles may not be commercially viable, at least due to the instability of the botulinum coating or loading material. See, e.g., Johnson, E., et al. According to al., "Botulinum toxin is highly susceptible to denaturation due to surface denaturation, heat, and alkaline conditions. Lyophilization, or freeze-drying, of botulinum toxin is the most economically rational and practical method of distributing the product in a form that is stable and easily used by clinicians." U.S. Pat. No. 5,512,547. Also, as will be appreciated by those of skill in the art upon reading this specification, the techniques described herein have certain advantages, including the absence of the need to leave microneedles in or with tissue. For example, those of skill in the art will appreciate that leaving microneedles in the skin may risk skin irritation, inflammation, allergic reactions, and / or cosmetically undesirable scarring. In contrast to the present invention, techniques such as those described in US 2017 / 0209553 utilise microneedle arrays where botulinum is loaded into the needles and the microneedles are designed to be detached and penetrated into the skin (per US 2017 / 0209553 and 2016 / 0263362).
[0164] Despite the expectation that MSCs are only useful in facilitating the transdermal delivery of small compounds, the present disclosure teaches that the already highly effective transdermal delivery of large drugs by nanoemulsion compositions can be dramatically enhanced by combination with microneedle technology. This is particularly surprising considering that, as described by Gomaa, microneedle preparation combined with encapsulation of small molecule drugs in solid nanoparticles provided small amounts of penetration only 6 hours after administration, with no penetration of the material observed until 24 hours after administration.
[0165] In some embodiments, the nanoemulsion formulation containing a large agent is administered in conjunction with microneedle preparation using a solid microneedle. In some embodiments, MSC of the site is performed prior to application of the nanoemulsion formulation containing a large agent to the site (e.g., prior to a particular application and / or prior to each application). In some embodiments, MSC of the site is performed after application of the nanoemulsion formulation containing a large agent to the site. In some embodiments, MSC of the site and application of the nanoemulsion formulation containing a large agent to the site are performed substantially simultaneously. In some embodiments, the macroemulsion formulation containing a large agent is not injected through one or more microneedles. In some embodiments, the microneedle is part of an array of microneedles. In some embodiments, the microneedle may have a length of about 1 μm to about 4,000 μm. In some embodiments, the microneedle may have a length of about 1 μm to about 2,000 μm. In some embodiments, the microneedle may have a length of about 50 μm to about 400 μm. In some embodiments, the microneedles may have a length of about 800 μm to about 1500 μm.
[0166] In some embodiments, the invention utilizes nanoemulsion compositions that include large drugs that are particularly effective and / or useful in medical settings, e.g., for therapeutic purposes. In some embodiments, certain nanoemulsion compositions are particularly effective and / or useful for local administration of drugs to subjects in need thereof. In some embodiments, nanoemulsion compositions may include one or more large drugs. Exemplary nanoemulsion compositions and methods of manufacture are described, for example, in WO2012 / 103035, the disclosure of which is incorporated by reference in its entirety.
[0167] In some embodiments, the nanoemulsions can be formulated into compositions suitable for topical administration, hi some embodiments, compositions suitable for topical administration can be lotions, creams, powders, ointments, liniments, gels, or drops.
[0168] In some embodiments, the nanoemulsion formulation comprises water, medium chain triglycerides, polysorbate 80, methylparaben, and propylparaben. In some embodiments, the nanoemulsion formulation comprises water, medium chain triglycerides, and polysorbate 80. Exemplary premixes, which are not meant to be limiting, are provided in Table 2. [Table 2] *The buffer solution contained (w / w) 0.199% gelatin, 0.398% dibasic sodium phosphate, 99.4% purified water, and the pH was adjusted to 6.0±0.2 with hydrochloric acid. **One of skill in the art, having regard to this specification, may make reasonable adjustments to this and other ingredients depending on the volume, weight, and / or dose of the larger drug being utilized.
[0169] These compositions are particularly useful in that they can be used to deliver a drug to a subject in need thereof via topical and / or transdermal (e.g., by lotion, cream, powder, ointment, liniment, gel, drop, etc.) administration. In some embodiments, the provided cream and / or lotion formulations can be administered to a subject in need thereof via topical and / or transdermal (e.g., by lotion, cream, powder, ointment, liniment, gel, drop, etc.) administration. In some embodiments, the provided nanoemulsion compositions can be formulated into cream and / or lotion formulations. In some embodiments, the provided cream and / or lotion formulations comprising the nanoemulsion compositions can be useful and / or effective for topical administration to a subject. In some embodiments, the provided nanoemulsion compositions can be mixed with one or more cream components in a cream formulation (e.g., a provided cream formulation) and / or saline to prepare a pharmaceutical composition.
[0170] The present invention encompasses the recognition that emulsion compositions (e.g., macroemulsion and nanoemulsion compositions) can be formulated into cream and / or lotion formulations for administration to a subject. The present invention encompasses the recognition that the cream and / or lotion formulations provided can be particularly useful for formulating emulsions, such as those described herein, for administration to a subject. Exemplary nanoemulsion formulations, which are not meant to be limiting, are provided in Table 3. [Table 3] *Those of skill in the art, having regard to this specification, may make reasonable adjustments to this and other ingredients depending on the volume, weight, and / or dose of the large drug being utilized.
[0171] In some embodiments, provided compositions comprise a mixture of the provided nanoemulsion compositions and one or more pharma- ceutically acceptable excipients, hi some embodiments, cream and / or lotion formulations comprise a mixture of the provided nanoemulsion compositions and / or saline.
[0172] In some embodiments, a provided composition comprises a provided nanoemulsion composition. In some embodiments, a provided composition is a cream and / or lotion formulation. In some embodiments, a provided cream and / or lotion formulation comprises a nanoemulsion composition. In some embodiments, a composition comprises a provided nanoemulsion composition but is not a cream and / or lotion formulation. In some embodiments, a suitable composition is formulated into a cream and / or lotion but does not comprise a nanoemulsion composition.
[0173] In some embodiments, provided compositions comprise a mixture of provided nanoemulsion compositions with one or more pharma- ceutically acceptable excipients, e.g., for topical and / or transdermal administration (e.g., via lotions, creams, powders, ointments, liniments, gels, drops, etc.).
[0174] In some embodiments, in the case of nanoemulsion compositions that include known therapeutic agents and / or independently active biologically active agents, such nanoemulsion compositions are prepared, configured, and administered in combination with MSCs such that an amount of the therapeutic agent is delivered to the desired target site (e.g., to the epidermal and / or dermal structures) sufficient to treat the condition or disorder. In some embodiments, provided nanoemulsion compositions are prepared and configured (e.g., by selection and / or combination of agents, composition structure, etc.) such that they achieve a desired therapeutic effect upon administration to the skin. In some embodiments, provided nanoemulsion compositions are prepared and configured such that they do not induce undesirable clinical effects within and / or outside the desired site of action (e.g., the surface of the skin, the dermis, etc.). In some embodiments, provided nanoemulsion compositions are prepared, configured, and administered in combination with MSCs such that they have a systemic effect.
[0175] In some embodiments, provided compositions may be formulated and delivered in combination with MSCs to achieve systemic delivery; in some embodiments, provided compositions may be formulated and / or delivered to achieve local, but not systemic, delivery.
[0176] The present disclosure specifically demonstrates the effective and efficient delivery of therapeutic agents (and in particular large biological agents such as botulinum toxin or antibody agents) to the dermis using the compositions provided in combination with MSCs. For example, in some embodiments, the present invention provides methods that include administration of the compositions described herein without clinically significant side effects. By way of example only, when local delivery is contemplated, clinically significant side effects include, but are not limited to, undesirable systemic side effects, damage to nerve tissue underlying the dermis (e.g., nerve paralysis), undesirable effects on muscles (e.g., muscle paralysis), and / or undesirable blood levels of the therapeutic agent. Exemplary formulations of botulinum nanoemulsion premixes, which are not meant to be limiting, are provided in Table 4. [Table 4] *The buffer solution contained (w / w) 0.199% gelatin, 0.398% dibasic sodium phosphate, 99.4% purified water, and the pH was adjusted to 6.0±0.2 with hydrochloric acid.
[0177] Diseases, Disorders, and Conditions The present invention provides techniques for treating and / or preventing any of a variety of systemic or skin diseases, disorders, and / or conditions. In some embodiments, the present invention provides techniques for treating and / or preventing diseases, disorders, or conditions associated with sweat and / or sebaceous gland activity. In some embodiments, the present invention provides techniques for treating and / or preventing diseases, disorders, or conditions associated with infectious diseases. In some embodiments, the present invention provides techniques for treating and / or preventing diseases, disorders, or conditions associated with inflammation. In some embodiments, the present invention provides techniques for treating and / or preventing diseases, disorders, or conditions associated with inflammation. In some embodiments, the present invention provides techniques for treating and / or preventing diseases, disorders, or conditions associated with cancer. In some embodiments, the present invention provides techniques for treating and / or preventing diseases, disorders, or conditions that are systemic. In some embodiments, the present invention provides techniques for treating and / or preventing diseases, disorders, or conditions that are autoimmune. In some embodiments, the present invention provides techniques for treating and / or preventing diseases, disorders, or conditions associated with the epidermal and / or dermal levels of the skin.
[0178] In some embodiments, the present invention provides a method for treating acne, unwanted sweating, body odor, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, alopecia, psoriasis, actinic keratosis, eczematoid dermatitis (e.g., atopic dermatitis, etc.), disorders of excess sebum production (e.g., seborrhea, seborrheic dermatitis, etc.), burns, Raynaud's phenomenon, lupus erythematosus, disorders of hyperpigmentation (e.g., melasma, etc.), disorders of hypopigmentation (e.g., vitiligo, etc.), skin cancer (e.g., squamous cell skin cancer, basal cell skin cancer, etc.), skin infections (e.g., bacterial infections, viral infections, fungal infections, etc.), facial wrinkles (e.g., forehead, glabellar, creases, and / or periorbital wrinkles, etc.), and / or facial wrinkles (e.g., wrinkles on the forehead, glabellar, creases, and / or periorbital wrinkles, etc.). In one embodiment, the present invention provides techniques for treating and / or preventing one or more of the following: facial wrinkles (including those around the eyelids), headaches, disfigurement of the face (e.g., due to overactivity of the underlying facial musculature), neuromuscular disorders and conditions including neck muscles, polyfunctional facial muscles, hypercontractile facial muscles, platysma band, muscle spasms and / or contractures (including various forms of facial paralysis, cerebral palsy, blepharospasm, facial contractures), dystonia, prostatic hypertrophy, headaches, strabismus, hemifacial spasm, tremors, spasticity such as that resulting from multiple sclerosis, retroorbital muscles, various ophthalmic and urological conditions (e.g., penile and / or bladder disorders), and / or combinations thereof.
[0179] In some embodiments, the present invention provides techniques for treating and / or preventing rheumatoid arthritis. In some embodiments, the present invention provides techniques for treating and / or preventing psoriatic arthritis. In some embodiments, the present invention provides techniques for treating and / or preventing osteoarthritis.
[0180] In some embodiments, the present invention provides techniques for treating and / or preventing lupus erythematosus, hi some embodiments, lupus erythematosus is systemic, discoid, drug-induced, or neonatal.
[0181] In some embodiments, the present invention provides techniques for treating and / or preventing Crohn's disease. In some embodiments, the present invention provides techniques for treating and / or preventing inflammatory bowel disease. In some embodiments, the present invention provides techniques for treating and / or preventing ulcerative colitis.
[0182] In some embodiments, the present invention provides techniques for treating and / or preventing a pulmonary disorder, hi some embodiments, the pulmonary disorder may be asthma or chronic obstructive pulmonary disease.
[0183] In some embodiments, the present invention provides techniques for treating and / or preventing amyloidosis, hi some embodiments, the amyloidosis is systemic or cutaneous.
[0184] In some embodiments, the present invention provides techniques for treating and / or preventing cancer, hi some embodiments, the cancer is of the skin, blood, breast, colon, or lung.
[0185] In some embodiments, the present invention provides techniques for treating and / or preventing dyslipidemia, hi some embodiments, the dyslipidemia is hypercholesterolemia.
[0186] In some embodiments, the present invention provides techniques for treating and / or preventing an infectious disease, hi some embodiments, the infectious disease is or is caused by C. difficile or Staphylococcus.
[0187] In some embodiments, the present invention provides techniques for treating and / or preventing pain. In some embodiments, the pain is associated with arthritis. In some embodiments, the arthritis is rheumatoid arthritis, psoriatic arthritis, or osteoarthritis.
[0188] In some embodiments, the present invention provides techniques for treating and / or preventing a neurological condition, hi some embodiments, the neurological condition is Alzheimer's disease, Parkinson's disease, or stroke.
[0189] In some embodiments, the present invention provides a method for treating a skin condition comprising administering to a subject in accordance with a dosing regimen sufficient to achieve a reduction in the severity and / or prevalence of the associated skin condition by at least about 20%; in some embodiments, according to a dosing regimen sufficient to achieve a reduction by at least about 25%; in some embodiments, according to a dosing regimen sufficient to achieve a reduction by at least about 30%; in some embodiments, according to a dosing regimen sufficient to achieve a reduction by at least about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, about 41%, about 42%, about 43%, about 44%, about 45%, about 46%, about 47%, about 48%, about 49%, or a combination thereof. The method comprises administering at least one provided composition administered in combination with MSCs according to a dosing regimen sufficient to achieve a reduction of about 50%, about 51%, about 52%, about 53%, about 54%, about 55%, about 56%, about 57%, about 58%, about 59%, about 60%, about 61%, about 62%, about 63%, about 64%, about 65%, about 66%, about 67%, about 68%, about 69%, about 70%, about 71%, about 72%, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90% or more.
[0190] In some embodiments, the present invention provides a method for treating skin conditions comprising administering the composition to a patient in need thereof, in accordance with a dosing regimen sufficient to achieve a reduction in the severity and / or prevalence of the associated skin condition by at least about 20% in a particular percentage of a patient population to which the composition is administered; in some embodiments, according to a dosing regimen sufficient to achieve a reduction in the severity and / or prevalence of the associated skin condition by at least about 25% in a particular percentage of a patient population to which the composition is administered; in some embodiments, according to a dosing regimen sufficient to achieve a reduction in the severity and / or prevalence of the associated skin condition by at least about 30% in a particular percentage of a patient population to which the composition is administered; in some embodiments, according to a dosing regimen sufficient to achieve a reduction in the severity and / or prevalence of the associated skin condition by at least about 31%, about 32%, about 33%, about 34%, about 35%, about 36%, about 37%, about 38%, about 39%, about 40%, or about 42% in a particular percentage of a patient population to which the composition is administered. 0%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72% %, about 73%, about 74%, about 75%, about 76%, about 77%, about 78%, about 79%, about 80%, about 81%, about 82%, about 83%, about 84%, about 85%, about 86%, about 87%, about 88%, about 89%, about 90%, or more reduction in IL-16 expression. In some embodiments, the particular percentage of the population of patients to whom the composition is administered is at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, or about 100%. To take a few illustrative examples, in some embodiments, the invention involves administration of at least one provided composition according to a dosing regimen sufficient to achieve a reduction in the severity and / or prevalence of an associated skin condition by at least about 20% in at least about 50% of a population of patients to which the composition is administered.In some embodiments, the invention involves administration of at least one provided composition according to a dosing regimen sufficient to achieve a reduction in the severity and / or prevalence of an associated skin condition by at least about 30% in at least about 50% of a population of patients to which the composition is administered.
[0191] The present invention provides techniques for treating and / or preventing skin conditions, including administration of a provided composition in combination with MSCs to a subject suffering from, susceptible to, and / or exhibiting symptoms of a skin condition. In some embodiments, the provided compositions for treating the skin conditions described herein are formulated for any route of administration described herein. In some embodiments, the provided compositions are formulated for topical administration. In some embodiments, the provided compositions are formulated as creams, liniments, lotions, gels, shampoos, conditioners, sunscreens, deodorants, and / or antiperspirants (e.g., roll-ons, solid sticks, gels, creams, aerosols, etc.), etc., as appropriate for the condition being treated.
[0192] In some embodiments, such provided compositions are administered locally in combination with MSCs to the affected area (e.g., axillae, hands, feet, scalp, hair follicles, face, neck, back, arms, chest, legs, groin, groin, etc., as appropriate for the particular condition being treated). In some embodiments, local administration is accomplished by topical administration in combination with MSCs.
[0193] Compositions and Formulations As described herein, the present invention provides and / or utilizes compositions comprising one or more large agents for administration in combination with MSCs. In some embodiments, the compositions provided may be formulated for topical and / or transdermal delivery (e.g., as a lotion, cream, liniment, ointment, powder, gel, drop, etc.). In some embodiments, the compositions provided may be or include a nanoemulsion. In some embodiments, the compositions provided may be or include a macroemulsion.
[0194] Formulations of the provided compositions can be prepared by any suitable method, e.g., as known or hereafter developed in the art of pharmacology. Generally, such preparation methods include the step of bringing the provided compositions into association with one or more excipients, and then, if necessary and / or desirable, shaping and / or packaging in a form suitable for administration, e.g., as or in a single or multiple dosage unit.
[0195] In some embodiments, the composition can be prepared, packaged, and / or sold in bulk, as a single unit dose, and / or as a plurality of single doses.As used herein, a "unit dose" is a discrete amount of a pharmaceutical composition that contains a predetermined amount of a provided composition.The amount of the provided composition is generally equal to the dosage of the provided composition that would be administered to a subject and / or a convenient fraction of such a dosage, such as a half or a third of such a dosage.
[0196] In some embodiments, excipients suitable for use in the composition (e.g., pharma- ceutically and / or cosmetically acceptable composition) may include, for example, one or more excipients, such as solvents, dispersion media, granulation media, diluents, or other liquid vehicles, dispersing or suspending aids, surface active agents and / or emulsifiers, isotonicity agents, thickening or emulsifying agents, preservatives, solid binders, lubricants, disintegrating agents, binders, preservatives, buffers, and the like, as appropriate for the particular dosage form desired. In some embodiments, excipients, such as cocoa butter and / or suppository waxes, coloring agents, coating agents, sweetening agents, flavoring agents, and / or fragrances, may be utilized. Remington's The Science and Practice of Pharmacy, 21 st Edition, A. R. Gennaro (Lippincott, Williams & Wilkins, Baltimore, MD, 2005; incorporated herein by reference) discloses various excipients used in formulating pharmaceutical compositions and known techniques for their preparation.
[0197] In some embodiments, a suitable excipient (e.g., a pharma- ceutically and / or cosmetically acceptable excipient) is at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% pure. In some embodiments, the excipient is approved by the U.S. Food and Drug Administration. In some embodiments, the excipient is pharmaceutical grade. In some embodiments, the excipient meets the standards of the United States Pharmacopoeia (USP), the European Pharmacopoeia (EP), the British Pharmacopoeia, and / or other international pharmacopoeias.
[0198] In some embodiments, the provided compositions are formulated as creams, liniments, ointments, oils, foams, sprays, lotions, liquids, powders, thickened lotions, or gels (e.g., formulated for transdermal delivery as described herein). Certain exemplary such formulations may be prepared as, for example, skin softeners, nourishing lotion-type emulsions, cleansing lotions, cleansing creams, skin milks, emollient lotions, massage creams, emollient creams, cosmetic bases, face packs or face gels, cleaning formulations such as shampoos, rinses, body washes, hair tonics, or soaps, or skin compositions such as lotions, ointments, gels, creams, liniments, patches, deodorants, or sprays. In some embodiments, the compositions for topical administration are not formulated for administration to mucosa (e.g., are not suitable for application to mucosa and / or are not formulated to deliver adequate amounts of large agents to or across mucosa).
[0199] treatment area The technology of the present invention is suitable for both human and veterinary use. Subjects suffering from any disorder that would benefit from the topical application of an active agent may be treated with the disclosed technology for transdermal drug delivery.
[0200] A suitable site of any site for MSCs is a suitable administration site. In some embodiments, the administration site is the skin overlying a muscle or muscle group of the subject. In some embodiments, the site is hairless. In some embodiments, the site is on the torso. In some embodiments, the site is on the back. In some embodiments, the site is on the chest. In some embodiments, the site is on the buttocks. In some embodiments, the site is on the groin. In some embodiments, the site is on the groin. In some embodiments, the site is on the head. In some embodiments, the site is on the scalp. In some embodiments, the site is on the face. In some embodiments, the site is on the neck. In some embodiments, the site is on the chest. In some embodiments, the site is under the arm. In some embodiments, the site is in the axilla. In some embodiments, the site is on the hand. In some embodiments, the site is on the foot. In some embodiments, the site is on the arm. In some embodiments, the site is on the leg. In some embodiments, the site is not a mucous membrane.
[0201] In some embodiments, the site is affected by a skin condition. In some embodiments, the site is the skin overlying a muscle or muscle group affected by a neuromuscular condition. In some embodiments, the length of the microneedles used with the MSCs is adjusted based on the thickness of the skin at the treatment site.
[0202] In some embodiments, the MSC comprises one impression of the MN or MN array. In some embodiments, the MSC comprises two impressions of the MN or MN array. In some embodiments, the MSC comprises three impressions of the MN or MN array. In some embodiments, the MSC comprises four impressions of the MN or MN array. In some embodiments, the MSC comprises five impressions of the MN or MN array. In some embodiments, the MSC comprises six impressions of the MN or MN array. In some embodiments, the MSC comprises seven impressions of the MN or MN array. In some embodiments, the MSC comprises eight impressions of the MN or MN array. In some embodiments, the MSC comprises nine impressions of the MN or MN array. In some embodiments, the MSC comprises ten impressions of the MN or MN array. In some embodiments, the MSC comprises eleven impressions of the MN or MN array. In some embodiments, the MSC comprises twelve impressions of the MN or MN array. In some embodiments, the MSC comprises thirteen impressions of the MN or MN array. In some embodiments, the MSCs comprise 14 indentations of the MN or MN array. In some embodiments, the MSCs comprise 15 indentations of the MN or MN array. In some embodiments, the MSCs comprise 16 indentations of the MN or MN array. In some embodiments, the MSCs comprise 17 indentations of the MN or MN array. In some embodiments, the MSCs comprise 18 indentations of the MN or MN array. In some embodiments, the MSCs comprise 19 indentations of the MN or MN array. In some embodiments, the MSCs comprise 20 indentations of the MN or MN array. In some embodiments, the MSCs comprise rotating the MN or MN array on the skin one or more times. In some embodiments, the MN array is rotated between indentations. In some embodiments, the MN array is not rotated between indentations. In some embodiments, the indentations are made on the same site. In some embodiments, the indentations are made on overlapping sites. In some embodiments, the indentations are made on different sites. In some embodiments, the indentations are made by stamping the MN array.In some embodiments, the impression is made by rolling the microneedle roller over the site one or more times. In accordance with established MN practice, in some embodiments, the skin impressions of the MN array last less than 1 second, or alternatively, in some embodiments, they may last more than 1 second, e.g., 30 seconds or more, 60 seconds or more, 2 minutes or more, 5 minutes or more, 10 minutes or more, 30 minutes or more, etc.
[0203] Administration The present invention provides technology for delivering emulsion compositions (e.g., botulinum emulsion compositions or antibody drug emulsion compositions) for a variety of applications, including, for example, cosmetic, nutraceutical, and medical applications. Such emulsion compositions may include one or more biologically active agents. In some embodiments, the emulsion compositions include a botulinum toxin. In some embodiments, the emulsion compositions include an antibody drug. In some embodiments, the emulsion compositions are nanoemulsion and / or macroemulsion compositions.
[0204] The present invention provides techniques for treating a condition or disorder using any of the provided compositions described herein in combination with MSCs (e.g., provided emulsion compositions; cream and / or lotion formulations; combinations of provided emulsion compositions with cream and / or lotion formulations; etc.).
[0205] In some embodiments, such methods include administration of a provided composition in combination with MSCs to a patient suffering from and / or susceptible to a disease, condition, or disorder. In some embodiments, such methods include administration of a provided nanoemulsion composition in combination with MSCs to a patient suffering from and / or susceptible to a disease, condition, or disorder associated with the dermal layer of the skin. In some embodiments, such methods include administration of an emulsion composition in combination with MSCs comprising at least one known therapeutic agent and / or independently active biologically active agent to a patient suffering from and / or susceptible to a disease, condition, or disorder. In some embodiments, such methods include administration of a provided emulsion composition formulated in a cream and / or lotion formulation in combination with MSCs to a patient suffering from and / or susceptible to a disease, condition, or disorder. In some embodiments, such methods include administration of the composition via topical and / or transdermal administration (e.g., by lotion, cream, powder, ointment, liniment, gel, drop, etc.) in combination with MSCs. Some embodiments further include administration of a penetration enhancer. Some embodiments further include administration of a non-irritating penetration enhancer.
[0206] In some embodiments, the present invention provides techniques for treating any condition or disorder. In some embodiments, the present invention demonstrates that certain compositions described herein in combination with MSCs can achieve controlled delivery of active agents efficiently and specifically to biologically relevant target sites (e.g., specific tissues, locations within the skin, cells, etc.). In some embodiments, the present invention demonstrates the achievement of controlled delivery and / or therapeutic effects at certain biologically relevant target sites without the significant side effects associated with delivery to other areas.
[0207] In some embodiments, the present invention provides techniques for treating conditions or disorders associated with epidermal and / or dermal structures (e.g., sweat glands, sebaceous glands, hair follicles, etc.). In some embodiments, the present invention demonstrates that provided compositions described herein in combination with MSCs (e.g., provided nanoemulsion compositions; cream and / or lotion formulations; combinations of provided nanoemulsion compositions with cream and / or lotion formulations; etc.) can efficiently and specifically deliver active agents to the dermis, and that provided compositions described herein can exert a therapeutic effect on the skin of a subject upon administration. In some embodiments, the present invention demonstrates dermal delivery and / or achievement of a therapeutic effect without significant side effects associated with delivery to other areas (e.g., subcutaneous or extradermal structures and / or tissues other than the dermis). In some embodiments, provided compositions described herein in combination with MSCs (e.g., provided emulsion compositions; cream and / or lotion formulations; combinations of provided emulsion compositions with cream and / or lotion formulations; etc.) can transdermally deliver an active agent, such as a therapeutic agent (e.g., a botulinum toxin, an antibody agent, etc.).
[0208] The present invention provides techniques for treating a condition or disorder by administering to a patient a provided composition described herein in combination with MSCs (e.g., provided emulsion compositions; cream and / or lotion formulations; combinations of provided emulsion compositions with cream and / or lotion formulations; etc.). In some embodiments, the present invention provides techniques for treating a condition or disorder by topically administering to a patient a composition comprising a provided emulsion composition in combination with MSCs described herein.
[0209] In some embodiments, the large agent penetrates the skin within about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 minutes of administration. In some embodiments, the large agent penetrates the skin within about 5 to about 60 minutes of administration. In some embodiments, the large agent penetrates the skin within about 5 to about 12 minutes of administration. In some embodiments, the large agent penetrates the skin within about 5 to about 15 minutes of administration. In some embodiments, the large agent penetrates the skin within about 15 to about 30 minutes of administration. In some embodiments, the large agent penetrates the skin within about 1 hour of administration. In some embodiments, the large agent penetrates the skin within about 2 hours of administration. In some embodiments, the large agent penetrates the skin within about 3 hours of administration. In some embodiments, the large agent penetrates the skin within about 4 hours of administration. In some embodiments, the large agent penetrates the skin within about 5 hours of administration. In some embodiments, the large agent penetrates the skin within about 6 hours of administration.
[0210] In some embodiments, the large agent penetrates the layer of the skin within about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 minutes of administration. In some embodiments, the large agent penetrates the layer of the skin within about 5 to about 60 minutes of administration. In some embodiments, the large agent penetrates the layer of the skin within about 5 to about 12 minutes of administration. In some embodiments, the large agent penetrates the layer of the skin within about 5 to about 15 minutes of administration. In some embodiments, the large agent penetrates the layer of the skin within about 15 to about 30 minutes of administration. In some embodiments, the large agent penetrates the layer of the skin within about 1 hour of administration. In some embodiments, the large agent penetrates the layer of the skin within about 2 hours of administration. In some embodiments, the large agent penetrates the layer of the skin within about 3 hours of administration. In some embodiments, the large agent penetrates the layer of the skin within about 4 hours of administration. In some embodiments, the large agent penetrates the layer of the skin within about 5 hours of administration. In some embodiments, the large drug penetrates the layers of the skin within about 6 hours of administration.
[0211] In some embodiments, the large agent penetrates the top layer of the skin within about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 minutes of administration. In some embodiments, the large agent penetrates the top layer of the skin within about 5 to about 60 minutes of administration. In some embodiments, the large agent penetrates the top layer of the skin within about 5 to about 12 minutes of administration. In some embodiments, the large agent penetrates the top layer of the skin within about 5 to about 15 minutes of administration. In some embodiments, the large agent penetrates the top layer of the skin within about 15 to about 30 minutes of administration. In some embodiments, the large agent penetrates the top layer of the skin within about 1 hour of administration. In some embodiments, the large agent penetrates the top layer of the skin within about 2 hours of administration. In some embodiments, the large agent penetrates the top layer of the skin within about 3 hours of administration. In some embodiments, the large agent penetrates the top layer of the skin within about 4 hours of administration. In some embodiments, the large drug penetrates the top layer of the skin within about 5 hours of administration, hi some embodiments, the large drug penetrates the top layer of the skin within about 6 hours of administration.
[0212] In some embodiments, the large agent penetrates the top layer of the skin, including the stratum corneum, dermal pores, and / or skin glands, within about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 minutes after administration. In some embodiments, the large agent penetrates the top layer of the skin, including the stratum corneum, dermal pores, and / or skin glands, within about 5 to about 60 minutes after administration. In some embodiments, the large agent penetrates the top layer of the skin, including the stratum corneum, dermal pores, and / or skin glands, within about 5 to about 12 minutes after administration. In some embodiments, the large agent penetrates the top layer of the skin, including the stratum corneum, dermal pores, and / or skin glands, within about 5 to about 15 minutes after administration. In some embodiments, the large agent penetrates the top layer of the skin, including the stratum corneum, dermal pores, and / or skin glands, within about 15 to about 30 minutes after administration. In some embodiments, the large agent penetrates the top layer of the skin, including the stratum corneum, dermal pores, and / or skin glands, within about 1 hour of administration. In some embodiments, the large agent penetrates the top layer of the skin, including the stratum corneum, dermal pores, and / or skin glands, within about 2 hours of administration. In some embodiments, the large agent penetrates the top layer of the skin, including the stratum corneum, dermal pores, and / or skin glands, within about 3 hours of administration. In some embodiments, the large agent penetrates the top layer of the skin, including the stratum corneum, dermal pores, and / or skin glands, within about 4 hours of administration. In some embodiments, the large agent penetrates the top layer of the skin, including the stratum corneum, dermal pores, and / or skin glands, within about 5 hours of administration. In some embodiments, the large agent penetrates the top layer of the skin, including the stratum corneum, dermal pores, and / or skin glands, within about 6 hours of administration.
[0213] kit In some embodiments, the present invention provides a pharmaceutical pack or kit comprising one or more emulsion compositions according to the present invention and one or more microneedle devices. In some embodiments, the pharmaceutical pack or kit comprises a preparation or pharmaceutical composition containing the provided composition in one or more containers, optionally filled with one or more additional components of the pharmaceutical composition. In some embodiments, the pharmaceutical pack or kit comprises an additional approved therapeutic agent for use in combination therapy (e.g., benzoyl peroxide for the treatment of acne; aluminum compounds for the treatment of hyperhidrosis; etc.). In some embodiments, a notice in the form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceutical products, reflecting approval by the agency of manufacture, use, or sale for human administration, may be optionally associated with such container(s).
[0214] In some embodiments, a kit is provided that includes a therapeutic agent.As one, but non-limiting example, the composition provided can be provided as a topical formulation and administered as a therapy in combination with the use of a microneedle processing device.Therefore, a pharmaceutical dosage or instructions for self-administration can be provided in the kit for administering to an individual suffering from or at risk of a disease state or disorder, such as those related to the dermis level of the skin.
[0215] In some embodiments, the kit may include (i) a provided composition; and (ii) at least one pharma- ceutically acceptable excipient; and (iii) at least one device for microneedling the skin; and (iv) instructions for use.
[0216] The present invention provides, inter alia, a technique for transdermal administration of large drugs, such as botulinum toxin or antibody drugs, by incorporating one or more large drugs into one or more emulsion compositions that are then administered in combination with MSCs. The inventors have surprisingly found that the transdermal penetration and bioavailability of botulinum toxin or antibody drugs incorporated into nanoemulsion compositions is dramatically improved when used in combination with MSCs. The benefit of the present invention is the ability to administer such large drugs intradermally while minimizing skin irritation or damage. The use of other drugs or steps with emulsion compositions and MSCs is not necessarily excluded, nor is it required, in all embodiments of the present invention.
[0217] Thus, the present invention provides techniques for administering large agents by topical application of novel emulsion compositions (e.g., macroemulsion and / or nanoemulsion compositions) in combination with MSCs. In some embodiments, the large agent is a botulinum toxin. In some embodiments, the botulinum emulsion composition is applied directly to the skin for absorption through the epidermal layers prior to MSCs. In some embodiments, the botulinum emulsion composition is applied directly to the skin for absorption through the epidermal layers after MSCs. In some embodiments, the botulinum emulsion composition is applied directly to the skin for absorption through the epidermal layers substantially simultaneously with MSCs.
[0218] In some embodiments, the botulinum emulsion composition in combination with MSCs may penetrate the top layers of the skin, including the stratum corneum, dermal pores, and / or skin glands, without the use of penetration enhancers. In some embodiments, the botulinum emulsion composition in combination with MSCs may penetrate the top layers of the skin, including the stratum corneum, dermal pores, and / or skin glands, without the use of disintegrating, irritating, and / or abrasive agents.
[0219] In some embodiments, the antibody drug emulsion composition in combination with MSCs may penetrate the top layers of the skin, including the stratum corneum, dermal pores, and / or skin glands, without the use of a penetration enhancer. In some embodiments, the large drug is an antibody drug. In some embodiments, the antibody drug emulsion composition is applied directly to the skin for absorption through the epidermal layer before the MSCs. In some embodiments, the antibody drug emulsion composition is applied directly to the skin for absorption through the epidermal layer after the MSCs. In some embodiments, the antibody drug emulsion composition is applied directly to the skin for absorption through the epidermal layer substantially simultaneously with the MSCs. In some embodiments, the antibody drug emulsion composition is applied directly to the skin for systemic absorption.
[0220] In some embodiments, the antibody drug emulsion composition in combination with MSCs may penetrate the top layers of the skin, including the stratum corneum, dermal pores, and / or skin glands, without the use of disintegrating, irritating, and / or abrasive agents.
[0221] It will be understood by those skilled in the art that the topical composition of the present invention may comprise a cosmetic formulation such as a skin softener, a nourishing lotion-type emulsion, a cleansing lotion, a cleansing cream, a skin milk, an emollient lotion, a massage cream, an emollient cream, a cosmetic base, a face pack or a face gel, a cleansing formulation such as a shampoo, a rinse, a body wash, a hair tonic, or a soap, or a dermatological composition such as a lotion, an ointment, a gel, a cream, a patch, or a spray. In some embodiments, the topical composition is not formulated for administration to a mucosa (e.g., is not suitable for application to a mucosa and / or is not formulated to deliver a suitable amount of a large agent to or across a mucosa).
[0222] Those skilled in the art will understand that the units herein refer to units that are biologically equivalent or bioactively equivalent to units defined by commercial manufacturers of botulinum toxin.
[0223] In some embodiments, the therapeutic effect of a botulinum toxin administered in accordance with the present invention may last as long as the effect of the injected solution. In some embodiments, the effect of such an injected solution may last for up to about 6-7 months. In some embodiments, the therapeutic effect of a botulinum toxin administered in accordance with the present invention may last for up to 6-7 months. In some embodiments, the use of a synthetic polymer carrier that can hold the botulinum toxin so that it is released gradually may prolong the effect for up to about 5 years (U.S. Patent No. 6,312,708).
[0224] In some embodiments, the present invention provides a topical formulation of botulinum toxin that avoids potential complications, including but not limited to systemic toxicity or botulism. In some embodiments, the dosage of botulinum toxin (including types A, B, C, D, E, F, or G or botulinum genetically engineered or chemically modified to act longer or shorter than botulinum toxin serotype A) can range from as little as about 1 unit to as much as about 20,000 units, with minimal risk of adverse side effects. The specific dosage can vary depending on the condition being treated and the treatment regimen being utilized. For example, treatment of subcutaneous overactive muscles may require a high transdermal dosage (e.g., 1000 units to 20,000 units) of botulinum toxin. In contrast, treatment of neurogenic inflammation or overactive sweat glands may require a relatively low transdermal dosage (e.g., about 1 unit to about 1,000 units) of botulinum toxin.
[0225] Some embodiments of the present invention contemplate a pharmaceutical composition comprising a stabilized botulinum toxin for transdermal delivery to a human patient. The botulinum toxin may be selected from the group consisting of botulinum toxin types A, B, C1, D, E, F and G, isolated and / or purified (i.e., about 150 kDa) botulinum toxin, and natural or recombinantly produced botulinum toxins. In some embodiments, the composition may contain from about 1 unit to about 20,000 units of botulinum toxin, and the composition may contain an amount of botulinum toxin sufficient to achieve a therapeutic effect lasting from 1 month to 5 years.
[0226] In some embodiments, the invention provides topical formulations of botulinum toxin (e.g., in botulinum emulsion compositions) that allow the botulinum toxin to penetrate through the skin of a subject without penetrating in significant amounts through blood vessels. For example, in some embodiments of the invention, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% of the botulinum toxin present in the pharmaceutical composition penetrates into the blood vessels upon application of the topical and / or transdermal preparations of the invention.
[0227] In some embodiments, the invention provides topical formulations of antibody drugs (e.g., antibody drug emulsion compositions) that allow the antibody drug to penetrate through the skin of a subject without penetrating in significant amounts through the blood vessels. For example, in some embodiments of the invention, less than about 25%, or even less than about 5%, of the antibody drug present in the pharmaceutical composition penetrates into the blood vessels upon application of the topical and / or transdermal preparations of the invention.
[0228] In some embodiments, the invention provides topical formulations of antibody drugs (e.g., antibody drug emulsion compositions) that allow the antibody drug to penetrate through the skin and penetrate through the blood vessels of a subject in significant amounts. In some embodiments, the invention provides topical formulations of antibody drugs (e.g., antibody drug emulsion compositions) that allow the antibody drug to penetrate through the skin and penetrate through the blood vessels of a subject in therapeutically effective amounts. For example, in some embodiments of the invention, more than about 25%, 50%, 75%, 90%, or 95% of the antibody drug present in the pharmaceutical composition penetrates into the blood vessels upon application of the topical and / or transdermal preparations of the invention. In some embodiments, the invention provides topical formulations of antibody drugs (e.g., antibody drug emulsion compositions) that allow the antibody drug to exert a systemic effect on the subject.
[0229] Those skilled in the art will appreciate that the compositions of the invention that achieve transdermal administration of a botulinum toxin or antibody agent can be incorporated into a device such as, for example, a patch. EXAMPLES
[0230] Example Example 1: Effect of Microneedle Skin Preconditioning (MSC) Pretreatment on Botulinum Toxin Bioavailability A single-dose topical study of the bioavailability of botulinum toxin following topical administration of botulinum nanoemulsion was conducted. The study was designed to test whether microneedle skin conditioning pretreatment (i.e., MSCs administered prior to any administration of botulinum treatment as described herein) significantly enhanced the bioavailability of botulinum.
[0231] The study included two test groups of eight rats each. Each group was treated once topically with a volume of botulinum nanoemulsion at a fixed concentration of botulinum on the skin overlying the biceps femoris, gastrocnemius, and tibialis anterior muscles of the right hind leg. Administration of the topical preparation to the skin took approximately 10 minutes, at which point the topical preparation was completely absorbed into the skin. The effect of such treatment was measured using a scale to measure limb paralysis, which is a known effect of administration of botulinum to that limb. The scale is based on the digit abduction score (DAS score), a four-point scale developed by Aoki (2001, Toxicon, 39:1815; and 2002, Toxicon, 40:923), and can be easily assessed in treated rats. A score of 0 is no paralysis and a score of 4 is complete paralysis. It is also known that doses of botulinum administered at concentrations sufficient to induce paralysis can also be continued to induce death in animals. Therefore, mortality rates were also compared between the two treatment groups.
[0232] Group 1 did not have the skin preconditioned with MN, as described in Table 5. Group 2 was treated (i.e., had the skin preconditioned) with five skin impressions of a microneedle array with 1400 mm needles in each area covering each of the biceps femoris, gastrocnemius, and tibialis anterior muscles of the right hind leg. The topical botulinum nanoemulsion treatment was thoroughly rubbed into the skin with a gloved finger until no treatment was observed or felt on the skin. [Table 5]
[0233] As shown in Figure 1, after one day of treatment, animals subjected to MSCs had DAS scores approximately twice as high as the control group without such preconditioning, establishing that MSCs unexpectedly increase the bioavailability of topical large drug nanoemulsions containing botulinum toxin. Similarly, as shown in Figure 2, the mortality rate in animals subjected to MSCs (100%) was found to be approximately twice as high after 40 hours of treatment when compared to the mortality rate in the control group without such preconditioning (50%), again establishing that MSCs unexpectedly increase the bioavailability of topical large drug nanoemulsions containing botulinum toxin.
[0234] In summary, the results of the study confirmed that MSCs significantly promoted the bioavailability of botulinum.
[0235] Example 2: Effect of MSC preconditioning on the bioavailability of botulinum toxin in humans: Effect on sweat reduction A single-dose topical study of the bioavailability of botulinum toxin following topical administration of a topical botulinum nanoemulsion formulation in humans is conducted. The study is designed to test whether microneedle skin preconditioning significantly enhanced the bioavailability of botulinum in humans by measuring sweat reduction in the skin following topical treatment with the botulinum nanoemulsion formulation.
[0236] The study involves one subject. Two spots, each located on the abdomen, each approximately 2 cm square in area, each 5 cm apart from each other, are selected and marked with a marker. Each spot is treated once topically with a volume of the botulinum nanoemulsion formulation at a fixed concentration of botulinum. Administration of the topical preparation to the skin takes approximately 5 minutes, at which point the topical preparation is completely absorbed into the skin. The first spot is not preconditioned with the microneedle array and is the control site. The second spot is preconditioned with three impressions of the 1400 micrometer long microneedle array before application of the botulinum formulation and is the intervention site.
[0237] The expected effect of such treatment is a reduction in sweating at the site of botulinum nanoemulsion treatment. The amount of sweating at the treatment site is measured by two methods: 1) an evaporometer test (an instrument used to measure the rate of water evaporation from the skin is used to detect the sweating rate (so that more evaporation is detected along with increased sweating); or 2) a starch-iodine test (a subject has povidone applied to the treatment site; it is allowed to dry; cornstarch is sprinkled over the treatment site; if the subject's sweat gets into the white cornstarch, it turns purple; if the subject does not sweat, it stays white; this is called the starch-iodine test). For either sweat detection method, the subject is placed under a heat lamp to induce sweating, and then the sweat detection method is used.
[0238] Sweat detection methods are used at baseline, prior to botulinum nanoemulsion treatment; 2 weeks post-treatment; and 4 weeks post-treatment. The study finds that at baseline, the average sweat volume detected by either the evaporometer test or the starch-iodine test is approximately equal at the control and intervention sites. At 2 and 4 weeks post-treatment, the average sweat volume detected by either the evaporometer test or the starch-iodine test at the control site is greater than that detected at the intervention site at these post-treatment weeks.
[0239] This study establishes that microneedle preconditioning unexpectedly increases the bioavailability of topical large drug nanoemulsions containing botulinum toxin.
[0240] Example 3: Effect of MSC preconditioning on the bioavailability of botulinum toxin in humans: Effect on sweat reduction A single-dose topical study of the bioavailability of botulinum toxin following topical administration of a topical botulinum nanoemulsion formulation in humans is conducted. The study is designed to test whether microneedle skin preconditioning significantly enhanced the bioavailability of botulinum in humans by measuring sweat reduction in the skin following topical treatment with the botulinum nanoemulsion formulation.
[0241] The study involves 12 subjects. Two spots, each on the back, approximately 2 cm square in area and 5 cm apart from each other, are selected and marked with a marker. Each spot is treated once topically with a volume of a botulinum nanoemulsion formulation at a fixed concentration of botulinum. Administration of the topical preparation to the skin takes approximately 5 minutes, at which point the topical preparation is completely absorbed into the skin. The first spot is not preconditioned with the microneedle array and is the control site. The second spot is preconditioned with three impressions of a 1400 micrometer long microneedle array before application of the botulinum formulation and is the intervention site.
[0242] The expected effect of such treatment is a reduction in sweating at the site of botulinum nanoemulsion treatment. The amount of sweating at the treatment site is measured by two methods: 1) an evaporometer test (an instrument used to measure the rate of water evaporation from the skin is used to detect the sweating rate (so that more evaporation is detected along with increased sweating); or 2) a starch-iodine test (a subject has povidine applied to the treatment site; it is allowed to dry; cornstarch is sprinkled over the treatment site; if the subject's sweat gets into the white cornstarch, it turns purple; if the subject does not sweat, it stays white; this is called the starch-iodine test). For either sweat detection method, the subject is placed in a sauna to induce sweating, and then the sweat detection method is used.
[0243] Sweat detection methods are used at baseline, prior to botulinum nanoemulsion treatment; 2 weeks post-treatment; and 4 weeks post-treatment. The study finds that at baseline, the average sweat volume detected by either the evaporometer test or the starch-iodine test is approximately equal at the control and intervention sites. At 2 and 4 weeks post-treatment, the average sweat volume detected by either the evaporometer test or the starch-iodine test at the control site is greater than that detected at the intervention site at these post-treatment weeks.
[0244] This study establishes that microneedle preconditioning unexpectedly increases the bioavailability of topical large drug nanoemulsions containing botulinum toxin.
[0245] Example 4: Effect of MSC preconditioning on the bioavailability of botulinum toxin in humans: Effect on sweat reduction A single-dose topical study of the bioavailability of botulinum toxin following topical administration of a topical botulinum nanoemulsion formulation in humans is conducted. The study is designed to test whether microneedle skin preparation significantly enhanced the bioavailability of botulinum in humans by measuring sweat reduction in the skin following topical treatment with the botulinum nanoemulsion formulation.
[0246] The study involves one subject. Two spots, each located on the abdomen, each approximately 3 cm square in area and 5 cm apart from each other, are selected and marked with a marker. Each spot is treated once topically with a volume of the botulinum nanoemulsion formulation. Administration of the topical preparation to the skin takes approximately 5 minutes, at which point the topical preparation is completely absorbed into the skin. The first spot is not preconditioned with the microneedle array before application of the botulinum formulation and is the control site. The second spot is preconditioned with three impressions of a 1400 micrometer long microneedle array before application of the botulinum formulation and is the intervention site, where the concentration of the botulinum formulation administered to the intervention site is half that of the control site.
[0247] The expected effect of such treatment is a reduction in sweating at the site of botulinum nanoemulsion treatment. The amount of sweating at the treatment site is measured by two methods: 1) an evaporometer test (an instrument used to measure the rate of water evaporation from the skin is used to detect the sweating rate (so that more evaporation is detected along with increased sweating); or 2) a starch-iodine test (a subject has povidone applied to the treatment site; it is allowed to dry; cornstarch is sprinkled over the treatment site; if the subject's sweat gets into the white cornstarch, it turns purple; if the subject does not sweat, it stays white; this is called the starch-iodine test). For either sweat detection method, the subject is placed under a heat lamp to induce sweating, and then the sweat detection method is used.
[0248] Sweat detection methods are used at baseline, prior to botulinum nanoemulsion treatment; 2 weeks after treatment; and 4 weeks after treatment. The study finds that at baseline, the average sweat volume detected by either the evaporometer sweat test or the starch-iodine test is approximately equal at the control and intervention sites. At 2 and 4 weeks after treatment, the average sweat volume detected by either the evaporometer test or the starch-iodine test at the control sites is comparable to each other, despite the fact that the concentration of the botulinum formulation administered at the intervention sites is half that of the control sites. This study establishes that microneedle preconditioning unexpectedly increases the bioavailability of topical large drug nanoemulsions containing botulinum toxin.
[0249] Example 5: Effect of Microneedling (MN) Skin Preconditioning on Botulinum Toxin Bioavailability in Humans: Effects on Sweat and Wrinkle Reduction A single dose topical study of the bioavailability of botulinum toxin following topical administration of a topical botulinum nanoemulsion formulation in humans is conducted. The study is designed to test whether microneedle skin preconditioning significantly enhanced the bioavailability of botulinum in humans by measuring sweat reduction and wrinkle reduction in the skin following topical treatment with the botulinum nanoemulsion formulation.
[0250] The study involves one subject with severe frontal (or horizontal) wrinkles on the forehead. Two spots, each approximately 2 cm square in area and 5 cm apart from each other, are selected and marked with a marker, each on the subject's forehead. Each spot is treated once topically with a volume of a botulinum nanoemulsion formulation at a fixed concentration of botulinum. Administration of the topical formulation to the skin takes approximately 5 minutes, at which point the topical formulation is completely absorbed into the skin. The first spot is not preconditioned with the microneedle array and is the control site. The second spot is preconditioned with three impressions of a 1400 micrometer long microneedle array prior to application of the botulinum formulation and is the intervention site.
[0251] The expected effect of such treatment is a reduction in sweating at the site of botulinum nanoemulsion treatment. The amount of sweating at the treatment site is measured by two methods: 1) an evaporometer test (an instrument used to measure the rate of water evaporation from the skin is used to detect its sweating rate (so that more evaporation is detected along with increased sweating); or 2) a starch-iodine test (a subject has povidone applied to the treatment site; it is allowed to dry; cornstarch is sprinkled over the treatment site; if the subject's sweat gets into the white cornstarch, it turns purple; if the subject does not sweat, it stays white; this is called the starch-iodine test). For either sweat detection method, the subject is placed in a sauna to induce sweating and then the method is used.
[0252] The expected effect of botulinum nanoemulsion treatment is to reduce frontal wrinkles at the sites of botulinum nanoemulsion treatment. The severity of wrinkles is measured using a 4-point Wrinkle Scale (Wrinkle Scale): 0=none, 1=mild, 2=moderate, 3=severe.
[0253] Sweat detection methods are used at baseline, prior to botulinum nanoemulsion treatment; 2 weeks after treatment; and 4 weeks after treatment. The study finds that at baseline, the average sweat volume detected by either the evaporometer test or the starch-iodine test is approximately equal at the control and intervention sites. At 2 and 4 weeks after treatment, the average sweat volume detected by either the evaporometer test or the starch-iodine test at the control sites is greater than that detected at the intervention sites at these post-treatment weeks. The study finds that at baseline, the average severity of frontal wrinkles as measured by the wrinkle scale is approximately equal at the control and intervention sites. At 2 and 4 weeks after treatment, the average severity of frontal wrinkles as measured by the wrinkle scale at the control sites is greater than that detected at the intervention sites at these post-treatment weeks.
[0254] This study establishes that microneedle preconditioning unexpectedly increases the bioavailability of topical large drug nanoemulsions containing botulinum toxin.
[0255] Example 6: Effect of Microneedling (MN) Skin Preconditioning on Botulinum Toxin Bioavailability in Humans: Effect on Sweat Reduction in Subjects with Hyperhidrosis A single-dose topical study of the bioavailability of botulinum toxin following topical administration of a topical botulinum nanoemulsion formulation in humans is conducted. The study is designed to test whether microneedle skin preconditioning significantly enhanced the bioavailability of botulinum in humans by measuring sweat reduction in the skin following topical treatment with the botulinum nanoemulsion formulation.
[0256] The study includes two treatment groups of 20 subjects each with axillary hyperhidrosis, a condition characterized by excessive sweating in the armpits: Group 1 is the control group, with botulinum nanoemulsion applied to each subject's armpit; Group 2 is the intervention group, with each portion of the skin in the armpit preconditioned with three impressions of a 1400 micrometer long microneedle array prior to application of the botulinum nanoemulsion formulation. Each subject in groups 1 and 2 is treated once topically with a volume of the botulinum nanoemulsion formulation at a fixed concentration of botulinum. Administration of the topical formulation to the skin takes approximately 5 minutes, at which point the topical formulation is completely absorbed into the skin.
[0257] The expected effect of such treatment is a reduction in sweating at the site of botulinum nanoemulsion treatment, which is the armpit. The amount of sweating at the treatment site is measured by gravimetric sweat measurement (GS test): the subject's armpit is dried with a paper towel; a filter paper is weighed; the filter paper is applied to the armpit for 5 minutes; then it is weighed again; the excess weight after reweighing the paper is the weight of sweat produced by the subject in 5 minutes. The severity of the subject's hyperhidrosis condition is measured by the subject using the Hyperhidrosis Sweat Severity Scale (HDSS), a 4-point scale rated by the subject: 0=none, 1=mild, 2=moderate, 3=severe.
[0258] The GS test and HDSS are used at baseline, prior to botulinum nanoemulsion treatment; 2 weeks after treatment; and 4 weeks after treatment. The study finds that at baseline, the average amount of sweat detected by the GS test or disease severity measured by the HDSS is approximately equal across groups 1-2. At 2 and 4 weeks after treatment, the average amount of sweat detected or disease severity in group 1 is greater than that of group 2 at these post-treatment weeks.
[0259] This study establishes that microneedle preconditioning unexpectedly increases the bioavailability of topical large drug nanoemulsions containing botulinum toxin.
[0260] Example 7: Effect of Microneedling (MN) Skin Preconditioning on Botulinum Toxin Bioavailability in Humans: Effect on Reduction of Crow's Feet Wrinkles A single-dose topical study of the bioavailability of botulinum toxin following topical administration of a topical botulinum nanoemulsion formulation in humans was conducted. The study was designed to test whether microneedle skin preconditioning significantly enhanced the bioavailability of botulinum in humans by measuring wrinkle reduction in the skin following topical treatment with a botulinum nanoemulsion formulation.
[0261] The study included one subject who had severe crow's feet wrinkles on the side of her eye. Botulinum nanoemulsion was applied to the subject's crow's feet wrinkles. The dose of botulinum applied to the skin was approximately 15% of the effective dose when botulinum nanoemulsion was applied without microneedle skin preconditioning. The effective dose was defined as the dose that would cause at least a 2 point improvement in the appearance of wrinkles as measured by a 5-point wrinkle rating scale when the subject was contracting the muscles that cause crow's feet wrinkles. Prior to application of the botulinum nanoemulsion formulation to one side of the face, the subject was preconditioned with two impressions of a 1400 micrometer long microneedle array on each area of the skin where the crow's feet wrinkles were located, and prior to application of the botulinum emulsion formulation to the other side of the face, the subject was preconditioned with two impressions of an 800 micrometer long microneedle array on each area of the skin where the crow's feet wrinkles were located. Application of the topical formulation to the skin took approximately 5 minutes, at which point the topical formulation was completely absorbed into the skin.
[0262] The expected effect of botulinum nanoemulsion treatment is a reduction in crow's feet wrinkles at the sites of botulinum nanoemulsion treatment. Wrinkle severity was measured using a 5-point wrinkle scale (Wrinkle Scale): 0=none, 1=minimal, 2=mild, 3=moderate, 4=severe.
[0263] The wrinkle scale was used at baseline, prior to botulinum nanoemulsion treatment; 2 weeks after treatment; and 4 weeks after treatment. The study found that at baseline, subjects had severe wrinkles as assessed by the wrinkle scale, with a score of 4 on a 5-point wrinkle scale. Two weeks after treatment, the average severity of wrinkles decreased by 1 point on the wrinkle scale to a score of 3 (moderate) on each side of the face. Four weeks after treatment, the average severity of wrinkles decreased by 2 points on the wrinkle scale to a score of 2 (mild) on each side of the face.
[0264] This study established that microneedle preconditioning unexpectedly increased the bioavailability of a topical large drug nanoemulsion containing botulinum toxin.
[0265] Example 8: Effect of Microneedling (MN) Skin Preconditioning on Botulinum Toxin Bioavailability in Humans: Effect on Reduction of Crow's Feet Wrinkles A single dose topical study of the bioavailability of botulinum toxin following topical administration of a topical botulinum nanoemulsion formulation in humans is conducted. The study is designed to test whether microneedle skin preconditioning significantly enhanced the bioavailability of botulinum in humans by measuring wrinkle reduction in the skin following topical treatment with the botulinum nanoemulsion formulation.
[0266] The study includes two treatment groups of 20 subjects, each with severe crow's feet on the side of their eye: Group 1 is the control group, with botulinum nanoemulsion applied to each subject's crow's feet; Group 2 is the intervention group, preconditioned with three impressions of a 1400 micrometer long microneedle array on each area of skin where the crow's feet are located prior to application of the botulinum nanoemulsion formulation. Each subject in groups 1 and 2 is treated once topically with a volume of the botulinum nanoemulsion formulation at a fixed concentration of botulinum. Administration of the topical formulation to the skin takes approximately 5 minutes, at which point the topical formulation is completely absorbed into the skin.
[0267] The expected effect of botulinum nanoemulsion treatment is a reduction in crow's feet wrinkles at the sites of botulinum nanoemulsion treatment. Wrinkle severity is measured using a 4-point Wrinkle Scale (Wrinkle Scale): 0=none, 1=mild, 2=moderate, 3=severe.
[0268] The wrinkle scale is used at baseline, prior to botulinum nanoemulsion treatment; 2 weeks post-treatment; and 4 weeks post-treatment. The study finds that at baseline, the mean severity of wrinkles detected by the wrinkle scale is approximately equal across groups 1-2. At 2 and 4 weeks post-treatment, the mean severity of wrinkles in group 1 is higher than that detected in group 2 at these post-treatment weeks.
[0269] This study establishes that microneedle preconditioning unexpectedly increases the bioavailability of topical large drug nanoemulsions containing botulinum toxin.
[0270] Example 9: Effect of Microneedling (MN) Skin Preconditioning on Botulinum Toxin Bioavailability in Humans: Effect of Varying Dose on Reduction of Crow's Feet Wrinkles A single dose topical study of the bioavailability of botulinum toxin following topical administration of a topical botulinum nanoemulsion formulation in humans is conducted. The study is designed to test whether microneedle skin preconditioning significantly enhanced the bioavailability of botulinum in humans by measuring wrinkle reduction in the skin following topical treatment with the botulinum nanoemulsion formulation.
[0271] The study includes two treatment groups of 20 subjects, each with severe crow's feet: Group 1 is the control group, with botulinum nanoemulsion applied to each subject's crow's feet; Group 2 is the intervention group, with each area of skin where the crow's feet are located preconditioned with three indentations of a 1400 micrometer long microneedle array prior to application of the botulinum nanoemulsion formulation. Each subject is treated once topically with a volume of the botulinum nanoemulsion formulation at a fixed concentration of botulinum, except that the treatment in Group 1 has twice the botulinum concentration of the treatment in Group 2. Administration of the topical formulation to the skin takes approximately 5 minutes, at which point the topical formulation is completely absorbed into the skin.
[0272] The expected effect of botulinum nanoemulsion treatment is a reduction in crow's feet wrinkles at the sites of botulinum nanoemulsion treatment. Wrinkle severity is measured using a 4-point Wrinkle Scale (Wrinkle Scale): 0=none, 1=mild, 2=moderate, 3=severe.
[0273] The Wrinkle Scale is used at baseline, prior to botulinum nanoemulsion treatment; 2 weeks after treatment; and 4 weeks after treatment. The study finds that at baseline, the mean severity of wrinkles as detected by the Wrinkle Scale is approximately equal across Groups 1 and 2. At 2 weeks and 4 weeks after treatment, the mean severity of wrinkles in Groups 1 and 2 is reduced by approximately the same amount compared to baseline, even though Group 1 was treated with twice the concentration of Group 2.
[0274] This study establishes that microneedle preconditioning unexpectedly increases the bioavailability of a topical large drug nanoemulsion containing botulinum toxin, such that lower doses of botulinum can be used to obtain equivalent therapeutic efficacy when compared to patients who did not receive microneedle skin preconditioning.
[0275] Example 10: Effect of Microneedling (MN) Skin Preconditioning on Botulinum Toxin Bioavailability in Humans: Effect of Varying Dose on Reduction of Crow's Feet Wrinkles A single dose topical study of the bioavailability of botulinum toxin following topical administration of a topical botulinum macroemulsion formulation in humans is conducted. The study is designed to test whether microneedle skin preconditioning significantly enhanced the bioavailability of botulinum in humans by measuring wrinkle reduction in the skin following topical treatment with a botulinum macroemulsion formulation.
[0276] The study includes two treatment groups of 20 subjects, each with severe crow's feet: Group 1 is the control group, with botulinum macroemulsion applied to each subject's crow's feet; Group 2 is the intervention group, with each area of skin where the crow's feet are located preconditioned with three impressions of a 1400 micrometer long microneedle array prior to application of the botulinum macroemulsion formulation. Each subject is treated once topically with a volume of the botulinum nanoemulsion formulation at a fixed concentration of botulinum. Administration of the topical formulation to the skin takes approximately 5 minutes, at which point the topical formulation is completely absorbed into the skin.
[0277] The expected effect of botulinum nanoemulsion treatment is a reduction in crow's feet wrinkles at the sites of botulinum nanoemulsion treatment. Wrinkle severity is measured using a 4-point Wrinkle Scale (Wrinkle Scale): 0=none, 1=mild, 2=moderate, 3=severe.
[0278] The Wrinkle Scale is used at baseline, prior to botulinum nanoemulsion treatment; 2 weeks after treatment; and 4 weeks after treatment. The study finds that at baseline, the mean severity of wrinkles as detected by the Wrinkle Scale is approximately equal across Groups 1 and 2. At 2 weeks and 4 weeks after treatment, the mean severity of wrinkles in Group 1 is greater than the mean severity of wrinkles in Group 2.
[0279] This study establishes that microneedle skin preconditioning unexpectedly increases the bioavailability of a topical large drug macroemulsion containing botulinum toxin when compared to patients who did not receive microneedle skin preconditioning.
[0280] References Alkilani, A.Z., et al., “Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum.” Pharmaceutics. 7:438 - 470(2015). Gomaa, Y., et al, “Effect of microneedle treatment on the skin permeation of a nanoencapsulated dye.” J Pharm Pharmacol. 2012 November ;64(11):1592 - 1602. Guo, L., et al., “Enhanced transcutaneous immunization via dissolving microneedle array loaded with liposome encapsulated antigen and adjuvant.” International Journal of Pharmaceutics. 447:22 - 30(2013) Hiraishi, Y., et al., “Development of a novel therapeutic approach using a retinoic acid - loaded microneedle patch for seborrheic keratosis treatment and safety study in humans.” Journal of Controlled Release. 171:93 - 103(2013). Ling, M. & Chen, M., “Dissolving polymer microneedle patches for rapid and efficient transdermal delivery of insulin to diabetic rats.” Acta Biomaterialia, 9, 8952 - 8961(2013). Prausnitz,M.R.& Langer,R.“Transdermal drug delivery,”Nat Biotechnol.26(11):1261-1268(2008). Qin,G.,et al.,“Simultaneous basal-bolus delivery of fast-acting insulin and its significance in diabetes management.” Nanomedicine:NBM,8:221-227(2012). Tang,H.,et al.,“Theoretical description of transdermal transport of hydrophilic permeants:Application to low-frequency sonophoresis.” Journal of Pharmaceutical Sciences.90(5):545-568(2001). Verbaan,F.J.,et al.,“Assembled microneedle arrays enhance the transport of compounds varying over a large range of molecular weight across human dermatomed skin.” Journal of Controlled Release.117:238-245(2007). Wu,X.,et al.,“Effects of pretreatment of needle puncture and sandpaper abrasion on the in vitro skin permeation of fluorescein isothiocyanate(FITC)-dextran.” International Journal of Pharmaceutics.316:102-108(2006). Zhang, S., et al., “Enhanced bioavailability of L-carnitine after painless intradermal delivery vs. oral administration in rats.” Pharm Res. 28:117-123 (2011). Zhang, S., et al., “Enhanced delivery of hydrophilic peptides in vitro by transdermal microneedle pretreatment.” Acta Pharmaceutica Sinica B.4(1):100-104(2014).
[0281] Equivalent Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The scope of the invention is not intended to be limited to the above description, but is as set forth in the following claims. The present invention provides the following: (Item 1) A method comprising applying to a site an emulsion composition comprising a large drug having a molecular weight of 100,000 KDa or greater in combination with microneedle skin preparation (MSC) of said site. (Item 2) 2. The method of claim 1, wherein the composition comprising a large drug comprises a nanoemulsion comprising the large drug. (Item 3) 2. The method of claim 1, wherein the composition comprising a large drug comprises a macroemulsion comprising the large drug. (Item 4) The method according to any one of items 1 to 3, further comprising administration of a non-irritating penetration enhancer. (Item 5) 5. The method of claim 4, wherein the non-irritating penetration enhancer is selected from a carrier peptide and a copeptide. (Item 6) The non-irritating penetration enhancer comprises a cationic peptide and the sequence RKKRRQRRRG-(K) 15 The method according to any one of items 4 to 5, wherein the positively charged carrier has the formula: -GRKKRRQRRR. (Item 7) 7. The method according to any one of items 1 to 6, wherein the MSCs at the site are performed prior to applying the composition comprising a large agent to the site. (Item 8) 7. The method according to any one of items 1 to 6, wherein the MSCs at the site are administered after application of the composition comprising a large agent to the site. (Item 9) 7. The method according to any one of items 1 to 6, wherein application of the composition comprising the MSCs and large agent to the site is performed substantially simultaneously. (Item 10) 10. The method according to any one of items 1 to 9, wherein the large agent is a botulinum toxin. (Item 11) 11. The method of claim 10, further comprising delivering the botulinum toxin with a biologically active agent. (Item 12) 12. The method of claim 11, wherein the biologically active agent is selected from steroids, retinoids, anesthetics, fillers, silicones, and / or collagen. (Item 13) 13. The method of claim 12, wherein the biologically active agent is selected from hydrocortisone, retin A, and / or lidocaine. (Item 14) 10. The method according to any one of items 1 to 9, wherein the large drug is an antibody drug. (Item 15) 15. The method of claim 14, wherein the antibody drug is selected from an anti-TNFα antibody, an anti-CD2 antibody, an anti-CD4 antibody, an anti-IL-12 antibody, an anti-IL-17 antibody, an anti-IL-22 antibody, and an anti-IL-23 antibody. (Item 16) 16. The method of any one of items 14-15, wherein the antibody drug is selected from antibodies having an epitope binding member found in one or more of infliximab, adalimumab, golimumab, etanercept, etanercept-szzs, certolizumab pegol, sipilizumab, zanolimumab, briakinumab, secukinumab, brodalumab, fezakinumab, ustekinumab and / or guselkumab. (Item 17) 17. The method of any one of items 14 to 16, further comprising delivering the antibody drug together with a biologically active agent. (Item 18) 18. The method of any one of items 14 to 17, further comprising delivering the antibody agent together with a non-irritating penetration enhancer. (Item 19) 19. The method of claim 18, wherein the non-irritant penetration enhancer is selected from a copeptide and a carrier peptide. (Item 20) 20. The method of any one of items 1 to 19, wherein the MSCs at the site are achieved with a device comprising multiple needles. (Item 21) 21. The method of claim 20, wherein the device is a patch, roller, stamp, or pen. (Item 22) 22. The method according to any one of items 1 to 21, wherein the site is a skin surface overlying a muscle or muscle group of a target. (Item 23) 23. The method according to any one of items 1 to 22, wherein the site is a skin surface containing sweat glands. (Item 24) 24. The method according to any one of items 1 to 23, wherein the site is a skin surface containing sebaceous glands. (Item 25) 25. The method according to any one of items 1 to 24, wherein the site is a skin surface containing hair follicles. (Item 26) 26. The method according to any one of items 20 to 25, wherein the needle has a length sufficient to protrude through the stratum corneum of the skin. (Item 27) 27. The method according to any one of items 20 to 26, wherein the needle has an insufficient length to reach nerves in the dermis of the skin. (Item 28) 28. The method according to any one of items 20 to 27, wherein the needle has a length of about 10 to about 4000 μm. (Item 29) 29. The method according to any one of items 20 to 28, wherein the needle has a length of about 100 μm or more. (Item 30) 29. The method according to any one of items 20 to 28, wherein the needle has a length of about 25 μm or more. (Item 31) 29. The method according to any one of items 20 to 28, wherein the needle has a length of about 300 μm, about 500 μm, about 800 μm, about 1000 μm, about 1500 μm, about 2000 μm, or about 4000 μm or more. (Item 32) 32. The method according to any one of items 20 to 31, wherein the needle is made of a biocompatible material. (Item 33) 32. The method according to any one of items 20 to 31, wherein the needle is made of metal. (Item 34) 34. The method of any one of items 1 to 33, wherein said MSC comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 administrations of MN or MN array impressions. (Item 35) 35. The method of claim 34, wherein the MN array is rotated between one or more impressions. (Item 36) 35. The method of claim 34, wherein the MN array is not rotated between one or more impressions. (Item 37) The method according to any one of items 34 to 36, wherein the indentations are made on approximately the same site. (Item 38) 37. The method according to any one of items 34 to 36, wherein the indentation is performed on an overlapping site. (Item 39) The method according to any one of items 34 to 36, wherein the indentations are made on different sites. (Item 40) 40. The method of any one of items 34 to 39, wherein the MN array is in the form of a stamp or roller. (Item 41) 41. The method according to claim 40, wherein the impression is made by stamping or rolling a roller. (Item 42) 42. The method of any one of items 1-41, wherein the large drug penetrates the skin within about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 minutes of administration. (Item 43) 42. The method according to any one of items 1 to 41, wherein the large drug penetrates the skin within about 5 to about 60 minutes, about 5 to about 12 minutes, about 5 to about 15 minutes, or about 15 to about 30 minutes of administration. (Item 44) 42. The method of any one of items 1-41, wherein the large drug penetrates the skin within about 1, 2, 3, 4, 5, or 6 hours of administration. (Item 45) 33. The method according to any one of items 20 to 32, wherein the needle is composed of a dissolving polymer. (Item 46) 46. The method of any one of items 1 to 45, wherein said administering comprises administering said composition comprising a large drug in a smaller dose compared to a reference local treatment regimen in which microneedles are not used. (Item 47) 47. The method of any one of items 1 to 46, comprising administering the composition comprising multiple doses of a large drug over time. (Item 48) 48. The method of claim 47, wherein said administering comprises administering said composition comprising a smaller dose of a large drug over a period of treatment to produce a comparable therapeutic effect compared to a reference treatment regime in which microneedles are not used. (Item 49) 49. The method of claim 47 or 48, wherein each dose of the composition containing a large drug is separated by a specific period of time. (Item 50) 50. The method of claim 49, wherein the specified time period is longer than the specified time period for administering a reference treatment regimen in which microneedles are not used. (Item 51) 51. The method of any one of items 46 to 50, wherein the reference treatment regimen comprises administering the composition comprising a large agent without MSCs. (Item 52) 52. A method for treating a skin disorder, comprising the method according to any one of items 1 to 51. (Item 53) 53. The method of item 52, wherein the skin disorder is selected from acne, unwanted sweating, body odor, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, alopecia, psoriasis, actinic keratosis, eczematoid dermatitis, sebum excess production disorders, burns, lupus erythematosus, hyperpigmentation disorders, hypopigmentation disorders, skin cancer, skin infections, facial wrinkles, facial disfigurement, neck, multifunctional facial muscles, hypercontractile facial muscles, platysma band, and / or combinations thereof. (Item 54) 52. A method for treating unwanted sweating, body odor, hyperhidrosis, bromhidrosis, chromhidrosis, alopecia, Raynaud's phenomenon, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, lupus erythematosus, systemic lupus erythematosus, discoid lupus, drug-induced lupus, neonatal lupus, Crohn's disease, inflammatory bowel disease, ulcerative colitis, lung disorders, asthma, chronic obstructive airway disorders, amyloidosis, systemic amyloidosis, cutaneous amyloidosis, cancer, skin cancer, blood cancer, breast cancer, colon cancer, lung cancer, prostate hyperplasia, dyslipidemia, hypercholesterolemia. , an infection, a C. difficile infection, a Staphylococcus infection, dystonia, headache, pain, pain associated with arthritis, pain associated with rheumatoid arthritis, pain associated with psoriatic arthritis, pain associated with osteoarthritis, certain ophthalmologic conditions, certain urological conditions, neuromuscular disorders, conditions involving muscle spasms and / or contractures, strabismus, hemifacial spasm, tremor, spasticity such as that resulting from multiple sclerosis, retroorbital muscles, neurological conditions, Alzheimer's disease, Parkinson's disease, or stroke. (Item 55) The method according to any one of items 1 to 54, wherein the composition containing a large drug is formulated as a lotion, cream, powder, ointment, liniment, gel, or drop. A patch comprising a macrodrug-containing composition and a plurality of microneedles. (Item 57) 57. The patch of item 56, wherein the composition comprising a large drug comprises a nanoemulsion. (Item 58) Item 59. The patch according to item 56, wherein the composition containing a large drug comprises a macroemulsion. 59. The patch of any one of items 56 to 58, wherein the needles have a length sufficient to protrude through the stratum corneum of the skin. (Item 60) 60. The patch of any one of items 57 to 59, wherein the needles have an insufficient length to reach nerves in the dermis of the skin. (Item 61) 61. The patch according to any one of items 57 to 60, wherein the needle has a length of about 10 to about 1000 μm. (Item 62) 62. The patch according to any one of items 57 to 61, wherein the needle has a length of about 100 μm or more. (Item 63) 63. The patch of any one of items 57 to 62, wherein the needle has a length of about 300 μm or more. (Item 64) 64. The patch of any one of items 57 to 63, wherein the needle is made of a biocompatible material. (Item 65) 65. The patch according to any one of items 57 to 64, wherein the needle is made of metal. (Item 66) 65. The patch of any one of items 57 to 64, wherein the needle is composed of a dissolving polymer. (Item 67) 67. The patch of any one of items 57 to 66, wherein the large drug has a molecular weight of 100 KDa or more. (Item 68) 68. The patch of any one of items 57 to 67, wherein the large drug is a botulinum toxin. (Item 69) 68. The patch of any one of items 57 to 67, wherein the large drug is an antibody drug. (Item 70) A kit comprising a composition containing a large drug and a patch for use in applying said composition containing a large drug to a site. (Item 71) 71. The kit of claim 70, wherein the composition containing the large drug is incorporated into the patch. (Item 72) A kit comprising a composition comprising a macrophages and a device for microneedle preparation of a site. (Item 73) 73. The kit of any one of items 70 to 72, wherein the composition comprising a large drug comprises a nanoemulsion. (Item 74) 73. The kit according to any one of items 70 to 72, wherein the composition comprising a large drug comprises a macroemulsion. (Item 75) 75. The kit of any one of items 70 to 74, wherein the device comprises a plurality of needles. (Item 76) 76. The kit of any one of items 70 to 75, wherein the device is a patch, a roller, a stamp, or a pen. (Item 77) The kit according to any one of Items 70 to 76, comprising the patch according to any one of Items 56 to 68. (Item 78) 78. The kit of any one of items 70 or 72-77, wherein the composition comprising a macro drug is formulated as a lotion, cream, powder, ointment, liniment, gel, or drop. The present invention provides, for example, the following items. (Item 1) A method comprising applying to a site an emulsion composition comprising a large drug having a molecular weight of 100,000 Da or greater in combination with microneedle skin preparation (MSC) of said site. (Item 2) 2. The method of claim 1, wherein the composition comprising a large drug comprises a nanoemulsion comprising the large drug. (Item 3) 2. The method of claim 1, wherein the composition comprising a large drug comprises a macroemulsion comprising the large drug. (Item 4) The method according to any one of items 1 to 3, further comprising administration of a non-irritating penetration enhancer. (Item 5) 5. The method of claim 4, wherein the non-irritating penetration enhancer is selected from a carrier peptide and a copeptide. (Item 6) The non-irritating penetration enhancer comprises a cationic peptide and the sequence RKKRRQRRRG-(K) 15 The method according to any one of items 4 to 5, wherein the positively charged carrier has the formula: -GRKKRRQRRR. (Item 7) 7. The method according to any one of items 1 to 6, wherein the MSCs at the site are performed prior to applying the composition comprising a large agent to the site. (Item 8) 7. The method according to any one of items 1 to 6, wherein the MSCs at the site are administered after application of the composition comprising a large agent to the site. (Item 9) 7. The method according to any one of items 1 to 6, wherein application of the composition comprising the MSCs and large agent to the site is performed substantially simultaneously. (Item 10) 10. The method according to any one of items 1 to 9, wherein the large agent is a botulinum toxin. (Item 11) 11. The method of claim 10, further comprising delivering the botulinum toxin with a biologically active agent. (Item 12) 12. The method of claim 11, wherein the biologically active agent is selected from steroids, retinoids, anesthetics, fillers, silicones, and / or collagen. (Item 13) 13. The method of claim 12, wherein the biologically active agent is selected from hydrocortisone, retin A, and / or lidocaine. (Item 14) 10. The method according to any one of items 1 to 9, wherein the large drug is an antibody drug. (Item 15) 15. The method of claim 14, wherein the antibody drug is selected from an anti-TNFα antibody, an anti-CD2 antibody, an anti-CD4 antibody, an anti-IL-12 antibody, an anti-IL-17 antibody, an anti-IL-22 antibody, and an anti-IL-23 antibody. (Item 16) 16. The method of any one of items 14-15, wherein the antibody drug is selected from antibodies having an epitope binding member found in one or more of infliximab, adalimumab, golimumab, etanercept, etanercept-szzs, certolizumab pegol, siplizumab, zanolimumab, briakinumab, secukinumab, brodalumab, fezakinumab, ustekinumab and / or guselkumab. (Item 17) 17. The method of any one of items 14 to 16, further comprising delivering the antibody drug together with a biologically active agent. (Item 18) 18. The method of any one of items 14 to 17, further comprising delivering the antibody agent together with a non-irritating penetration enhancer. (Item 19) 19. The method of claim 18, wherein the non-irritant penetration enhancer is selected from a copeptide and a carrier peptide. (Item 20) 20. The method of any one of items 1 to 19, wherein the MSCs at the site are achieved with a device comprising multiple needles. (Item 21) 21. The method of claim 20, wherein the device is a patch, roller, stamp, or pen. (Item 22) 22. The method according to any one of items 1 to 21, wherein the site is a skin surface overlying a muscle or muscle group of a target. (Item 23) 23. The method according to any one of items 1 to 22, wherein the site is a skin surface containing sweat glands. (Item 24) 24. The method according to any one of items 1 to 23, wherein the site is a skin surface containing sebaceous glands. (Item 25) 25. The method according to any one of items 1 to 24, wherein the site is a skin surface containing hair follicles. (Item 26) 26. The method according to any one of items 20 to 25, wherein the needle has a length sufficient to protrude through the stratum corneum of the skin. (Item 27) 27. The method according to any one of items 20 to 26, wherein the needle has an insufficient length to reach nerves in the dermis of the skin. (Item 28) 28. The method according to any one of items 20 to 27, wherein the needle has a length of about 10 to about 4000 μm. (Item 29) 29. The method according to any one of items 20 to 28, wherein the needle has a length of about 100 μm or more. (Item 30) 29. The method according to any one of items 20 to 28, wherein the needle has a length of about 25 μm or more. (Item 31) 29. The method according to any one of items 20 to 28, wherein the needle has a length of about 300 μm, about 500 μm, about 800 μm, about 1000 μm, about 1500 μm, about 2000 μm, or about 4000 μm or more. (Item 32) 32. The method according to any one of items 20 to 31, wherein the needle is made of a biocompatible material. (Item 33) 32. The method according to any one of items 20 to 31, wherein the needle is made of metal. (Item 34) 34. The method of any one of items 1 to 33, wherein said MSC comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 administrations of MN or MN array impressions. (Item 35) 35. The method of claim 34, wherein the MN array is rotated between one or more impressions. (Item 36) 35. The method of claim 34, wherein the MN array is not rotated between one or more impressions. (Item 37) The method according to any one of items 34 to 36, wherein the indentations are made on approximately the same site. (Item 38) 37. The method according to any one of items 34 to 36, wherein the indentation is performed on an overlapping site. (Item 39) The method according to any one of items 34 to 36, wherein the indentations are made on different sites. (Item 40) 40. The method of any one of items 34 to 39, wherein the MN array is in the form of a stamp or roller. (Item 41) 41. The method according to claim 40, wherein the impression is made by stamping or rolling a roller. (Item 42) 42. The method of any one of items 1-41, wherein the large drug penetrates the skin within about 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 minutes of administration. (Item 43) 42. The method according to any one of items 1 to 41, wherein the large drug penetrates the skin within about 5 to about 60 minutes, about 5 to about 12 minutes, about 5 to about 15 minutes, or about 15 to about 30 minutes of administration. (Item 44) 42. The method of any one of items 1-41, wherein the large drug penetrates the skin within about 1, 2, 3, 4, 5, or 6 hours of administration. (Item 45) 33. The method according to any one of items 20 to 32, wherein the needle is composed of a dissolving polymer. (Item 46) 46. The method of any one of items 1 to 45, wherein said administering comprises administering said composition comprising a large drug in a smaller dose compared to a reference local treatment regimen in which microneedles are not used. (Item 47) 47. The method of any one of items 1 to 46, comprising administering the composition containing multiple doses of a large drug over time. (Item 48) 48. The method of claim 47, wherein said administering comprises administering said composition comprising a smaller dose of a large drug over a period of treatment to produce a comparable therapeutic effect compared to a reference treatment regime in which microneedles are not used. (Item 49) 49. The method of claim 47 or 48, wherein each dose of the composition containing a large drug is separated by a specific period of time. (Item 50) 50. The method of claim 49, wherein the specified time period is longer than the specified time period for administering a reference treatment regimen in which microneedles are not used. (Item 51) 51. The method of any one of items 46 to 50, wherein the reference treatment regimen comprises administering the composition comprising a large agent without MSCs. (Item 52) 52. A method for treating a skin disorder, comprising the method according to any one of items 1 to 51. (Item 53) 53. The method of item 52, wherein the skin disorder is selected from acne, unwanted sweating, body odor, hyperhidrosis, bromhidrosis, chromhidrosis, rosacea, alopecia, psoriasis, actinic keratosis, eczematoid dermatitis, sebum excess production disorders, burns, lupus erythematosus, hyperpigmentation disorders, hypopigmentation disorders, skin cancer, skin infections, facial wrinkles, facial disfigurement, neck, multifunctional facial muscles, hypercontractile facial muscles, platysma band, and / or combinations thereof. (Item 54) 52. A method for treating unwanted sweating, body odor, hyperhidrosis, bromhidrosis, chromhidrosis, alopecia, Raynaud's phenomenon, rheumatoid arthritis, psoriatic arthritis, osteoarthritis, lupus erythematosus, systemic lupus erythematosus, discoid lupus, drug-induced lupus, neonatal lupus, Crohn's disease, inflammatory bowel disease, ulcerative colitis, lung disorders, asthma, chronic obstructive airway disorders, amyloidosis, systemic amyloidosis, cutaneous amyloidosis, cancer, skin cancer, blood cancer, breast cancer, colon cancer, lung cancer, prostate hyperplasia, dyslipidemia, hypercholesterolemia. , an infection, a C. difficile infection, a Staphylococcus infection, dystonia, headache, pain, pain associated with arthritis, pain associated with rheumatoid arthritis, pain associated with psoriatic arthritis, pain associated with osteoarthritis, certain ophthalmologic conditions, certain urological conditions, neuromuscular disorders, conditions involving muscle spasms and / or contractures, strabismus, hemifacial spasm, tremor, spasticity such as that resulting from multiple sclerosis, retroorbital muscles, neurological conditions, Alzheimer's disease, Parkinson's disease, or stroke. (Item 55) The method according to any one of items 1 to 54, wherein the composition containing a large drug is formulated as a lotion, cream, powder, ointment, liniment, gel, or drop. A patch comprising an emulsion composition containing a large drug having a molecular weight of 100,000 Da or more and a plurality of microneedles. (Item 57) 57. The patch of item 56, wherein the composition comprising a large drug comprises a nanoemulsion. (Item 58) Item 59. The patch according to item 56, wherein the composition containing a large drug comprises a macroemulsion. 59. The patch of any one of items 56 to 58, wherein the needles have a length sufficient to protrude through the stratum corneum of the skin. (Item 60) 60. The patch of any one of items 57 to 59, wherein the needles have an insufficient length to reach nerves in the dermis of the skin. (Item 61) 61. The patch according to any one of items 57 to 60, wherein the needle has a length of about 10 to about 1000 μm. (Item 62) 62. The patch according to any one of items 57 to 61, wherein the needle has a length of about 100 μm or more. (Item 63) 63. The patch of any one of items 57 to 62, wherein the needle has a length of about 300 μm or more. (Item 64) 64. The patch of any one of items 57 to 63, wherein the needle is made of a biocompatible material. (Item 65) 65. The patch according to any one of items 57 to 64, wherein the needle is made of metal. (Item 66) 65. The patch of any one of items 57 to 64, wherein the needle is composed of a dissolving polymer. (Item 68) 67. The patch of any one of items 57 to 66, wherein the large drug is a botulinum toxin. (Item 69) 67. The patch of any one of items 57 to 66, wherein the large drug is an antibody drug. (Item 70) A kit comprising an emulsion composition containing a large drug having a molecular weight of 100,000 Da or more, and a patch containing multiple needles for use in applying the emulsion composition to a site. (Item 71) Item 72. The kit according to item 70, wherein the emulsion composition is incorporated into the patch. A kit comprising an emulsion composition containing a large drug having a molecular weight of 100,000 Da or greater and a device for microneedle preparation of a site. (Item 73) 73. The kit according to any one of items 70 to 72, wherein the emulsion composition comprises a nanoemulsion. (Item 74) 73. The kit according to any one of items 70 to 72, wherein the emulsion composition comprises a macroemulsion. (Item 75) 75. The kit of any one of items 72 to 74, wherein the device comprises a plurality of needles. (Item 76) 76. The kit of any one of items 72 to 75, wherein the device is a patch, roller, stamp, or pen. (Item 77) 72. The kit according to any one of items 70 or 71, comprising the patch according to any one of items 56 to 69. (Item 78) 78. The kit of any one of items 70 or 72-77, wherein the emulsion composition is formulated as a lotion, cream, powder, ointment, liniment, gel, or drop.
Claims
[Claim 1] The invention as depicted in the drawings.
Citation Information
Patent Citations
Clostridium botulinum nanoemulsion
JP2009518307A
High aspect ratio microdevice and method for transdermal delivery and sampling of active substances
JP2010502268A
Nanoparticle composition, formulation thereof, and use thereof
JP2014510041A
